日本臨牀　80/増刊5　免疫性神経疾患（第2版）

出版社： 日本臨牀社
発行日： 2022-05-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 免疫性神経疾患（第2版）
電子書籍版： 2022-05-31 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 特集　免疫性神経疾患（第2版）
    　　　―基礎・臨床の最新知見―

    序文

    I．総　論
    　１．免疫性神経疾患の研究・診断・治療の動向
    　２．知っておきたい免疫性神経疾患の遺伝的要因
    　３．知っておきたい免疫性神経疾患の疫学・環境要因
    　４．知っておきたい自然免疫の免疫性神経疾患への関わり
    　５．知っておきたい獲得免疫の免疫性神経疾患への関わり
    　６．腸内環境の神経変性疾患への関わり
    　７．知っておきたいグリアの免疫性神経疾患への関わり
    　８．知っておきたい免疫性神経疾患に対する分子標的療法のリスク・ベネフィットバランス
    　９．知っておきたい免疫性神経疾患治療薬のワクチン接種への影響
    　10．診療に役立つ免疫性中枢神経疾患の画像検査とその解釈
    　11．診療に役立つ免疫性末梢神経疾患の画像検査とその解釈
    　12．診療に役立つ免疫性中枢神経疾患の臨床神経生理検査とその解釈
    　13．診療に役立つ免疫性末梢神経疾患の臨床神経生理検査とその解釈
    　14．診療に役立つ免疫性神経筋接合部疾患・筋疾患の臨床神経生理検査とその解釈
    　15．診療に役立つ免疫性神経疾患の血液バイオマーカーとその解釈
    　16．診療に役立つ免疫性神経疾患の髄液検査とその解
    　17．診療に役立つ免疫性神経疾患の自己抗体測定法とその解釈
    　18．診療に役立つ免疫性神経疾患の神経・筋病理検査とその解釈

    II．中枢神経脱髄疾患
    　１．多発性硬化症の病態・病理
    　２．MSの病型と経過
    　３．MSの臨床・検査
    　４．MSの障害度評価とQOL評価
    　５．MSの最新の治療戦略オーバービュー
    　６．再発寛解型MSの抗B細胞療法の意義とメカニズム
    　７．二次性進行型多発性硬化症の治療とモニター
    　８．一次進行型MSの治療の現状と展望
    　９．視神経脊髄炎スペクトルム(NMOSD)の病理・病態
    　10．NMOSDの臨床・検査と診断基準・障害度評価
    　11．NMSDOの最新の治療戦略オーバービュー
    　12．NMOSDの抗補体抗体療法
    　13．NMOSDの抗サイトカイン療法
    　14．NMOSDの抗B細胞療法
    　15．MOGAD（抗MOG抗体関連疾患）
    　16．Tumefactive MS,Baló病
    　17．急性散在性脳脊髄炎(ADEM)
    　18．MS/NMOSDの疾患修飾薬に関連した進行性多巣性白質脳症(PML)

    III．末梢神経脱髄疾患
    　１．Guillain-Barré 症候群の診断と治療update
    　２．フィッシャー症候群
    　３．CIDPの病型と診断
    　４．CIDPの治療戦略
    　５．自己免疫性ノドパチー
    　６．中枢末梢連合脱髄症
    　７．抗MAG抗体陽性ニューロパチー

    IV．脱髄以外の中枢神経免疫疾患
    　１．自己免疫性脳炎・脳症のオーバービュー
    　２．自己免疫性てんかん
    　３．自己免疫性運動異常症
    　４．Rasmussen脳炎
    　５．小児急性脳症
    　６．橋本脳症
    　７．自己免疫性小脳失調症
    　８．Bickerstaff脳幹脳炎
    　９． Primary angiitis of the CNS (PACNS) / Primary CNS vasculitis (PCNSV)
    　10．肥厚性硬膜炎
    　11．HTLV-1-associated myelopathy (HAM)
    　12．アトピー性脊髄炎,Hopkins症候群
    　13．Stiff person sydrome,Progressive encephalomyelitis with rigidity and myoclonus
    　14．Acute encephalomyeloradiculoneuritisと抗中性糖脂質抗体
    　15．CLIPPERS，Susac症候群

    V．脱髄以外の末梢神経免疫疾患
    　１．Crow-深瀬症候群（POEMＳ症候群）
    　２．血管炎性症候群・好酸球性多発血管炎性肉芽腫症
    　３．Isaacs症候群/neuromyotonia/抗VGKC複合体抗体関連疾患
    　４．自己免疫性自律神経節障害、急性自律神経性感覚性ニューロパチー
    　５．Neuropathic pain（Small fiber neuropathy）/
    　　　　painful trigeminal neuropathyと抗Plexin D1抗体

    VI．免疫性神経筋接合部疾患
    　１．免疫性神経筋接合部疾患における自己抗体と病態における意義
    　２．重症筋無力症(MG)の疫学・遺伝的背景・環境因子
    　３．MGの臨床と診断基準
    　４．MGの最新の治療戦略オーバービュー
    　５．MGの抗補体療法
    　６．Lambert-Eaton筋無力症候群

    VII．免疫性筋疾患
    　１．免疫性筋疾患における自己抗体オバービュー　　
    　２．多発筋炎,皮膚筋炎,amyopathic dermatomyositis
    　３．封入体筋炎
    　４．壊死性筋炎・筋症
    　５．筋炎の鑑別診断：好酸球性筋膜炎とリウマチ性多発筋痛症

    VIII．内科疾患や腫瘍に伴う神経免疫疾患
    　１．Neuropsychiatric SLE
    　２．神経ベーチェット病/神経スウィート病
    　３．シェーグレン症候群による神経障害
    　４．神経サルコイドーシス
    　５．傍腫瘍性神経症候群
    　６．神経リンパ腫症
    　７．IgG4関連疾患に伴う神経障害

    IX．トピックス・今知りたいこと
    　１．新型コロナウイルス感染症（COVID‑19）と神経免疫疾患
    　２．免疫チェックポイント阻害薬と神経免疫疾患
    　３．小児の免疫性神経疾患に対する免疫療法のポイント
    　４．慢性ウイルス感染症キャリアの免疫性神経疾患に対する治療のポイント
    　５．妊娠・授乳中の免疫性神経疾患の治療方針
    　６．免疫性神経疾患におけるshared decision making
    　７．免疫性神経疾患の支援制度と医療経済

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.16 掲載の参考文献
1) International Multiple Sclerosis Genetics Consortium : Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365 : eaav7188, 2019.
PubMed
2) International Multiple Sclerosis Genetics Consortium : Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell 175 : 1679-1687.e7, 2018.
 
3) Isobe N, et al : An ImmunoChip study of multiple sclerosis risk in African Americans. Brain 138 : 1518-1530, 2015.
PubMed
4) Sato S, et al : Copy number variations in multiple sclerosis and neuromyelitis optica. Ann Neurol 78 : 762-774, 2015.
PubMed
5) Masterman T, et al : HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 48 : 211-219, 2000.
PubMed
6) Nakamura Y, et al ; Japan Multiple Sclerosis Genetics Consortium : Latitude and HLA-DRB1*04 : 05 independently influence disease severity in Japanese multiple sclerosis : a cross-sectional study. J Neuroinflammation 13 : 239, 2016.
PubMed
7) Shinoda K, et al : HLA-DRB1*04 : 05 allele is associated with intracortical lesions on 3-dimensional double inversion recovery images in Japanese patients with multiple sclerosis. Mult Scler 24 : 710-720, 2018.
PubMed
8) Watanabe M, et al : Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod. J Neuroinflammation 17 : 206, 2020.
PubMed
9) Matsushita T, et al : Genetic factors for susceptibility to and manifestations of neuromyelitis optica. Ann Clin Transl Neurol 7 : 2082-2093, 2020.
PubMed
10) Sakoda A, et al : Environmental risk factors for multiple sclerosis in Japanese people. Mult Scler Relat Disord 38 : 101872, 2020.
PubMed
11) Takewaki D, et al : Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. Proc Natl Acad Sci U S A 117 : 22402-22412, 2020.
PubMed
12) Hayashi F, et al : A new clustering method identifies multiple sclerosis-specific T-cell receptors. Ann Clin Transl Neurol 8 : 163-176, 2021.
PubMed
13) Glanville J, et al : Identifying specificity groups in the T cell receptor repertoire. Nature 547 : 94-98, 2017.
 
14) Raveney BJ, et al : Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. Nat Commun 6 : 8437, 2015.
PubMed
15) Raveney BJ, et al : Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis. Proc Natl Acad Sci U S A 118 : e2021818118, 2021.
PubMed
16) Zhao Y, et al : Oligodendroglial connexin 47 regulates neuroinflammation upon autoimmune demyelination in a novel mouse model of multiple sclerosis. Proc Natl Acad Sci U S A 117 : 2160-2169, 2020.
 
17) Une H, et al : Brain gray matter astroglia-specific connexin 43 ablation attenuates spinal cord inflammatory demyelination. J Neuroinflammation 18 : 126, 2021.
PubMed
18) Liddelow SA, et al : Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541 : 481-487, 2017.
PubMed
19) Hammond TR, et al : Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50 : 253-271.e6, 2019.
 
20) Keren-Shaul H, et al : A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell 169 : 1276-1290.e17, 2017.
 
21) Masuda T, et al : Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566 : 388-392, 2019.
PubMed
22) Van Hove H, et al : A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat Neurosci 22 : 1021-1035, 2019.
PubMed
23) Galli E, et al : GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. Nat Med 25 : 1290-1300, 2019.
 
24) Sand IK, et al : Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler 20 : 1654-1657, 2014.
 
25) Lorscheider J, et al : Defining secondary progressive multiple sclerosis. Brain 139 : 2395-2405, 2016.
PubMed
26) Kremenchutzky M, et al : The natural history of multiple sclerosis : a geographically based study 9 : observations on the progressive phase of the disease. Brain 129 : 584-594, 2006.
PubMed
27) University of California, San Francisco MS-EPIC Team ; Cree BAC, et al : Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 85 : 653-666, 2019.
PubMed
28) Kappos L, et al : Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol 77 : 1132-1140, 2020.
 
29) Watanabe M, et al : Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93 : e1299-e1311, 2019.
PubMed
30) Aktas O, et al : Serum Glial Fibrillary Acidic Protein : A Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol 89 : 895-910, 2021.
PubMed
31) Kira JI : Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination : Strategies for Diagnosis and Treatment Based on the Disease Mechanism. Front Neurol 12 : 665136, 2021.
PubMed
32) Ogata H, et al : Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol 7 : 2297-2309, 2020.
PubMed
33) Hashimoto Y, et al : Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy : An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey. Front Neurol 9 : 997, 2018.
PubMed
34) Fujii T, et al : A Novel Autoantibody against Plexin D1 in Patients with Neuropathic Pain. Ann Neurol 84 : 208-224, 2018.
 
35) Fujii T, et al : Painful trigeminal neuropathy associated with anti-Plexin D1 antibody. Neurol Neuroimmunol Neuroinflamm 7 : e819, 2020.
PubMed
36) Fujii T, et al : Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals. Neurol Neuroimmunol Neuroinflamm 8 : e1028, 2021.
PubMed
37) Shibuya K, et al : Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 77 : 333-337, 2015.
PubMed
38) Maggi P, et al : Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol 83 : 283-294, 2018.
PubMed
39) Shinoda K, et al : Contribution of cortical lesions to cognitive impairment in Japanese patients with multiple sclerosis. Sci Rep 10 : 5228, 2020.
PubMed
40) Frischer JM, et al : Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 78 : 710-721, 2015.
PubMed
41) Absinta M, et al : Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol 76 : 1474-1483, 2019.
PubMed
42) Ighani M, et al : No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis. Mult Scler 26 : 165-176, 2020.
PubMed
43) Lorscheider J, et al : Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology 89 : 1050-1059, 2017.
PubMed
44) Kappos L, et al : Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND) : a double-blind, randomised, phase 3 study. Lancet 391 : 1263-1273, 2018.
PubMed
45) Montalban X, et al : Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 : 209-220, 2017.
PubMed
P.22 掲載の参考文献
1) Compston A, et al : Multiple sclerosis. Lancet 372 : 1502-1517, 2008.
PubMed
2) Thompson AJ, et al : Multiple sclerosis. Lancet 391 : 1622-1636, 2018.
PubMed
3) Isobe N, Oksenberg JR : Genetic studies of multiple sclerosis and neuromyelitis optica : Current status in European, African American and Asian populations. Clin Exp Neuroimmunol 5 : 61-68, 2014.
 
4) Yoshimura S, et al : Genetic and Infectious Profiles of Japanese Multiple Sclerosis Patients. PLoS One 7 : e48592, 2012.
PubMed
5) International Multiple Sclerosis Genetics Consortium ; De Jager PL, et al : Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365 : eaav7188, 2019.
PubMed
6) Olsson T, et al : Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 13 : 25-36, 2017.
PubMed
7) Hedstrom AK, et al : Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 134 : 653-664, 2011.
PubMed
8) Sundqvist E, et al : Epstein-Barr virus and multiple sclerosis : interaction with HLA. Genes Immun 13 : 14-20, 2012.
PubMed
9) Hedstrom AK, et al : Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 82 : 865-872, 2014.
PubMed
10) Hayashi F, et al : A new clustering method identifies multiple sclerosis-specific T-cell receptors. Ann Clin Transl Neurol 8 : 163-176, 2021.
PubMed
11) Watanabe M, et al : Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod. J Neuroinflammation 17 : 206, 2020.
PubMed
12) Alvarenga MP, et al : Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis : a systematic review with meta-analysis. Sci Rep 11 : 152, 2021.
PubMed
13) Estrada K, et al : A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun 9 : 1929, 2018.
 
14) Matsushita T, et al : Genetic factors for susceptibility to and manifestations of neuromyelitis optica. Ann Clin Transl Neurol 7 : 2082-2093, 2020.
PubMed
15) Alborzian Deh Sheikh A, et al : A Guillain-Barre syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides. J Autoimmun 116 : 102571, 2021.
PubMed
16) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. Eur J Neurol 28 : 3556-3583, 2021.
PubMed
17) Ogata H, et al : Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 339 : 577139, 2020.
PubMed
18) Iijima M, et al : Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 73 : 1348-1352, 2009.
 
19) Penova M, et al : Genome wide association study of HTLV-1-associated myelopathy/tropical spastic paraparesis in the Japanese population. Proc Natl Acad Sci U S A 118 : e2004199118, 2021.
PubMed
20) Gilhus NE, et al : Myasthenia gravis. Nat Rev Dis Primers 5 : 30, 2019.
PubMed
21) Rider LG, et al : Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis Rheum 41 : 710-719, 1998.
PubMed
22) Rothwell S, et al : Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis 75 : 1558-1566, 2016.
PubMed
23) Oyama M, et al : HLA-DRB1 allele and autoantibody profiles in Japanese patients with inclusion body myositis. PLoS One 15 : e0237890, 2020.
PubMed
P.27 掲載の参考文献
1) The Multiple Sclerosis International Federation : Atlas of MS, 3rd edition : Mapping multiple sclerosis around the world, 2020.
 
2) 吉良潤一, ほか : 第5回多発性硬化症・視神経脊髄炎全国臨床疫学調査結果 第2報. 令和2 (2020) 年度厚生労働科学研究費補助金 (難治性疾患政策研究事業) 神経免疫疾患のエビデンスに基づく診断基準・重症度分類・ガイドラインの妥当性と患者QOLの検証分担研究報告書, p29-31, 2021.
 
3) Belbasis L, et al : Environmental factors and risk of multiple sclerosis : Findings from meta-analyses and Mendelian randomization studies. Mult Scler 26 : 397-404, 2020.
PubMed
4) Hernan MA, et al : Cigarette smoking and the progression of multiple sclerosis. Brain 128 : 1461-1465, 2005.
PubMed
5) Ramanujam R, et al : Effect of Smoking Cessation on Multiple Sclerosis Prognosis. JAMA Neurol 72 : 1117-1123, 2015.
PubMed
6) Sakoda A, et al : Environmental risk factors for multiple sclerosis in Japanese people. Mult Scler Relat Disord 38 : 101872, 2020.
PubMed
7) Miyake S, Yamamura T : Gut environmental factors and multiple sclerosis. J Neuroimmunol 329 : 20-23, 2019.
PubMed
8) Haase S, et al : Dietary fatty acids and susceptibility to multiple sclerosis. Mult Scler 24 : 12-16, 2018.
PubMed
9) Langer-Gould A, et al : Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility. Mult Scler 26 : 1476-1485, 2020.
PubMed
10) Mori M, et al : Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 89 : 555-556, 2018.
PubMed
11) Hor JY, et al : Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol 11 : 501, 2020.
PubMed
12) Papp V, et al : Worldwide Incidence and Prevalence of Neuromyelitis Optica : A Systematic Review. Neurology 96 : 59-77, 2021.
PubMed
13) Bizzoco E, et al : Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256 : 1891-1898, 2009.
PubMed
14) Yoshimura S, et al : Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry 84 : 29-34, 2013.
PubMed
15) Varrin-Doyer M, et al : Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 72 : 53-64, 2012.
PubMed
16) Pereira WL, et al : Epidemiological, clinical, and immunological characteristics of neuromyelitis optica : A review. J Neurol Sci 355 : 7-17, 2015.
PubMed
17) Kieseier BC, et al : Immune-mediated neuropathies. Nat Rev Dis Primers 4 : 31, 2018.
PubMed
18) Shahrizaila N, et al : Guillain-Barre syndrome. Lancet 397 : 1214-1228, 2021.
PubMed
19) Marini A, et al : Neurologic Adverse Events of Immune Checkpoint Inhibitors : A Systematic Review. Neurology 96 : 754-766, 2021.
PubMed
20) Iijima M, et al : Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 79 : 1040-1043, 2008.
PubMed
21) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26 : 242-268, 2021.
PubMed
22) Salari N, et al : Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment : a systematic review and meta-analysis. J Transl Med 19 : 516, 2021.
 
23) 吉川弘明, ほか : 重症筋無力症の全国疫学調査 二次調査による臨床像解析. 令和1 (2019) 年度 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 神経免疫疾患のエビデンスによる診断基準・重症度分類・ガイドラインの妥当性と患者QOLの検証分担研究報告書, p22-25, 2020.
 
24) HTLV-1関連脊髄症 (HAM) 診療ガイドライン 2019 (厚生労働省「HAMならびにHTLV-1陽性難治性疾患に関する国際的な総意形成を踏まえた診療ガイドラインの作成」研究班, 「HTLV-1関連脊髄症 (HAM) 診療ガイドライン 2019」作成委員会編, 日本神経学会, ほか監), 南江堂, 2019.
 
25) Yamauchi J, et al : An update on human T-cell leukemia virus type I (HTLV-1) -associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. Pharmacol Ther 218 : 107669, 2021.
 
P.34 掲載の参考文献
1) Flannagan RS, et al : The cell biology of phagocytosis. Annu Rev Pathol 7 : 61-98, 2012.
PubMed
2) Brinkmann V, et al : Neutrophil extracellular traps kill bacteria. Science 303 : 1532-1535, 2004.
PubMed
3) Wartha F, Henriques-Normark B : ETosis : a novel cell death pathway. Sci Signal 1 : pe25, 2008.
 
4) Takeuchi O, Akira S : Pattern recognition receptors and inflammation. Cell 140 : 805-820, 2010.
PubMed
5) Patel S : Danger-Associated Molecular Patterns (DAMPs) : the Derivatives and Triggers of Inflammation. Curr Allergy Asthma Rep 18 : 63, 2018.
 
6) Lamkanfi M, Dixit VM : Mechanisms and functions of inflammasomes. Cell 157 : 1013-1022, 2014.
PubMed
7) Shin JI, et al : Inflammasomes and autoimmune and rheumatic diseases : A comprehensive review. J Autoimmun 103 : 102299, 2019.
PubMed
8) Deerhake ME, et al : Pattern Recognition Receptors in Multiple Sclerosis and Its Animal Models. Front Immunol 10 : 2644, 2019.
PubMed
9) Reu P, et al : The Lifespan and Turnover of Microglia in the Human Brain. Cell Rep 20 : 779-784, 2017.
PubMed
10) Swirski FK, et al : Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325 : 612-616, 2009.
PubMed
11) Muller WA : Transendothelial migration : unifying principles from the endothelial perspective. Immunol Rev 273 : 61-75, 2016.
PubMed
12) Mamdouh Z, et al : Transcellular migration of leukocytes is mediated by the endothelial lateral border recycling compartment. J Exp Med 206 : 2795-2808, 2009.
PubMed
13) Miller DH, et al : A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348 : 15-23, 2003.
PubMed
14) Mills CD, et al : M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164 : 6166-6173, 2000.
 
15) Mantovani A, et al : Macrophage polarization : tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23 : 549-555, 2002.
PubMed
P.41 掲載の参考文献
1) Fraussen J, et al : Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 13 : 1126-1137, 2014.
PubMed
2) Glatigny S, Bettelli E : Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS). Cold Spring Harb Perspect Med 8 : a028977, 2018.
PubMed
3) Martin R, et al : Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis. Eur J Immunol 46 : 2078-2090, 2016.
PubMed
4) Geginat J, et al : Plasticity of human CD4 T cell subsets. Front Immunol 5 : 630, 2014.
PubMed
5) Venken K, et al : Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med 16 : 58-68, 2010.
PubMed
6) Hiltensperger M, Korn T : The Interleukin (IL) -23/T helper (Th) 17 Axis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Cold Spring Harb Perspect Med 8 : a029637, 2018.
PubMed
7) Sakaguchi S, et al : Regulatory T Cells and Human Disease. Annu Rev Immunol 38 : 541-566, 2020.
PubMed
8) Vinuesa CG, et al : Follicular Helper T Cells. Annu Rev Immunol 34 : 335-368, 2016.
PubMed
9) Constantinescu CS, Gran B : The essential role of T cells in multiple sclerosis : a reappraisal. Biomed J 37 : 34-40, 2014.
PubMed
10) Veroni C, Aloisi F : The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue : A Central Issue in Multiple Sclerosis Pathogenesis. Front Immunol 12 : 665718, 2021.
PubMed
11) Rawlings DJ, et al : Altered B cell signalling in autoimmunity. Nat Rev Immunol 17 : 421-436, 2017.
PubMed
12) Negron A, et al : Ectopic Lymphoid Follicles in Multiple Sclerosis : Centers for Disease Control? Front Neurol 11 : 607766, 2020.
PubMed
13) Cancro MP : Age-Associated B Cells. Annu Rev Immunol 38 : 315-340, 2020.
PubMed
14) Raveney BJ, et al : Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. Nat Commun 6 : 8437, 2015.
PubMed
15) Raveney BJE, et al : Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis. Proc Natl Acad Sci U S A 118 : e2021818118, 2021.
PubMed
P.46 掲載の参考文献
1) Noto D, Miyake S : Gut dysbiosis and multiple sclerosis. Clin Immunol 235 : 108380, 2022.
PubMed
2) Miyake S, et al : Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS One 10 : e0137429, 2015.
PubMed
3) Mizuno M, et al : The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models. PLoS One 12 : e0173032, 2017.
PubMed
4) Haase S, et al : Dietary fatty acids and susceptibility to multiple sclerosis. Mult Scler 24 : 12-16, 2018.
PubMed
5) Chen T, et al : Butyrate suppresses demyelination and enhances remyelination. J Neuroinflammation 16 : 165, 2019.
PubMed
6) Takewaki D, et al : Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. Proc Natl Acad Sci USA 117 : 22402-22412, 2020.
PubMed
7) Planas R, et al : GDP-l-fucose synthase is a CD4+ T cell-specific autoantigen in DRB3*02 : 02 patients with multiple sclerosis. Sci Transl Med 10 : eaat4301, 2018.
PubMed
8) Miyauchi E, et al : Gut microorganisms act together to exacerbate inflammation in spinal cords. Nature 585 : 102-106, 2020.
PubMed
9) Gate D, et al : CD4+ T cells contribute to neurodegeneration in Lewy body dementia. Science 374 : 868-874, 2021.
PubMed
10) Sulzer D, et al : T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature 546 : 656-661, 2017.
 
11) Uemura N, et al : Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Mol Neurodegener 13 : 21, 2018.
 
12) Pfeiffer RF : Gastrointestinal Dysfunction in Parkinson's Disease. Curr Treat Options Neurol 20 : 54, 2018.
PubMed
13) Scheperjans F, et al : Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 30 : 350-358, 2015.
PubMed
14) Nishiwaki H, et al : Meta-Analysis of Gut Dysbiosis in Parkinson's Disease. Mov Disord 35 : 1626-1635, 2020.
PubMed
15) Barrett JC, et al : Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40 : 955-962, 2008.
PubMed
P.55 掲載の参考文献
1) Kettenmann H, Verkhratsky A : Neuroglia : the 150 years after. Trends Neurosci 31 : 653-659, 2008.
PubMed
2) von Bartheld CS, et al : The search for true numbers of neurons and glial cells in the human brain : A review of 150 years of cell counting. J Comp Neurol 524 : 3865-3895, 2016.
 
3) Schulz C, et al : A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336 : 86-90, 2012.
 
4) Chu T, et al : Dynamic glial response and crosstalk in demyelination-remyelination and neurodegeneration processes. Neural Regen Res 16 : 1359-1368, 2021.
PubMed
5) 越智博文 : 多発性硬化症の疫学-多発性硬化症は本当に増えているか. BRAIN and NERVE 72 : 467-484, 2020.
 
6) Patrikios P, et al : Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129 : 3165-3172, 2006.
 
7) Wilkins A, Scolding N : Protecting axons in multiple sclerosis. Mult Scler 14 : 1013-1025, 2008.
PubMed
8) Boyd A, et al : Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models. Acta Neuropathol 125 : 841-859, 2013.
PubMed
9) O'Loughlin E, et al : Microglial Phenotypes and Functions in Multiple Sclerosis. Cold Spring Harb Perspect Med 8 : a028993, 2018.
 
10) Skripuletz T, et al : Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 136 : 147-167, 2013.
PubMed
11) Trapp BD, et al : Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 : 278-285, 1998.
PubMed
12) Schultz V, et al : Acutely damaged axons are remyelinated in multiple sclerosis and experimental models of demyelination. Glia 65 : 1350-1360, 2017.
PubMed
13) Lassmann H, Bradl M : Multiple sclerosis : experimental models and reality. Acta Neuropathol 133 : 223-244, 2017.
PubMed
14) Reynolds R, et al : The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J Neurocytol 31 : 523-536, 2002.
 
15) Hampton DW, et al : An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol 201-202 : 200-211, 2008.
 
16) Mecha M, et al : Viral models of multiple sclerosis : neurodegeneration and demyelination in mice infected with Theiler's virus. Prog Neurobiol 101-102 : 46-64, 2013.
 
17) Lindner M, et al : Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci Lett 453 : 120-125, 2009.
PubMed
18) Chu T, et al : Dynamic response of microglia/macrophage polarization following demyelination in mice. J Neuroinflammation 16 : 188, 2019.
PubMed
19) McMurran CE, et al : Toxin-Based Models to Investigate Demyelination and Remyelination. Methods Mol Biol 1936 : 377-396, 2019.
 
20) Ransohoff RM : A polarizing question : do M1 and M2 microglia exist? Nat Neurosci 19 : 987-991, 2016.
 
21) Miron VE : Microglia-driven regulation of oligodendrocyte lineage cells, myelination, and remyelination. J Leukoc Biol 101 : 1103-1108, 2017.
PubMed
22) Lloyd AF, et al : Central nervous system regeneration is driven by microglia necroptosis and repopulation. Nat Neurosci 22 : 1046-1052, 2019.
PubMed
23) Voskuhl RR, et al : Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 29 : 11511-11522, 2009.
PubMed
24) Keough MB, et al : An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. Nat Commun 7 : 11312, 2016.
PubMed
25) Anderson MA, et al : Astrocyte scar formation aids central nervous system axon regeneration. Nature 532 : 195-200, 2016.
PubMed
26) Liddelow SA, et al : Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541 : 481-487, 2017.
PubMed
27) Tanuma N, et al : Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol 112 : 195-204, 2006.
 
28) Brambilla R, et al : Astrocytes play a key role in EAE pathophysiology by orchestrating in the CNS the inflammatory response of resident and peripheral immune cells and by suppressing remyelination. Glia 62 : 452-467, 2014.
PubMed
29) Omari KM, et al : CXC chemokine receptors on human oligodendrocytes : implications for multiple sclerosis. Brain 128 : 1003-1015, 2005.
PubMed
30) Calderon TM, et al : A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis : regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol 177 : 27-39, 2006.
PubMed
31) Crawford AH, et al : Remyelination : the true regeneration of the central nervous system. J Comp Pathol 149 : 242-254, 2013.
PubMed
32) Dai X, et al : The trophic role of oligodendrocytes in the basal forebrain. J Neurosci 23 : 5846-5853, 2003.
PubMed
33) Zeis T, et al : The immunomodulatory oligodendrocyte. Brain Res 1641 (Pt A) : 139-148, 2016.
 
34) Kirby L, et al : Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination. Nat Commun 10 : 3887, 2019.
PubMed
35) Moll NM, et al : Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 66 : 44-53, 2009.
PubMed
36) Miron VE, et al : M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 16 : 1211-1218, 2013.
PubMed
37) Voss EV, et al : Characterisation of microglia during de- and remyelination : can they create a repair promoting environment? Neurobiol Dis 45 : 519-528, 2012.
 
38) Stankoff B, et al : Ciliary neurotrophic factor (CNTF) enhances myelin formation : a novel role for CNTF and CNTF-related molecules. J Neurosci 22 : 9221-9227, 2002.
PubMed
39) Thummler K, et al : Polarizing receptor activation dissociates fibroblast growth factor 2 mediated inhibition of myelination from its neuroprotective potential. Acta Neuropathol Commun 7 : 212, 2019.
PubMed
40) Yamasaki R : Connexins in health and disease. Clin Exp Neuroimmunol 9 (Suppl 1) : 30-36, 2018.
 
41) Masaki K, et al : Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica. PLoS One 8 : e72919, 2013.
PubMed
42) Fang M, et al : Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia. Front Immunol 9 : 2588, 2018.
 
43) Une H, et al : Brain gray matter astroglia-specific connexin 43 ablation attenuates spinal cord inflammatory demyelination. J Neuroinflammation 18 : 126, 2021.
PubMed
44) Zhao Y, et al : Oligodendroglial connexin 47 regulates neuroinflammation upon autoimmune demyelination in a novel mouse model of multiple sclerosis. Proc Natl Acad Sci U S A 117 : 2160-2169, 2020.
 
P.63 掲載の参考文献
1) Goodin DS : The epidemiology of multiple sclerosis : insights to disease pathogenesis. Handb Clin Neurol 122 : 231-266, 2014.
PubMed
2) Polman CH, et al : A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 : 899-910, 2006.
PubMed
3) Butzkueven H, et al : Long-term safety and effectiveness of natalizumab treatment in clinical practice : 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry 91 : 660-668, 2020.
 
4) Major EO, et al : Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis : a decade of lessons learned. Lancet Neurol 17 : 467-480, 2018.
PubMed
5) 中道一生, 西條政幸 : I. 神経・筋 進行性多巣性白質脳症. 生体の科学 71 : 420-421, 2020.
 
6) Sorensen PS, et al : Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18 : 143-152, 2012.
PubMed
7) Ho PR, et al : Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis : a retrospective analysis of data from four clinical studies. Lancet Neurol 16 : 925-933, 2017.
PubMed
8) Clerico M, et al : Extending the Interval of Natalizumab Dosing : Is Efficacy Preserved? Neurotherapeutics 17 : 200-207, 2020.
PubMed
9) Ryerson LZ, et al : Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93 : e1452-e1462, 2019.
PubMed
10) Hauser SL, et al : Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 383 : 546-557, 2020.
PubMed
11) Laroni A, et al : COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Mult Scler 27 : 2126-2136, 2021.
PubMed
12) Sahraian MA, et al : Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord 46 : 102472, 2020.
PubMed
13) Samjoo IA, et al : Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis : a network meta-analysis. J Comp Eff Res 9 : 1255-1274, 2020.
PubMed
14) Wiendl H, et al : Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Mult Scler 27 : 719-728, 2021.
PubMed
15) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
PubMed
16) Lennon VA, et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473-477, 2005.
 
17) Wingerchuk DM, et al : The spectrum of neuromyelitis optica. Lancet Neurol 6 : 805-815, 2007.
PubMed
18) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
19) Akaishi T, et al : Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm 7 : e640, 2020.
PubMed
20) Pittock SJ, et al : Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 614-625, 2019.
PubMed
21) Yamamura T, et al : Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 2114-2124, 2019.
PubMed
22) Traboulsee A, et al : Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder : a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19 : 402-412, 2020.
 
23) Chen D, et al : Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases : Insights from Preclinical Studies. J Clin Med 5 : 107, 2016.
 
24) Cree BAC, et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019.
PubMed
25) Gilhus NE : Myasthenia Gravis. N Engl J Med 375 : 2570-2581, 2016.
PubMed
26) Howard JF Jr, et al : Safety and efficacy of eculizumab in anti-acetylcholine receptor antibodypositive refractory generalised myasthenia gravis (REGAIN) : a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16 : 976-986, 2017.
 
27) Muppidi S, et al : Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60 : 14-24, 2019.
PubMed
P.68 掲載の参考文献
1) Greenbook. Chapter 14a-COVID-19-SARS-CoV-2. 16 Sep 2021.
 
2) 日本脳卒中学会, 日本血栓止血学会 : アストラゼネカ社COVID-19ワクチン接種後の血小板減少を伴う血栓症の診断と治療の手引き・第2版. 2021年6月. [http://www.jsth.org/wordpress/wp-content/uploads/2021/06/TTS%E6%89%8B%E5%BC%95%E3%81%8Dver.2.3.pdf]
 
3) Shapiro Ben David S, et al : Rate of Recurrent Guillain-Barre Syndrome After mRNA COVID-19 Vaccine BNT162b2. JAMA Neurol 78 : 1409-1411, 2021.
PubMed
4) Finsterer J : Exacerbating Guillain-Barre syndrome eight days after vector-based COVID-19 vaccination. Case Rep Infect Dis 2021 : 3619131, 2021.
PubMed
5) 荒井元美 : COVID-19ワクチン接種を受けたSjogren症候群患者に生じたGuillain-Barre症候群と後根神経節炎. 脳神経内科 95 : 692-694, 2021.
 
6) Di Filippo M, et al : mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry, 2021. (DOI : org/10.1136/jnnp-2021-327200)
PubMed
7) Reder AT, et al : COVID-19 in Patients with Multiple Sclerosis : Associations with Disease-Modifying Therapies. CNS Drugs 35 : 317-330, 2021.
PubMed
8) Sormani MP, et al : Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol 89 : 780-789, 2021.
PubMed
9) Achiron A, et al : Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 14 : 1-8, 2021.
PubMed
10) Sormani MP, et al : Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 72 : 103581, 2021.
PubMed
11) Tanaka M, Fujihara K : Difference of anti-viral immunity induced by two mRNA vaccines : implications in MS patients treated with anti-CD20 depleting therapy. Clin Exp Neuroimmunol 13 : 5-6, 2021.
 
12) Chow RM, et al : The COVID-19 vaccine and interventional procedures : Exploring the relationship between steroid administration and subsequent vaccine efficacy. Pain Pract 21 : 966-973, 2021.
PubMed
13) Furer V, et al : Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population : a multicentre study. Ann Rheum Dis 80 : 1330-1338, 2021.
PubMed
14) Kageyama T, et al : Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin Microbiol Infect 27 : 1861.e1-1861.e5, 2021.
 
P.77 掲載の参考文献
1) Miki Y : Magnetic resonance imaging diagnosis of demyelinating diseases : an update. Clin Exp Neuroimmunol 10 (Suppl 1) : 32-48, 2019.
 
2) Hagiwara A, et al : Analysis of White Matter Damage in Patients with Multiple Sclerosis via a Novel In Vivo MR Method for Measuring Myelin, Axons, and G-Ratio. AJNR Am J Neuroradiol 38 : 1934-1940, 2017.
 
3) Fujita S, et al : 3D Quantitative Synthetic MRI in the Evaluation of Multiple Sclerosis Lesions. AJNR Am J Neuroradiol 42 : 471-478, 2021.
PubMed
4) Thompson AJ, et al : Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 17 : 162-173, 2018.
PubMed
5) 渡邊充, 吉良潤一 : 診断基準 (McDonald 2017 基準). Clinical Neuroscience 36 : 1283-1285, 2018.
 
6) Miki Y, et al : Isolated U-fiber involvement in MS : preliminary observations. Neurology 50 : 1301-1306, 1998.
PubMed
7) Absinta M, et al : Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol 76 : 1474-1483, 2019.
PubMed
8) Wattjes MP, Barkhof F : Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 27 : 260-270, 2014.
PubMed
9) 三木幸雄 : 多発性硬化症のMRI-診断ツール, バイオマーカー, 副作用モニタリングツールとしての役割. BRAIN and NERVE 72 : 493-508, 2020.
 
10) 宍戸-原由紀子, 鹿戸将史 : 進行性多巣性白質脳症 (PML) のMRI画像診断-MRIが捉えた, 伸展する脱髄病変の病理. BRAIN and NERVE 72 : 973-986, 2020.
 
11) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
12) Tatekawa H, et al : Imaging Differences between Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis : A Multi-Institutional Study in Japan. AJNR Am J Neuroradiol 39 : 1239-1247, 2018.
PubMed
13) Kim HJ, et al : MRI characteristics of neuromyelitis optica spectrum disorder : an international update. Neurology 84 : 1165-1173, 2015.
PubMed
14) Jarius S, et al : MOG encephalomyelitis : international recommendations on diagnosis and antibody testing. J Neuroinflammation 15 : 134, 2018.
PubMed
15) Marignier R, et al : Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20 : 762-772, 2021.
PubMed
16) Krupp LB, et al : International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions. Mult Scler 19 : 1261-1267, 2013.
 
17) Callen DJ, et al : Role of MRI in the differentiation of ADEM from MS in children. Neurology 72 : 968-973, 2009.
PubMed
18) Varadan B, et al : Acute hemorrhagic leukoencephalitis in a COVID-19 patient-a case report with literature review. Neuroradiology 63 : 653-661, 2021.
 
P.81 掲載の参考文献
1) Soldatos T, et al : High-resolution 3-T MR neurography of the lumbosacral plexus. Radiographics 33 : 967-987, 2013.
 
2) Chhabra A, et al : High-resolution 3T MR neurography of the brachial plexus and its branches, with emphasis on 3D imaging. AJNR Am J Neuroradiol 34 : 486-497, 2013.
PubMed
3) Hiwatashi A, et al : Evaluation of chronic inflammatory demyelinating polyneuropathy : 3D nervesheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). Eur Radiol 27 : 447-453, 2017.
PubMed
4) Hiwatashi A, et al : Lumbar plexus in patients with chronic inflammatory demyelinating polyneuropathy : Evaluation with 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). Eur J Radiol 93 : 95-99, 2017.
PubMed
5) Hiwatashi A, et al : Simultaneous MR neurography and apparent T2 mapping in brachial plexus : Evaluation of patients with chronic inflammatory demyelinating polyradiculoneuropathy. Magn Reson Imaging 55 : 112-117, 2019.
PubMed
6) Hiwatashi A, et al : Lumbar plexus in patients with chronic inflammatory demyelinating polyradiculoneuropathy : evaluation with simultaneous T2 mapping and neurography method with SHINKEI. Br J Radiol 91 : 20180501, 2018.
PubMed
7) Yamashita T, et al : Whole-body magnetic resonance neurography. N Engl J Med 361 : 538-539, 2009.
PubMed
8) Kakuda T, et al : Diffusion tensor imaging of peripheral nerve in patients with chronic inflammatory demyelinating polyradiculoneuropathy : a feasibility study. Neuroradiology 53 : 955-960, 2011.
PubMed
9) Adachi Y, et al : Brachial and lumbar plexuses in chronic inflammatory demyelinating polyradiculoneuropathy : MRI assessment including apparent diffusion coefficient. Neuroradiology 53 : 3-11, 2011.
PubMed
P.89 掲載の参考文献
1) Thompson AJ, et al : Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 17 : 162-173, 2018.
PubMed
2) Huda S, et al : Neuromyelitis optica spectrum disorders. Clin Med (Lond) 19 : 169-176, 2019.
 
3) Kira J-I : Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination : Strategies for Diagnosis and Treatment Based on the Disease Mechanism. Front Neurol 12 : 665136, 2021. (DOI : 10.3389/fneur.2021.665136)
 
4) 多発性硬化症・視神経脊髄炎診療ガイドライン 2017 (日本神経学会監, 「多発性硬化症・視神経脊髄炎診療ガイドライン」作成委員会編), 医学書院, 2017.
 
5) Gronseth GS, Ashman EJ : Practice parameter : the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review) : Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54 : 1720-1725, 2000.
 
6) 飛松省三 : ベッドサイドの臨床神経生理学, 中外医学社, 2017.
 
7) 飛松省三 : ここに気をつける! 誘発電位ナビはじめの一歩から臨床と研究のヒントまで, 南山堂, 2017.
 
8) Leocani L, et al : Multimodal evoked potentials to assess the evolution of multiple sclerosis : a longitudinal study. J Neurol Neurosurg Psychiatry 77 : 1030-1035, 2006.
PubMed
9) 黒川智美, ほか : 電気生理学的診断法. 日本臨牀 61 : 1347-1354, 2003.
Medical*Online
10) 萩原綱一, ほか : 多発性硬化症の電気生理診断学. 多発性硬化症の診断と治療 (吉良潤一編), p66-72, 新興医学出版社, 2008.
 
11) 飛松省三 : 誘発電位の利用の仕方. 診断のコツとピットフォール. MS Frontier 3 : 47-50, 2014.
 
12) Kira J, et al : Primary progressive versus relapsing remitting multiple sclerosis in Japanese patients : a combined clinical, magnetic resonance imaging and multimodality evoked potential study. J Neurol Sci 117 : 179-185, 1993.
PubMed
13) Watanabe A, et al : Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and-negative multiple sclerosis patients. J Neurol Sci 281 : 34-40, 2009.
PubMed
14) Ogata H, et al : Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol 7 : 2297-2309, 2020.
PubMed
P.96 掲載の参考文献
1) 桑原聡, ほか : ギラン・バレー症候群の電気診断. 臨床神経生理学 33 : 35-44, 2005.
Medical*Online
2) Olsson Y : Microenvironment of the peripheral nervous system under normal and pathological conditions. Crit Rev Neurobiol 5 : 265-311, 1990.
PubMed
3) Kuwabara S, et al : Sensory nerve conduction in demyelinating and axonal Guillain-Barre syndromes. Eur Neurol 51 : 196-198, 2004.
PubMed
4) Brown WF, Snow R : Patterns and severity of conduction abnormalities in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 54 : 768-774, 1991.
PubMed
5) Tamura N, et al : Superficial radial sensory nerve potentials in immune-mediated and diabetic neuropathies. Clin Neurophysiol 116 : 2330-2333, 2005.
PubMed
6) Hiraga A, et al : Recovery patterns and long term prognosis for axonal Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 76 : 719-722, 2005.
PubMed
7) Bromberg MB, Albers JW : Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders. Muscle Nerve 16 : 262-266, 1993.
PubMed
8) Kuwabara S : The blood-nerve barrier and sensory nerve conduction. Clin Neurophysiol 118 : 1901-1902, 2007.
PubMed
9) Kuwabara S, et al : Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86 : 1054-1059, 2015.
PubMed
P.103 掲載の参考文献
1) Yamamoto D, et al : Effect of local cooling on excitation-contraction coupling in myasthenic muscle : Another mechanism of ice-pack test in myasthenia gravis. Clin Neurophysiol 128 : 2309-2317, 2017.
PubMed
2) Park JY, et al : Diagnostic value of repeated ice tests in the evaluation of ptosis in myasthenia gravis. PLoS One 12 : e0177078, 2017.
PubMed
3) Fakiri MO, et al : Accuracy of the ice test in the diagnosis of myasthenia gravis in patients with ptosis. Muscle Nerve 48 : 902-904, 2013.
 
4) Marinos E, et al : Evaluating the temperature effects of ice and heat tests on ptosis due to Myasthenia Gravis. Eye (Lond) 32 : 1387-1391, 2018.
PubMed
5) Sanders DB, et al : Is the decremental pattern in Lambert-Eaton syndrome different from that in myasthenia gravis? Clin Neurophysiol 125 : 1274-1277, 2014.
PubMed
6) Maddison P, et al : Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 65 : 213-217, 1998.
PubMed
7) Ogawa G, et al : A new maneuver for repetitive nerve stimulation testing in the trapezius muscle. Muscle Nerve 47 : 668-672, 2013.
PubMed
8) Abraham A, et al : Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. Muscle Nerve 55 : 166-170, 2017.
 
9) Rubin DI, Hentschel K : Is exercise necessary with repetitive nerve stimulation in evaluating patients with suspected myasthenia gravis? Muscle Nerve 35 : 103-106, 2007.
PubMed
10) Hatanaka Y, Oh SJ : Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 37 : 572-575, 2008.
PubMed
11) Titulaer MJ, et al : Lambert-Eaton myasthenic syndrome : from clinical characteristics to therapeutic strategies. Lancet Neurol 10 : 1098-1107, 2011.
PubMed
12) Chiou-Tan FY, Gilchrist JM : Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome : Review of recent literature. Muscle Nerve 52 : 455-462, 2015.
PubMed
13) Kokubun N, et al : Reference values for voluntary and stimulated single-fibre EMG using concentric needle electrodes : a multicentre prospective study. Clin Neurophysiol 123 : 613-620, 2012.
PubMed
14) Padua L, et al : Reliability of SFEMG in diagnosing myasthenia gravis : sensitivity and specificity calculated on 100 prospective cases. Clin Neurophysiol 125 : 1270-1273, 2014.
PubMed
15) 今井富裕, 幸原伸夫 : 同芯針電極を用いた針筋電図検査. モノグラフ神経筋電気診断を基礎から学ぶ人のために (日本臨床神経生理学会 筋・末梢神経電気診断技術向上委員会, 認定委員会編), p67-73, 日本臨床神経生理学会, 2013.
 
P.109 掲載の参考文献
1) Bjornevik K, et al : Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol 77 : 58-64, 2020.
PubMed
2) Delcoigne B, et al : Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 94 : e1201-e1212, 2020.
PubMed
3) Bridel C, et al : Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. Neurology 97 : e1898-e1905, 2021.
PubMed
4) Abdelhak A, et al : Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep 8 : 14798, 2018.
PubMed
5) Watanabe M, et al : Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93 : e1299-e1311, 2019.
PubMed
6) Pietrasik S, et al : Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing-Remitting from Secondary Progressive Multiple Sclerosis. A Review. Int J Mol Sci 22 : 11887, 2021.
PubMed
7) Agah E, et al : Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis : A systematic review and meta-analysis. PLoS One 13 : e0190252, 2018.
PubMed
8) van Lierop ZY, et al : Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. Mult Scler 28 : 102-110, 2022.
PubMed
9) Calabresi PA, et al : The incidence and significance of anti-natalizumab antibodies : results from AFFIRM and SENTINEL. Neurology 69 : 1391-1403, 2007.
PubMed
10) Ellrichmann G, et al : Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol 266 : 57-67, 2019.
PubMed
11) Cohen M, et al : Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab : Results from a bicentric study. J Neurol Sci 373 : 335-338, 2017.
PubMed
12) Trewin BP, et al : Precision therapy for neuromyelitis optica spectrum disorder : A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Mult Scler Relat Disord 43 : 102175, 2020.
 
13) Kimura K, et al : Th1-CD11c+ B Cell Axis Associated with Response to Plasmapheresis in Multiple Sclerosis. Ann Neurol 90 : 595-611, 2021.
PubMed
14) Dunn N, et al : Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis. Front Immunol 11 : 583560, 2020.
 
15) Nakatsuji Y, et al : Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis. J Immunol 188 : 4858-4865, 2012.
 
P.115 掲載の参考文献
1) Wright BL, et al : Cerebrospinal fluid and lumbar puncture : a practical review. J Neurol 259 : 1530-1545, 2012.
PubMed
2) Jurynczyk M, et al : Overlapping CNS inflammatory diseases : differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 86 : 20-25, 2015.
 
3) Gross CC, et al : Classification of neurological diseases using multi-dimensional CSF analysis. Brain 144 : 2625-2634, 2021.
PubMed
4) Breiner A, et al : Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45 g/L : a systematic review. J Neurol 266 : 616-624, 2019.
 
5) Solomon AJ, et al : Misdiagnosis of multiple sclerosis : Impact of the 2017 McDonald criteria on clinical practice. Neurology 92 : 26-33, 2019.
PubMed
6) Petzold A : Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J Neuroimmunol 262 : 1-10, 2013.
PubMed
7) Magliozzi R, Cross AH : Can CSF biomarkers predict future MS disease activity and severity? Mult Scler 26 : 582-590, 2020.
PubMed
8) Matute-Blanch C, et al : Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. In : Handbook of Clinical Neurology ; Cerebrospinal Fluid in Neurologic Disorders (ed by Deisenhammer F, et al), p67-84, Elsevier BV, Amsterdam, 2017.
 
9) Kothur K, et al : CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders : A systematic review. Cytokine 77 : 227-237, 2016.
PubMed
10) Kaneko K, et al : CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS : a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 89 : 927-936, 2018.
 
11) Hirohata S, et al : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 22 : 405-413, 2012.
PubMed
12) DiSano KD, et al : Intrathecally produced CXCL13 : A predictive biomarker in multiple sclerosis. Mult Scler J Exp Transl Clin 6 : 2055217320981396, 2020.
PubMed
13) Costerus JM, et al : Technological advances and changing indications for lumbar puncture in neurological disorders. Lancet Neurol 17 : 268-278, 2018.
PubMed
14) Gaetani L, et al : CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases : Implications for Treatment. Trends Pharmacol Sci 41 : 1023-1037, 2020.
PubMed
15) Tobin WO, Pittock SJ : Autoimmune Neurology of the Central Nervous System. Continuum (Minneap Minn) 23 : 627-653, 2017.
PubMed
P.120 掲載の参考文献
1) Waters PJ, et al : Serologic diagnosis of NMO : a multicenter comparison of aquaporin-4-IgG assays. Neurology 78 : 665-671 ; discussion 669, 2012.
 
2) Lindstrom J, Einarson B : Antigenic modulation and receptor loss in experimental autoimmune myasthenia gravis. Muscle Nerve 2 : 173-179, 1979.
PubMed
3) Gambino CM, et al : Comparative Analysis of BIOCHIP Mosaic-Based Indirect Immunofluorescence with Enzyme-Linked Immunosorbent Assay for Diagnosing Myasthenia Gravis. Diagnostics (Basel) 11 : 2098, 2021.
PubMed
4) Higuchi O, et al : Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69 : 418-422, 2011.
PubMed
5) Nakane S, et al : Clinical features of autoimmune autonomic ganglionopathy and the detection of subunit-specific autoantibodies to the ganglionic acetylcholine receptor in Japanese patients. PLoS One 10 : e0118312, 2015.
 
6) Bodle CR, et al : Development of a bimolecular luminescence complementation assay for RGS : G protein interactions in cells. Anal Biochem 522 : 10-17, 2017.
PubMed
7) Eglen RM, et al : The use of AlphaScreen technology in HTS : current status. Curr Chem Genomics 1 : 2-10, 2008.
 
8) Hwang J, et al : Quantitation of low abundant soluble biomarkers using high sensitivity Single Molecule Counting technology. Methods 158 : 69-76, 2019.
PubMed
9) Tzartos SJ, Changeux JP : High affinity binding of alpha-bungarotoxin to the purified alpha-subunit and to its 27,000-dalton proteolytic peptide from Torpedo marmorata acetylcholine receptor. Requirement for sodium dodecyl sulfate. EMBO J 2 : 381-387, 1983.
 
10) Noridomi K, et al : Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications. Elife 6 : e23043, 2017.
PubMed
11) Lennon VA, et al : Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol 146 : 2245-2248, 1991.
PubMed
12) Lazaridis K, et al : Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains. J Neuroimmunol 303 : 13-21, 2017.
PubMed
P.127 掲載の参考文献
1) Collins MP, et al : Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy : executive summary. J Peripher Nerv Syst 15 : 176-184, 2010.
 
2) Ikeda S, et al : Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 90 : 988-996, 2019.
PubMed
3) Tracy JA, et al : Onion-bulb patterns predict acquired or inherited demyelinating polyneuropathy. Muscle Nerve 59 : 665-670, 2019.
PubMed
4) Oka N, et al : Two subtypes of Churg-Strauss syndrome with neuropathy : the roles of eosinophils and ANCA. Mod Rheumatol 21 : 290-295, 2011.
PubMed
5) Nishi R, et al : Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology 94 : e1726-e1737, 2020.
PubMed
6) Hafer-Macko CE, et al : Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 39 : 625-635, 1996.
PubMed
7) Yan WX, et al : P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50 : 286-292, 2001.
PubMed
8) Oka N, et al : Different profiles of onion bulb in CIDP and CMT1A in relation to extracellular matrix. Clin Neuropathol 32 : 406-412, 2013.
PubMed
9) Gaspar BL, et al : Inflammatory Myopathies. In : Myopathology : A Practical Clinico-pathological Approach to Skeletal Muscle Biopsies, p154-157, Springer, Singapore, 2019.
 
10) Isenberg DA, et al : Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol 63 : 450-458, 1986.
PubMed
11) Uruha A, et al : Sarcoplasmic MxA expression : A valuable marker of dermatomyositis. Neurology 88 : 493-500, 2017.
PubMed
12) Aouizerate J, et al : Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol Commun 2 : 154, 2014.
PubMed

II 中枢神経脱髄疾患

P.137 掲載の参考文献
1) Lassmann H, et al : Immunopathology of multiple sclerosis : report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 86 : 213-217, 1998.
 
2) Lucchinetti C : Multiple sclerosis pathology during early and late disease phases : pathogenic and clinical relevance. In : Immune Regulation and Immunotherapy in Autoimmune Disease (ed by Zhang J), p2141-2264, Springer, New York, 2007.
 
3) Prineas JW, et al : Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50 : 646-657, 2001.
PubMed
4) Kutzelnigg A, et al : Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 : 2705-2712, 2005.
PubMed
5) Frischer JM, et al : Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 78 : 710-721, 2015.
PubMed
6) Lassmann H, et al : Progressive multiple sclerosis : pathology and pathogenesis. Nat Rev Neurol 8 : 647-656, 2012.
PubMed
7) Hametner S, et al : Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 74 : 848-861, 2013.
 
8) Vercellino M, et al : Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex : correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 66 : 732-739, 2007.
PubMed
9) Lucchinetti CF, et al : Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365 : 2188-2197, 2011.
PubMed
10) Serafini B, et al : Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14 : 164-174, 2004.
PubMed
11) Magliozzi R, et al : Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130 : 1089-1104, 2007.
PubMed
12) Howell OW, et al : Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134 : 2755-2771, 2011.
PubMed
13) Reali C, et al : B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. Brain Pathol 30 : 779-793, 2020.
PubMed
14) Trapp BD, et al : Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis : a retrospective study. Lancet Neurol 17 : 870-884, 2018.
PubMed
15) Matsuoka T, et al : Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 120 : 651-660, 2010.
PubMed
16) Matsuoka T, et al : Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol 21 : 516-532, 2011.
PubMed
17) Masaki K, et al : Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica. PLoS One 8 : e72919, 2013.
PubMed
18) Masaki K : Early disruption of glial communication via connexin gap junction in multiple sclerosis, Balo's disease and neuromyelitis optica. Neuropathology 35 : 469-480, 2015.
 
19) Bar-Or A, et al : Epstein-Barr Virus in Multiple Sclerosis : Theory and Emerging Immunotherapies. Trends Mol Med 26 : 296-310, 2020.
 
20) Serafini B, et al : Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204 : 2899-2912, 2007.
 
21) Lanz TV, et al : Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM. Nature 603 : 321-327, 2022.
PubMed
P.142 掲載の参考文献
1) Reich DS, et al : Multiple Sclerosis. N Engl J Med 378 : 169-180, 2018.
PubMed
2) Walton C, et al : Rising prevalence of multiple sclerosis worldwide : Insights from the Atlas of MS, third edition. Mult Scler 26 : 1816-1821, 2020.
PubMed
3) Isobe N, et al : Continued increase of multiple sclerosis and neuromyelitis optica and the North-South gradient in Japan ; updates from the 5th nationwide survey. Multiple Sclerosis Journal 26 (3 Suppl) : 334-335, 2020.
 
4) Lublin FD, Reingold SC : Defining the clinical course of multiple sclerosis : results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 : 907-911, 1996.
PubMed
5) Lublin FD, et al : Defining the clinical course of multiple sclerosis : the 2013 revisions. Neurology 83 : 278-286, 2014.
PubMed
6) Thompson AJ, et al : Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 17 : 162-173, 2018.
PubMed
7) Scalfari A, et al : Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 85 : 67-75, 2014.
PubMed
8) Confavreux C, Vukusic S : The clinical course of multiple sclerosis. Handb Clin Neurol 122 : 343-369, 2014.
PubMed
9) Miller DH, Leary SM : Primary-progressive multiple sclerosis. Lancet Neurol 6 : 903-912, 2007.
PubMed
10) Brown JWL, et al : Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 321 : 175-187, 2019.
PubMed
11) Hauser SL, Cree BAC : Treatment of Multiple Sclerosis : A Review. Am J Med 133 : 1380-1390.e2, 2020.
 
12) Inojosa H, et al : A focus on secondary progressive multiple sclerosis (SPMS) : challenges in diagnosis and definition. J Neurol 268 : 1210-1221, 2021.
PubMed
13) Lorscheider J, et al : Defining secondary progressive multiple sclerosis. Brain 139 : 2395-2405, 2016.
PubMed
14) Freedman MS : Induction vs. escalation of therapy for relapsing Multiple Sclerosis : The evidence. Neurol Sci 29 (Suppl 2) : S250-252, 2008.
 
15) Rush CA, et al : Aggressive multiple sclerosis : proposed definition and treatment algorithm. Nat Rev Neurol 11 : 379-389, 2015.
PubMed
P.148 掲載の参考文献
1) Thompson AJ, et al : Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria. Lancet Neurol 17 : 162-173, 2018.
PubMed
2) Okuda DT, et al : Radiologically isolated syndrome : 5-year risk for an initial clinical event. PLoS One 9 : e90509, 2014.
PubMed
3) Filippi M, et al : MRI criteria for the diagnosis of multiple sclerosis : MAGNIMS consensus guidelines. Lancet Neurol 15 : 292-303, 2016.
 
4) Thaler C, et al : T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis. AJNR Am J Neuroradiol 38 : 264-269, 2017.
PubMed
5) Sati P, et al : The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis : a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol 12 : 714-722, 2016.
 
6) Rotstein D, Montalban X : Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 15 : 287-300, 2019.
PubMed
7) Brownlee WJ, et al : Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain 142 : 2276-2287, 2019.
PubMed
8) Absinta M, et al : Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI. AJNR Am J Neuroradiol 39 : 1233-1238, 2018.
PubMed
9) Saidha S, et al : Optical coherence tomography reflects brain atrophy in multiple sclerosis : A four-year study. Ann Neurol 78 : 801-813, 2015.
PubMed
10) Martinez-Lapiscina EH, et al : Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis : a cohort study. Lancet Neurol 15 : 574-584, 2016.
PubMed
11) Martinez MA, et al : Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler 21 : 550-561, 2015.
PubMed
12) Disanto G, et al : Serum Neurofilament light : A biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81 : 857-870, 2017.
 
13) Barro C, et al : Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141 : 2382-2391, 2018.
PubMed
14) Takahashi K, et al : Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis. JAMA Neurol 72 : 176-179, 2015.
PubMed
15) Magliozzi R, et al : Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol 83 : 739-755, 2018.
PubMed
16) Marastoni D, et al : CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm 8 : e1083, 2021.
PubMed
P.152 掲載の参考文献
1) Kurtzke JF : Rating neurologic impairment in multiple sclerosis : an expanded disability status scale (EDSS). Neurology 33 : 1444-1452, 1983.
PubMed
2) Cutter GR, et al : Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122 (Pt 5) : 871-882, 1999.
 
3) Rudick RA, et al : Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 15 : 984-997, 2009.
PubMed
4) Miller DM, et al : Clinical significance of the multiple sclerosis functional composite : relationship to patient-reported quality of life. Arch Neurol 57 : 1319-1324, 2000.
PubMed
5) Sumowski JF, et al : Cognition in multiple sclerosis : State of the field and priorities for the future. Neurology 90 : 278-288, 2018.
PubMed
6) Drake AS, et al : Psychometrics and normative data for the Multiple Sclerosis Functional Composite : replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 16 : 228-237, 2010.
PubMed
7) Benedict RH, Zivadinov R : Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 7 : 332-342, 2011.
PubMed
8) Niino M, et al : Apathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis. BMC Neurol 14 : 3, 2014.
PubMed
9) Niino M, et al : Validation of the Brief International Cognitive Assessment for Multiple Sclerosis in Japan. Mult Scler J Exp Transl Clin 3 : 2055217317748972, 2017.
PubMed
10) Niino M, Miyazaki Y : Cognitive impairment as one of the important non-motor symptoms in multiple sclerosis and neuromyelitis optica spectrum disorders. Clin Exp Neuroimmunol 10 : 152-160, 2019.
 
11) Rao SM, et al : Processing speed test : Validation of a self-administered, iPad-based tool for screening cognitive dysfunction in a clinic setting. Mult Scler 23 : 1929-1937, 2017.
 
12) Niino M, et al : Developing standard data of cognitive function using processing speed test in Japanese healthy volunteers and comparison to the US normative data. The 8th Joint ACTRIMS-ECTRIMS meeting. Web, September 9-12, 2020.
 
13) Litster B, et al : Screening Tools for Anxiety in People with Multiple Sclerosis : A Systematic Review. Int J MS Care 18 : 273-281, 2016.
PubMed
14) Niino M, et al : Correlation of the Symbol Digit Modalities Test with the Quality of Life and Depression in Japanese patients with Multiple Sclerosis. Mult Scler Relat Disord 57 : 103427, 2022.
PubMed
15) Rudick RA, et al : Health-related quality of life in multiple sclerosis : effects of natalizumab. Ann Neurol 62 : 335-346, 2007.
PubMed
16) Kikuchi H, et al : Impact and characteristics of quality of life in Japanese patients with multiple sclerosis. Qual Life Res 20 : 119-131, 2011.
PubMed
17) Wynia K, et al : The impact of disabilities on quality of life in people with multiple sclerosis. Mult Scler 14 : 972-980, 2008.
PubMed
P.160 掲載の参考文献
1) 多発性硬化症・視神経脊髄炎診療ガイドライン 2017 (「多発性硬化症・視神経脊髄炎診療ガイドライン」作成委員会編, 日本神経学会監), 医学書院, 2017.
 
2) University of California, San Francisco MS-EPIC Team ; Cree BAC, et al : Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 80 : 499-510, 2016.
 
3) Coret F, et al : Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. Mult Scler J Exp Transl Clin 4 : 2055217318783347, 2018.
PubMed
4) Tremlett H, et al : Natural history of secondary-progressive multiple sclerosis. Mult Scler 14 : 314-324, 2008.
PubMed
5) Brown JWL, et al : Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 321 : 175-187, 2019.
PubMed
6) He A, et al : Timing of high-efficacy therapy for multiple sclerosis : a retrospective observational cohort study. Lancet Neurol 19 : 307-316, 2020.
 
7) Rotstein D, Montalban X : Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 15 : 287-300, 2019.
PubMed
8) Vukusic S, Confavreux C : Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 206 : 135-137, 2003.
PubMed
9) Malpas CB, et al : Early clinical markers of aggressive multiple sclerosis. Brain 143 : 1400-1413, 2020.
PubMed
10) Lebrun-Frenay C, et al : Radiologically Isolated Syndrome : 10-Year Risk Estimate of a Clinical Event. Ann Neurol 88 : 407-417, 2020.
PubMed
11) Brownlee WJ, et al : Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain 142 : 2276-2287, 2019.
PubMed
12) Chung KK, et al : A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. Ann Neurol 87 : 63-74, 2020.
PubMed
13) Tintore M, et al : Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology 97 : e1641-e1652, 2021.
PubMed
14) Kalincik T, et al : Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology 96 : e783-e797, 2021.
 
15) Spelman T, et al : Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis : Data From 2 Different National Strategies. JAMA Neurol 78 : 1197-1204, 2021.
PubMed
16) Kappos L, et al : Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND) : a double-blind, randomised, phase 3 study. Lancet 391 : 1263-1273, 2018.
PubMed
17) Hauser SL, et al : Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 383 : 546-557, 2020.
PubMed
P.166 掲載の参考文献
1) Li R, et al : Reassessing B cell contributions in multiple sclerosis. Nat Immunol 19 : 696-707, 2018.
 
2) Bar-Or A, Li R : Cellular immunology of relapsing multiple sclerosis : interactions, checks, and balances. Lancet Neurol 20 : 470-483, 2021.
 
3) Comi G, et al : Role of B Cells in Multiple Sclerosis and Related Disorders. Ann Neurol 89 : 13-23, 2021.
 
4) Shinoda K, et al : Cellular immune profiling pre- and post-aCD20 therapy points to differential effects on CD4+ and CD8+ T cells and implicates CD20-expressing CD8+ T cells in MS disease activity. Presented at ECTRIMS 189, 2021.
 
5) Bar-Or A, et al : Rituximab in relapsing-remitting multiple sclerosis : a 72-week, open-label, phase I trial. Ann Neurol 63 : 395-400, 2008.
 
6) Hauser SL, et al : B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358 : 676-688, 2008.
PubMed
7) Kappos L, et al : Ocrelizumab in relapsing-remitting multiple sclerosis : a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378 : 1779-1787, 2011.
PubMed
8) Hauser SL, et al : Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 376 : 221-234, 2017.
PubMed
9) Hauser SL, et al : Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 383 : 546-557, 2020.
PubMed
10) Kira JI, et al : Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia : Phase 2 APOLITOS study. Mult Scler, 2021. (DOI : 10.1177/13524585211055934)
 
11) Bar-Or A, et al : Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis : APLIOS, a randomized phase-2 study. Mult Scler, 2021. (DOI : 10.1177/13524585211044479)
 
12) Hawker K, et al : Rituximab in patients with primary progressive multiple sclerosis : results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66 : 460-471, 2009.
PubMed
13) Montalban X, et al : Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 : 209-220, 2017.
PubMed
14) Wolinsky JS, et al : Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial : 6.5-study year follow-up data. Presented at ECTRIMS 159, 2019.
 
15) de Seze J, et al : Effect of ofatumumab on serum immunoglobulin levels and infection risk in relapsing multiple sclerosis patients from the phase 3 ASCLEPIOS I and II trials. Presented at the 6th Congress of the European Academy of Neurology ; LB82.
 
16) Cross AH, et al : Outcomes of COVID-19 in patients with relapsing multiple sclerosis receiving ofatumumab : Data from the ALITHIOS study and post marketing surveillance. Presented at ECTRIMS p982, 2021.
 
17) Sormani MP, et al : Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol 89 : 780-789, 2021.
PubMed
18) National Multiple Sclerosis Society : COVID-19 Vaccine Guidance for People Living with MS, updated on December 17, 2021. [https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance]
 
P.171 掲載の参考文献
1) Bogosian A, et al : Multiple challenges for people after transitioning to secondary progressive multiple sclerosis : a qualitative study. BMJ Open 9 : e026421, 2019.
PubMed
2) Manouchehrinia A, et al : Predicting risk of secondary progression in multiple sclerosis : A nomogram. Mult Scler 25 : 1102-1112, 2019.
PubMed
3) Houzen H, et al : Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan. Eur J Neurol 25 : 334-339, 2018.
PubMed
4) Iaffaldano P, et al : Transition to secondary progression in relapsing-onset multiple sclerosis : Definitions and risk factors. Mult Scler 27 : 430-438, 2021.
PubMed
5) Lublin FD, et al : Defining the clinical course of multiple sclerosis : the 2013 revisions. Neurology 83 : 278-286, 2014.
PubMed
6) Kappos L, et al : Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler 24 : 963-973, 2018.
 
7) University of California, San Francisco MS-EPIC Team ; Cree BAC, et al : Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 85 : 653-666, 2019.
PubMed
8) Larochelle C, et al : Secondary Progression in Multiple Sclerosis : Neuronal Exhaustion or Distinct Pathology? Trends Neurosci 39 : 325-339, 2016.
PubMed
9) Kappos L, et al : Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND) : a double-blind, randomised, phase 3 study. Lancet 391 : 1263-1273, 2018.
PubMed
10) Benedict RHB, et al : Siponimod and Cognition in Secondary Progressive Multiple Sclerosis : EXPAND Secondary Analyses. Neurology 96 : e376-e386, 2021.
PubMed
11) Hauser SL, et al : Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 383 : 546-557, 2020.
PubMed
12) Cadavid D, et al : The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler 23 : 94-105, 2017.
PubMed
13) Eshaghi A, et al : Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 83 : 210-222, 2018.
PubMed
14) Colato E, et al : Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. J Neurol Neurosurg Psychiatry 92 : 995-1006, 2021.
PubMed
15) Absinta M, et al : Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 85 : 18-28, 2015.
PubMed
16) Makshakov G, et al : Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis. Neurol Res Int 2017 : 8652463, 2017.
PubMed
17) Barro C, et al : Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141 : 2382-2391, 2018.
PubMed
18) Bhan A, et al : Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler 24 : 1301-1307, 2018.
PubMed
19) Abdelhak A, et al : Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep 8 : 14798, 2018.
PubMed
20) Bsteh G, et al : Peripapillary retinal nerve fibre layer thinning rate as a biomarker discriminating stable and progressing relapsing-remitting multiple sclerosis. Eur J Neurol 26 : 865-871, 2019.
PubMed
21) Bsteh G, et al : Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis. Mult Scler 27 : 684-694, 2021.
PubMed
P.177 掲載の参考文献
1) Ontaneda D, et al : Progressive multiple sclerosis : prospects for disease therapy, repair, and restoration of function. Lancet 389 : 1357-1366, 2017.
PubMed
2) 多発性硬化症・視神経脊髄炎診療ガイドライン 2017 (日本神経学会監), p116-117, 医学書院, 2017.
 
3) Miller DH, et al : Primary-progressive multiple sclerosis. Lancet Neurol 6 : 903-912, 2007.
PubMed
4) Confavreux C, et al : Relapses and progression of disability in multiple sclerosis. N Engl J Med 343 : 1430-1438, 2000.
PubMed
5) 医療用医薬品 : メーゼント, 添付文書. [https://pins.japic.or.jp/pdf/newPINS/00068876.pdf]
 
6) Ocrelizumab accessdata.fda.gov. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf]
 
7) How does ocrevus work. [https://getonwithlife.co.nz/about-ocrevus/how-does-ocrevus-work/]
 
8) IBM Micromedex. Mayo Clinic. Ocrelizumab (Intravenous Route). [https://www.mayoclinic.org/drugs-supplements/ocrelizumab-intravenous-route/side-effects/drg-20406139?p=1]
 
9) Montalban X, et al : Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376 : 209-220, 2017.
PubMed
10) Ocrelizumab and PML. [https://www.ocrelizumabinfo.com/content/dam/gene/ocrelizumabinfo/pdfs/progressive-multifocal-leukoencephalopathy.pdf]
 
11) Patel A, et al : Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol 78 : 736-740, 2021.
 
12) Florou D, et al : Anti-CD20 Agents for Multiple Sclerosis : Spotlight on Ocrelizumab and Ofatumumab. Brain Sci 10 : 758, 2020. (DOI : 10.3390/brainsci10100758)
 
13) Dolgin E : BTK blockers make headway in multiple sclerosis. Nat Biotechnol 39 : 3-5, 2021.
PubMed
14) 医療用医薬品 : カルケンス, 添付文書. [https://pins.japic.or.jp/pdf/newPINS/00069234.pdf]
 
15) 多発性硬化症・視神経脊髄炎診療ガイドライン 2017 (日本神経学会監), p286-288, 医学書院, 2017.
 
P.181 掲載の参考文献
1) Jarius S, et al : The first Japanese report on neuromyelitis optica rediscovered : acute bilateral blindness, tetraparesis and respiratory insufficiency in a 35-year-old man (1891). J Neurol Sci 395 : 121-125, 2018.
 
2) Jarius S, Wildemann B : The history of neuromyelitis optica. J Neuroinflammation 10 : 8, 2013.
PubMed
3) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
PubMed
4) Lennon VA, et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473-477, 2005.
 
5) Wingerchuk DM, et al : The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 : 1107-1114, 1999.
PubMed
6) Lucchinetti CF, et al : A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125 : 1450-1461, 2002.
 
7) Nagelhus EA, et al : Aquaporin-4 in the central nervous system : cellular and subcellular distribution and coexpression with KIR4.1. Neuroscience 129 : 905-913, 2004.
PubMed
8) Saadoun S, et al : Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133 : 349-361, 2010.
PubMed
9) Soltys J, et al : Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica. J Clin Invest 129 : 2000-2013, 2019.
PubMed
10) Zhang H, Verkman AS : Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 123 : 2306-2316, 2013.
PubMed
11) Hinson SR, et al : Molecular outcomes of neuromyelitis optica (NMO) -IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 109 : 1245-1250, 2012.
PubMed
12) Guo Y, et al : Spectrum of sublytic astrocytopathy in neuromyelitis optica. Brain, awab394, 2021. (DOI : 10.1093/brain/awab394)
 
13) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108 : 3701-3706, 2011.
PubMed
14) Kimura A, Kishimoto T : IL-6 : regulator of Treg/Th17 balance. Eur J Immunol 40 : 1830-1835, 2010.
PubMed
15) Kaplin AI, et al : IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115 : 2731-2741, 2005.
PubMed
16) Pittock SJ, et al : Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 614-625, 2019.
PubMed
17) Yamamura T, et al : Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 2114-2124, 2019.
PubMed
18) Cree BAC, et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019.
PubMed
19) Nishiyama S, et al : A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 72 : 1960-1961, 2009.
 
20) Roemer SF, et al : Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130 : 1194-1205, 2007.
PubMed
21) Yanagawa K, et al : Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 73 : 1628-1637, 2009.
PubMed
22) Hokari M, et al : Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol 79 : 605-624, 2016.
PubMed
23) Ohara S, et al : Neuromyelitis optica spectrum disorder with massive basal ganglia involvement : a case report. BMC Neurol 19 : 351, 2019.
 
24) Saji E, et al : Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol 73 : 65-76, 2013.
PubMed
25) Guo Y, et al : Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathol 133 : 597-612, 2017.
PubMed
26) Kappos L, et al : Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol 77 : 1132-1140, 2020.
 
27) Lassmann H : Multiple Sclerosis Pathology. Cold Spring Harb Perspect Med 8 : a028936, 2018.
PubMed
28) Kawachi I, Lassman H : Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 88 : 137-145, 2017.
 
29) Thompson AJ, et al : Multiple sclerosis. Lancet 391 : 1622-1636, 2018.
PubMed
30) Ransohoff RM, et al : Multiple sclerosis-a quiet revolution. Nat Rev Neurol 11 : 134-142, 2015.
PubMed
31) 河内泉, 西澤正豊 : アクアポリンと視神経脊髄炎. Clinical Neuroscience 33 : 83-87, 2015.
 
P.188 掲載の参考文献
1) Lennon VA, et al : A serum autoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
PubMed
2) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
3) Hor JY, et al : Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol 11 : 501, 2020.
PubMed
4) 高橋利幸, ほか : M23抗原を用いたAQP4Ab ELISA「コスミック」II キットの基礎的・臨床的検討. 医学と薬学 73 : 1297-1300, 2016.
Medical*Online
5) Takano R, et al : Astrocytic damage is far more severe than demyelination in NMO : a clinical CSF biomarker study. Neurology 75 : 208-216, 2010.
PubMed
6) Salama S, Levy M : Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder. Mult Scler 1352458521994259, 2021.
PubMed
7) Kim HJ, et al : MRI characteristics of neuromyelitis optica spectrum disorder : an international update. Neurology 84 : 1165-1173, 2015.
PubMed
8) Oertel FC, et al : Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurol Neuroimmunol Neuroinflamm 8 : 2021.
PubMed
9) Weinshenker BG, et al : NMO-IgG : a specific biomarker for neuromyelitis optica. Dis Markers 22 : 197-206, 2006.
PubMed
10) Kanamori Y, et al : Pain in neuromyelitis optica and its effect on quality of life : a cross-sectional study. Neurology 77 : 652-658, 2011.
PubMed
11) Ayzenberg I, et al : Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder : A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients. Neurol Neuroimmunol Neuroinflamm 8 : e985, 2021.
PubMed
12) Seok JM, et al : Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life. PLoS One 12 : e0177230, 2017.
PubMed
13) Saji E, et al : Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol 73 : 65-76, 2013.
PubMed
14) Liu Y, et al : Structural MRI substrates of cognitive impairment in neuromyelitis optica. Neurology 85 : 1491-1499, 2015.
PubMed
P.195 掲載の参考文献
1) Jarius S, et al : Neuromyelitis optica. Nat Rev Dis Primers 6 : 85, 2020.
PubMed
2) 多発性硬化症・視神経脊髄炎診療ガイドライン 2017 (日本神経学会監, 「多発性硬化症・視神経脊髄炎診療ガイドライン」作成委員会編), 医学書院, 2017.
 
3) Yamasaki R, et al : Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler 22 : 1337-1348, 2016.
PubMed
4) Watanabe S, et al : Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13 : 128-132, 2007.
PubMed
5) Fujihara K : Neuromyelitis optica spectrum disorders : still evolving and broadening. Curr Opin Neurol 32 : 385-394, 2019.
PubMed
6) Mimura O, et al : Intravenous immunoglobulin treatment for steroid-resistant optic neuritis : a multicenter, double-blind, randomized, controlled phase III study. Jpn J Ophthalmol 65 : 122-132, 2021.
PubMed
7) Takai Y, et al : Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord 49 : 102750, 2021.
PubMed
8) Mao-Draayer Y, et al : Neuromyelitis optica spectrum disorders and pregnancy : therapeutic considerations. Nat Rev Neurol 16 : 154-170, 2020.
PubMed
9) Nikoo Z, et al : Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder : a randomized clinical trial. J Neurol 264 : 2003-2009, 2017.
PubMed
10) Costanzi C, et al : Azathioprine : tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77 : 659-666, 2011.
PubMed
11) Torres J, et al : Analysis of the treatment of neuromyelitis optica. J Neurol Sci 351 : 31-35, 2015.
PubMed
12) Huh SY, et al : Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 71 : 1372-1378, 2014.
PubMed
13) Kojima M, et al : Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody. Mult Scler Relat Disord 39 : 101907, 2019.
PubMed
14) Kageyama T, et al : Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 260 : 627-634, 2013.
PubMed
15) Zhang C, et al : Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO) : an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19 : 391-401, 2020.
 
P.199 掲載の参考文献
1) Fujihara K, et al : Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3 : 58-73, 2012.
 
2) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
3) Kuroda H, Fujihara K : [Current Status and Prospects of Complement-Targeting Therapy for Neuromyelitis Optica]. Brain Nerve 71 : 573-580, 2019.
PubMed
4) Hinson SR, et al : Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69 : 2221-2231, 2007.
PubMed
5) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108 : 3701-3706, 2011.
PubMed
6) Cree BA, et al : An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 : 1270-1272, 2005.
PubMed
7) Annovazzi P, et al : Rituximab in the treatment of Neuromyelitis optica : a multicentre Italian observational study. J Neurol 263 : 1727-1735, 2016.
PubMed
8) Pittock SJ, et al : Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 614-625, 2019.
PubMed
9) Cree BAC, et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019.
PubMed
10) Yamamura T, et al : Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 2114-2124, 2019.
PubMed
11) Miyata T, et al : Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 330 : 249-255, 1994.
PubMed
12) Hillmen P, et al : Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350 : 552-559, 2004.
PubMed
13) Legendre CM, et al : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368 : 2169-2181, 2013.
PubMed
14) Howard JF, et al : Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN) : a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16 : 976-986, 2017.
PubMed
15) Pittock SJ, et al : Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders : an open-label pilot study. Lancet Neurol 12 : 554-562, 2013.
PubMed
16) Wingerchuk DM, et al : Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol 89 : 1088-1098, 2021.
PubMed
17) Pittock SJ, et al : Eculizumab monotherapy for NMOSD : Data from PREVENT and its open-label extension. Mult Scler 28 : 480-486, 2022.
PubMed
18) Nishimura J, et al : Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370 : 632-639, 2014.
PubMed
19) McKeage K : Ravulizumab : First Global Approval. Drugs 79 : 347-352, 2019.
PubMed
P.205 掲載の参考文献
1) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
2) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 108 : 3701-3706, 2011.
PubMed
3) Araki M, et al : Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica : a pilot study. Neurology 82 : 1302-1306, 2014.
PubMed
4) Yamamura T, et al : Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381 : 2114-2124, 2019.
PubMed
5) Traboulsee A, et al : Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder : a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19 : 402-412, 2020.
 
6) 竹内勤 : RAにおける抗サイトカイン療法. Drug Delivery System 19 : 95-102, 2004.
 
7) Sellner J, et al : Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders : Implications from immunology, the FcRn pathway and clinical experience. Drug Discov Today 26 : 1591-1601, 2021.
PubMed
8) Fujihara K, et al : Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm 7 : e841, 2020.
PubMed
9) エンスプリング皮下注120 mg シリンジ添付文書, 中外製薬株式会社, 2022年1月改訂 (第4版).
 
10) エンスプリング皮下注120 mg シリンジ適正使用ガイド, 中外製薬株式会社.
 
P.210 掲載の参考文献
1) Pittock SJ, et al : Hope for patients with neuromyelitis optica spectrum disorders-from mechanisms to trials. Nat Rev Neurol 17 : 759-773, 2021.
PubMed
2) Nakamura M, et al : An autopsied case of neuromyelitis optica with a large cavitary cerebral lesion. Mult Scler 11 : 735-738, 2005.
PubMed
3) Takeshita Y, et al : Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 4 : e311, 2017.
PubMed
4) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108 : 3701-3706, 2011.
PubMed
5) Kowarik MC, et al : CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol 4 : 369-380, 2017.
PubMed
6) Nishiyama S, et al : A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 72 : 1960-1961, 2009.
 
7) Imamura H, et al : [Trial of rituximab in three patients with neuromyelitis optica]. Rinsho Shinkeigaku 49 : 457-462, 2009.
PubMed
8) Tahara M, et al : Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study) : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19 : 298-306, 2020.
 
9) Cree BAC, et al : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum) : a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394 : 1352-1363, 2019.
PubMed
10) Tahara M, et al : Compassionate open-label use of rituximab following a randomized clinical trial against neuromyelitis optica (RIN-2 study) : B cell monitoring-based administration. Mult Scler Relat Disord 60 : 103730, 2022. (DOI : https://doi.org/10.1016/j.msard.2022.103730)
 
11) Cree BA, et al : Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult Scler 27 : 2052-2061, 2021.
 
12) Rensel M, et al : Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder : Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for > 4 years in the N-MOmentum trial. Mult Scler, 2021. (DOI : 10.1177/13524585211047223)
 
13) Marignier R, et al : Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm 8 : e978, 2021.
 
14) Aktas O, et al : Serum Glial Fibrillary Acidic Protein : A Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol 89 : 895-910, 2021.
PubMed
15) Flanagan EP, et al : Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult Scler Relat Disord 57 : 103352, 2022.
 
16) Louapre C, et al : Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 93 : 24-31, 2022.
 
P.217 掲載の参考文献
1) 藤盛寿一, 中島一郎 : 抗MOG抗体関連疾患. BRAIN and NERVE 73 : 483-488, 2021.
 
2) Johns TG, Bernard CC : The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 72 : 1-9, 1999.
PubMed
3) Sato DK, et al : Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82 : 474-481, 2014.
PubMed
4) Ramanathan S, et al : Anti-MOG antibody : The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 15 : 307-324, 2016.
PubMed
5) Kaneko K, et al : CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS : a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 89 : 927-936, 2018.
 
6) Dos Passos GR, et al : MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis : Lessons Learned From Neuromyelitis Optica Spectrum Disorder. Front Neurol 9 : 217, 2018.
PubMed
7) Akaishi T, et al : Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol 299 : 152-157, 2016.
PubMed
8) Kitley J, et al : Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies : a comparative study. JAMA Neurol 71 : 276-283, 2014.
PubMed
9) Krupp LB, et al : International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions. Mult Scler 19 : 1261-1267, 2013.
 
10) Armangue T, et al : Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies : a multicentre observational study. Lancet Neurol 19 : 234-246, 2020.
 
11) Ogawa R, et al : MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4 : e322, 2017.
PubMed
12) Budhram A, et al : Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES) : characterization of a distinct clinico-radiographic syndrome. J Neurol 266 : 2481-2487, 2019.
PubMed
13) Ikeda T, et al : The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies : A case report. J Neurol Sci 392 : 113-115, 2018.
PubMed
14) Titulaer MJ, et al : Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 75 : 411-428, 2014.
PubMed
15) Fujimori J, et al : Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry 88 : 534-536, 2017.
 
16) Banks SA, et al : Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry 92 : 384-390, 2021.
 
17) Kunchok A, et al : Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)? Neurology 94 : 85-88, 2020.
PubMed
18) Jarius S, et al : MOG-IgG in NMO and related disorders : a multicenter study of 50 patients. Part 2 : Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13 : 280, 2016.
PubMed
19) Ramanathan S, et al : Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89 : 127-137, 2018.
PubMed
20) Bruijstens AL, et al : E.U. paediatric MOG consortium consensus : Part 1-Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29 : 2-13, 2020.
PubMed
21) de Mol CL, et al : The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler 26 : 806-814, 2020.
PubMed
22) Cobo-Calvo A, et al : Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Ann Neurol 89 : 30-41, 2021.
PubMed
23) Lopez-Chiriboga AS, et al : Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder. JAMA Neurol 77 : 1575-1577, 2020.
PubMed
P.224 掲載の参考文献
1) Lucchinetti CF, et al : Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131 : 1759-1775, 2008.
PubMed
2) Altintas A, et al : Clinical and radiological characteristics of tumefactive demyelinating lesions : follow-up study. Mult Scler 18 : 1448-1453, 2012.
PubMed
3) 清水優子 : Tumefactive Demyelinating Disease. MS Frontier 2 : 45-48, 2013.
Medical*Online
4) Kobayashi M, et al : Gadolinium enhancement patterns of tumefactive demyelinating lesions : correlations with brain biopsy findings and pathophysiology. J Neurol 261 : 1902-1910, 2014.
PubMed
5) Masdeu JC, et al : Multiple sclerosis--when and how to image. American College of Radiology. ACR Appropriateness Criteria. Radiology 215 (Suppl) : 547-562, 2000.
PubMed
6) Cha S, et al : Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 22 : 1109-1116, 2001.
PubMed
7) Given CA, et al : The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol 182 : 195-199, 2004.
PubMed
8) Schiepers C, et al : Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler 3 : 8-17, 1997.
PubMed
9) Visser F, et al : Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 79 : 2000-2003, 2012.
PubMed
10) Pilz G, et al : Tumefactive MS lesions under fingolimod : a case report and literature review. Neurology 81 : 1654-1658, 2013.
PubMed
11) Jander S, et al : Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 18 : 1650-1652, 2012.
PubMed
12) Lapucci C, et al : Different MRI patterns in MS worsening after stopping fingolimod. Neurol Neuroimmunol Neuroinflamm 6 : e566, 2019.
PubMed
13) Croteau D, et al : Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation. Mult Scler 27 : 903-912, 2021.
PubMed
14) Balo J : Encephalitis periaxialis concentrica. Arch NeurPsych 19 : 242-264, 1928.
 
P.227 掲載の参考文献
1) Stuve O, Zamvil SS : Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis. Curr Opin Neurol 12 : 395-401, 1999.
PubMed
2) Albert LJ, Inman RD : Molecular mimicry and autoimmunity. N Engl J Med 341 : 2068-2074, 1999.
PubMed
3) Jorens PG, et al : Encephalomyelitis-associated antimyelin autoreactivity induced by streptococcal exotoxins. Neurology 54 : 1433-1441, 2000.
PubMed
4) Tenembaum S, et al : Acute disseminated encephalomyelitis. Neurology 68 : S23-36, 2007.
PubMed
5) Paterson RW, et al : The emerging spectrum of COVID-19 neurology : clinical, radiological and laboratory findings. Brain 143 : 3104-3120, 2020.
PubMed
6) Baxter R, et al : Acute Demyelinating Events Following Vaccines : A Case-Centered Analysis. Clin Infect Dis 63 : 1456-1462, 2016.
PubMed
7) Yamaguchi Y, et al : A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 87 : 2006-2015, 2016.
PubMed
8) Cole J, et al : Acute Disseminated Encephalomyelitis in Children : An Updated Review Based on Current Diagnostic Criteria. Pediatr Neurol 100 : 26-34, 2019.
PubMed
9) Lopez-Chiriboga AS, et al : Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol 75 : 1355-1363, 2018.
PubMed
10) Duignan S, et al : Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 60 : 958-962, 2018.
PubMed
11) Callen DJ, et al : Role of MRI in the differentiation of ADEM from MS in children. Neurology 72 : 968-973, 2009.
PubMed
12) Pavone P, et al : Acute disseminated encephalomyelitis : a long-term prospective study and meta-analysis. Neuropediatrics 41 : 246-255, 2010.
PubMed
13) Krupp LB, et al : International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders : revisions to the 2007 definitions. Mult Scler 19 : 1261-1267, 2013.
 
14) Brenton JN, Banwell BL : Therapeutic Approach to the Management of Pediatric Demyelinating Disease : Multiple Sclerosis and Acute Disseminated Encephalomyelitis. Neurotherapeutics 13 : 84-95, 2016.
 
15) de Mol CL, et al : Incidence and outcome of acquired demyelinating syndromes in Dutch children : update of a nationwide and prospective study. J Neurol 265 : 1310-1319, 2018.
PubMed
P.232 掲載の参考文献
1) Langer-Gould A, et al : Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 : 375-381, 2005.
 
2) Polman CH, et al : A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 : 899-910, 2006.
PubMed
3) Plavina T, et al : Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76 : 802-812, 2014.
 
4) Ryerson LZ, et al : Natalizumab Extended Interval Dosing (EID) is Associated with a Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Compared with Every-4-week (Q4W) Dosing : Updated Analysis of the TOUCH Prescribing Program Database (4419). Neurology 96 (15 Suppl) : 4419, 2021.
 
5) Scarpazza C, et al : Early diagnosis of progressive multifocal leucoencephalopathy : longitudinal lesion evolution. J Neurol Neurosurg Psychiatry 90 : 261-267, 2019.
PubMed
6) Alleg M, et al : Progressive multifocal leukoencephalopathy : MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML. Eur Radiol 31 : 2944-2955, 2021.
PubMed
7) Landi D, et al : No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88 : 1144-1152, 2017.
PubMed
8) Clifford DB, et al : Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis : lessons from 28 cases. Lancet Neurol 9 : 438-446, 2010.
PubMed
9) Himedan M, et al : Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment. J Investig Med High Impact Case Rep 5 : 2324709617734248, 2017.
 
10) Stefoski D, et al : Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol 6 : 923-931, 2019.
PubMed
11) Cettomai D, et al : Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 66 : 255-258, 2009.
PubMed
12) Kappos L, et al : Natalizumab treatment for multiple sclerosis : updated recommendations for patient selection and monitoring. Lancet Neurol 10 : 745-758, 2011.
PubMed
13) Nakahara J, et al : Three cases of non-carryover fingolimod-PML : Is the risk in Japan increased? Neurol Neuroimmunol Neuroinflamm 6 : e559, 2019.
PubMed
14) Watanabe M, et al : Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod. J Neuroinflammation 17 : 206, 2020.
PubMed
15) Berger JR, et al : Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90 : e1815-e1821, 2018.
PubMed
16) Nishiyama S, et al : Fingolimod-associated PML with mild IRIS in MS : A clinicopathologic study. Neurol Neuroimmunol Neuroinflamm 5 : e415, 2018.
 
17) Berger JR : Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12 : 59-63, 2017.
PubMed
18) Jordan AL, et al : Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler. 28 : 7-15, 2022.
PubMed
19) Gomez-Cibeira E, et al : Eculizumab-related progressive multifocal leukoencephalopathy. Neurology 86 : 399-400, 2016.
PubMed
20) Anada M, et al : Progressive Multifocal Leukoencephalopathy during Tocilizumab Treatment for Rheumatoid Arthritis. Intern Med 59 : 2053-2059, 2020.
PubMed

III 末梢神経脱髄疾患

P.239 掲載の参考文献
1) van Doorn PA, et al : Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 7 : 939-950, 2008.
PubMed
2) Doets AY, et al : Regional variation of Guillain-Barre syndrome. Brain 141 : 2866-2877, 2018.
PubMed
3) ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013 (日本神経学会監), 南江堂, 2013.
 
4) Leonhard SE, et al : Antecedent infections in Guillain-Barre syndrome in endemic areas of arbovirus transmission : A multinational case-control study. J Peripher Nerv Syst 26 : 449-460, 2021.
PubMed
5) Asbury AK, Cornblath DR : Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 27 (Suppl) : S21-24, 1990.
 
6) Sejvar JJ, et al : Guillain-Barre syndrome and Fisher syndrome : case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29 : 599-612, 2011.
PubMed
7) Leonhard SE, et al : Diagnosis and management of Guillain-Barre syndrome in ten steps. Nat Rev Neurol 15 : 671-683, 2019.
PubMed
8) Yuki N, et al : Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49 : 712-720, 2001.
PubMed
9) Kusunoki S, et al : Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 39 : 424-431, 1996.
PubMed
10) Chiba A, et al : Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome : clinical and immunohistochemical studies. Neurology 43 : 1911-1917, 1993.
PubMed
11) Kaida K, et al : Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 56 : 567-571, 2004.
PubMed
12) Morikawa M, et al : Serological study using glycoarray for detecting antibodies to glycolipids and glycolipid complexes in immune-mediated neuropathies. J Neuroimmunol 301 : 35-40, 2016.
PubMed
13) Walgaard C, et al : Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis (SID-GBS) : a double-blind, randomised, placebo-controlled trial. Lancet Neurol 20 : 275-283, 2021.
PubMed
14) Misawa S, et al : Safety and efficacy of eculizumab in Guillain-Barre syndrome : a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 17 : 519-529, 2018.
PubMed
15) Wang Y, et al : IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barre syndrome. Exp Neurol 291 : 134-140, 2017.
 
16) Walgaard C, et al : Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann Neurol 67 : 781-787, 2010.
PubMed
17) Walgaard C, et al : Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 76 : 968-975, 2011.
PubMed
18) Kuitwaard K, et al : Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol 66 : 597-603, 2009.
PubMed
19) Yamagishi Y, et al : Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 91 : 1339-1342, 2020.
PubMed
20) Martin-Aguilar L, et al : Serum neurofilament light chain predicts long-term prognosis in Guillain-Barre syndrome patients. J Neurol Neurosurg Psychiatry, 2020. (DOI : 10.1136/jnnp-2020-323899)
 
21) Kusunoki S, et al : Antiglycolipid antibodies in Guillain-Barre and Fisher syndromes : discovery, current status and future perspective. J Neurol Neurosurg Psychiatry 92 : 311-318, 2021.
PubMed
P.245 掲載の参考文献
1) Fisher M : An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 255 : 57-65, 1956.
PubMed
2) Ilyas AA, et al : Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann Neurol 23 : 440-447, 1988.
 
3) Chiba A, et al : Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome : clinical and immunohistochemical studies. Neurology 43 : 1911-1917, 1993.
PubMed
4) 楠進, ほか : GBS疫学調査研究グループ. GBS疫学調査 : 本邦における脱髄型, 軸索型の頻度および臨床的特徴. 平成23年免疫性神経疾患に関する調査研究総括・分担研究報告書, p151-153, 2012.
 
5) Mori M, et al : Clinical features and prognosis of Miller Fisher syndrome. Neurology 56 : 1104-1106, 2001.
PubMed
6) Koga M, et al : Antecedent infections in Fisher syndrome : sources of variation in clinical characteristics. J Neurol 266 : 1655-1662, 2019.
PubMed
7) Chiba A, et al : Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 745 : 32-36, 1997.
PubMed
8) Kusunoki S, et al : Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 22 : 1071-1074, 1999.
PubMed
9) Ito M, et al : Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum : clinical analysis of 581 cases. J Neurol 255 : 674-682, 2008.
 
10) Kuwabara S, et al : Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Ann Neurol 45 : 533-536, 1999.
PubMed
11) Kaida K, et al : Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 56 : 567-571, 2004.
PubMed
12) Uchibori A, et al : Ca2+ -dependent anti-GQ1b antibody in GQ1b-seronegative Fisher syndrome and related disorders. J Neuroimmunol 298 : 172-177, 2016.
 
13) Uchibori A : Anti-GQ1b antibody : Recent topics. Clin Exp Neuroimmunol 12 : 158- 164, 2021.
 
14) Yoshikawa K, et al : Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases. Neurol Neuroimmunol Neuroinflamm 5 : e501, 2018.
PubMed
15) 内堀歩, ほか : Ca2+依存性GQ1b抗体陽性症例の臨床像. 末梢神経 32 : 125-130, 2021.
Medical*Online
P.251 掲載の参考文献
1) Dyck PJ, et al : Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50 : 621-637, 1975.
PubMed
2) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41 : 617-618, 1991.
 
3) Joint Task Force of the EFNS and the PNS ; European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 15 : 1-9, 2010.
 
4) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26 : 242-268, 2021.
PubMed
5) Katz JS, et al : Distal acquired demyelinating symmetric neuropathy. Neurology 54 : 615-620, 2000.
PubMed
6) Lewis RA, et al : Multifocal demyelinating neuropathy with persistent conduction block. Neurology 32 : 958-964, 1982.
PubMed
7) Shibuya K, et al : Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 77 : 333-337, 2015.
PubMed
8) Vlam L, et al : Multifocal motor neuropathy : diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 8 : 48-58, 2011.
PubMed
9) Thomas PK, et al : Focal upper limb demyelinating neuropathy. Brain 119 (Pt 3) : 765-774, 1996.
 
10) Doneddu PE, et al : Atypical CIDP : diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry 90 : 125-132, 2019.
PubMed
11) Kuwabara S, et al : Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86 : 1054-1059, 2015.
PubMed
12) Allen JA, Lewis RA : CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 85 : 498-504, 2015.
PubMed
13) Querol L, et al : Autoantibodies in chronic inflammatory neuropathies : diagnostic and therapeutic implications. Nat Rev Neurol 13 : 533-547, 2017.
PubMed
14) Koike H, et al : Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry 88 : 465-473, 2017.
PubMed
15) Lozeron P, et al : Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 91 : e143-e152, 2018.
PubMed
P.257 掲載の参考文献
1) Dyck PJ, et al : Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50 : 621-637, 1975.
PubMed
2) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26 : 242-268, 2021./Eur J Neurol 28 : 3556-3583, 2021.
 
3) Dyck PJ, et al : Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11 : 136-141, 1982.
PubMed
4) Dyck PJ, et al : Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314 : 461-465, 1986.
PubMed
5) Hahn AF, et al : Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119 (Pt 4) : 1055-1066, 1996.
 
6) Dyck PJ, et al : A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36 : 838-845, 1994.
PubMed
7) Allen JA, et al : Quantifying Treatment-Related Fluctuations in CIDP : Results of the GRIPPER Study. Neurology 96 : e1876-e1886, 2021.
PubMed
8) 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン 2013 (「慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン」作成委員会編, 日本神経学会監), 南江堂, 2013.
 
9) Kuwabara S, et al : Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy : a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 88 : 832-838, 2017.
PubMed
10) Merkies ISJ, et al : Efficacy and safety of IVIG in CIDP : Combined data of the PRIMA and PATH studies. J Peripher Nerv Syst 24 : 48-55, 2019.
PubMed
11) Kuwabara S, et al : Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86 : 1054-1059, 2015.
PubMed
12) Doneddu PE, et al : Atypical CIDP : diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry 90 : 125-132, 2019.
PubMed
13) Nobile-Orazio E, et al : Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy : a randomised controlled trial. Lancet Neurol 11 : 493-502, 2012.
PubMed
14) Cocito D, et al : Subcutaneous vs. intravenous immunoglobulin in CIDP : pharmacokinetic and clinical response. J Peripher Nerv Syst 21 : 114-116, 2016.
PubMed
15) van Schaik IN, et al : Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17 : 35-46, 2018.
PubMed
16) Racosta JM, et al : Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies : A meta-analysis. Muscle Nerve 55 : 802-809, 2017.
PubMed
17) van Schaik IN, et al : Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP : PATH extension study. Neurol Neuroimmunol Neuroinflamm 6 : e590, 2019.
PubMed
18) van Schaik IN, et al : Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study) : a double-blind, randomised, controlled trial. Lancet Neurol 9 : 245-253, 2010.
PubMed
19) van Lieverloo GGA, et al : Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol 265 : 2052-2059, 2018.
PubMed
20) Eftimov F, et al : Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 78 : 1079-1084, 2012.
PubMed
21) Nobile-Orazio E, et al : Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry 86 : 729-734, 2015.
PubMed
22) Muley SA, et al : Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 61 : 575-579, 2020.
PubMed
23) Godil J, et al : Refractory CIDP : Clinical characteristics, antibodies and response to alternative treatment. J Neurol Sci 418 : 117098, 2020.
PubMed
24) Dalakas MC : IgG4-Mediated Neurologic Autoimmunities : Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies. Neurol Neuroimmunol Neuroinflamm 9 : 2022.
PubMed
25) Fatehi F, et al : Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy. J Peripher Nerv Syst 26 : 469-474, 2021.
PubMed
26) Hu J, et al : Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy : a systematic review and meta-analysis. J Neurol 269 : 1250-1263, 2022.
PubMed
27) Kaplan A, Brannagan TH 3rd : Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 55 : 476-482, 2017.
PubMed
P.265 掲載の参考文献
1) Tang L, et al : Distinguish CIDP with autoantibody from that without autoantibody : pathogenesis, histopathology, and clinical features. J Neurol 268 : 2757-2768, 2021.
PubMed
2) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26 : 242-268, 2021.
PubMed
3) Shelly S, et al : Neurofascin-155 Immunoglobulin Subtypes : Clinicopathologic Associations and Neurologic Outcomes. Neurology 97 : e2392-e2403, 2021.
PubMed
4) Martin-Aguilar L, et al : Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurol Neuroimmunol Neuroinflamm 9 : e1098, 2021.
PubMed
5) Ogata H, et al : Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2 : 960-971, 2015.
PubMed
6) Devaux JJ, et al : Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86 : 800-807, 2016.
PubMed
7) Kadoya M, et al : IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy : Clinical significance and diagnostic utility of a conventional assay. J Neuroimmunol 301 : 16-22, 2016.
PubMed
8) Zhang X, et al : Chronic inflammatory demyelinating polyneuropathy with anti-NF155 IgG4 in China. J Neuroimmunol 337 : 577074, 2019.
 
9) Delmont E, et al : Antibodies against the node of Ranvier : a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. J Neurol 267 : 3664-3672, 2020.
 
10) Ogata H, et al : Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol 7 : 2297-2309, 2020.
PubMed
11) Franques J, et al : Teaching NeuroImages : Cranial nerve hypertrophy in IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Neurology 88 : e52, 2017.
PubMed
12) Koike H, et al : Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry 88 : 465-473, 2017.
PubMed
13) Ogata H, et al : Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 339 : 577139, 2020.
PubMed
14) Ogata H, et al : Intrathecal cytokine profile in neuropathy with anti-neurofascin 155 antibody. Ann Clin Transl Neurol 6 : 2304-2316, 2019.
PubMed
15) Manso C, et al : Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo. J Clin Invest 129 : 2222-2236, 2019.
PubMed
16) Dubey D, et al : Contactin-1 autoimmunity : Serologic, neurologic, and pathologic correlates. Neurol Neuroimmunol Neuroinflamm 7 : 2020.
PubMed
17) Hashimoto Y, et al : Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy : An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey. Front Neurol 9 : 997, 2018.
PubMed
18) Wald A, et al : Overlap of Bullous, Anti-Laminin-332, and Anti-p200 Pemphigoid With Concomitant Anti-Contactin-1-Positive Inflammatory Polyneuropathy Treated With Intravenous Immunoglobulins as a Manifestation of Epitope Spreading. JAMA Dermatol 155 : 631-633, 2019.
PubMed
19) Kouton L, et al : Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins. Clin Neurophysiol 131 : 921-927, 2020.
PubMed
20) Manso C, et al : Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain 139 : 1700-1712, 2016.
PubMed
21) Le Quintrec M, et al : Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. Kidney Int 100 : 1240-1249, 2021.
PubMed
22) Shimizu S, et al : Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE) : Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Res Protoc 9 : e17117, 2020.
PubMed
23) Fukami Y, et al : Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. J Neurol 268 : 3835-3844, 2021.
PubMed
24) Doppler K, et al : Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain 139 : 2617-2630, 2016.
PubMed
25) Cortese A, et al : Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP : Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm 7 : e639, 2019.
PubMed
26) Pascual-Goni E, et al : Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 144 : 1183-1196, 2021.
 
27) Delmont E, et al : Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain 140 : 1851-1858, 2017.
PubMed
28) Xie C, et al : From PNS to CNS : characteristics of anti-neurofascin 186 neuropathy in 16 cases. Neurol Sci 42 : 4673-4681, 2021.
PubMed
29) Stengel H, et al : Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy. Neurol Neuroimmunol Neuroinflamm 6 : e603, 2019.
PubMed
30) Fehmi J, et al : IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality. J Neurol Neurosurg Psychiatry 92 : 1089-1095, 2021.
PubMed
P.272 掲載の参考文献
1) Zee PC, et al : Peripheral nervous system involvement in multiple sclerosis. Neurology 41 : 457-460, 1991.
PubMed
2) Bouchard C, et al : Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52 : 498-503, 1999.
PubMed
3) Ogata H, et al : A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry 87 : 29-36, 2016.
PubMed
4) Cortese A, et al : Combined central and peripheral demyelination : Clinical features, diagnostic findings, and treatment. J Neurol Sci 363 : 182-187, 2016.
PubMed
5) Wang YQ, et al : The clinical features of combined central and peripheral demyelination in Chinese patients. J Neuroimmunol 317 : 32-36, 2018.
PubMed
6) Hou X, et al : The clinical features of combined central and peripheral demyelination and antibodies against the node of Ranvier. Mult Scler 28 : 453-462, 2022.
PubMed
7) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. J Peripher Nerv Syst 26 : 242-268, 2021.
PubMed
8) Kawamura N, et al : Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 81 : 714-722, 2013.
PubMed
9) Devaux JJ, et al : Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86 : 800-807, 2016.
PubMed
10) Ogata H, et al : Optic, trigeminal, and facial neuropathy related to anti-neurofascin 155 antibody. Ann Clin Transl Neurol 7 : 2297-2309, 2020.
PubMed
11) Verghese A, et al : Optic Nerve Demyelination in IgG4 Anti-Neurofascin 155 Antibody-Positive Combined Central and Peripheral Demyelination Syndrome. J Cent Nerv Syst Dis 13 : 11795735211039913, 2021.
PubMed
12) Kitada M, et al : Acute combined central and peripheral demyelination showing anti-aquaporin 4 antibody positivity. Intern Med 51 : 2443-2447, 2012.
PubMed
13) Warabi Y, et al : Abnormal nerve conduction study findings indicating the existence of peripheral neuropathy in multiple sclerosis and neuromyelitis optica. Biomed Res Int 2013 : 847670, 2013.
PubMed
14) Takai Y, et al : Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody. Neurology 79 : 1826-1828, 2012.
PubMed
15) Rinaldi S, et al : Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurol Neuroimmunol Neuroinflamm 8 : 2021.
PubMed
16) Nakamura T, et al : Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy. Neurol Sci 42 : 1135-1138, 2021.
PubMed
17) Shima S, et al : Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy. Neurology 82 : 114-118, 2014.
PubMed
P.277 掲載の参考文献
1) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst 15 : 185-195, 2010.
PubMed
2) Schachner M, Bartsch U : Multiple functions of the myelin-associated glycoprotein MAG (siglec-4a) in formation and maintenance of myelin. Glia 29 : 154-165, 2000.
PubMed
3) Hamada Y, et al : Binding specificity of anti-HNK-1 IgM M-protein in anti-MAG neuropathy : possible clinical relevance. Neurosci Res 91 : 63-68, 2015.
PubMed
4) Stalder AK, et al : Immunoglobulin M deposition in cutaneous nerves of anti-myelin-associated glycoprotein polyneuropathy patients correlates with axonal degeneration. J Neuropathol Exp Neurol 68 : 148-158, 2009.
PubMed
5) Kawagashira Y, et al : Morphological progression of myelin abnormalities in IgM-monoclonal gammopathy of undetermined significance anti-myelin-associated glycoprotein neuropathy. J Neuropathol Exp Neurol 69 : 1143-1157, 2010.
PubMed
6) Hellqvist E, et al : Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype : aberrant triggering of a patient's T cells. Haematologica 95 : 627-636, 2010.
 
7) Willison HJ, et al : Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle Nerve 11 : 1169-1176, 1988.
PubMed
8) Tatum AH : Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol 33 : 502-506, 1993.
PubMed
9) Ilyas AA, et al : Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol 193 : 87-93, 2008.
PubMed
10) Dalakas MC, et al : Tremor as a feature of chronic relapsing and dysgammaglobulinemic polyneuropathies. Incidence and management. Arch Neurol 41 : 711-714, 1984.
PubMed
11) Svahn J, et al : Anti-MAG antibodies in 202 patients : clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry 89 : 499-505, 2018.
PubMed
12) Vo ML, Latov N : Unreliability of commercial anti-MAG antibody and ganglioside assays. Muscle Nerve 51 : 458-459, 2015.
PubMed
13) Kaku DA, et al : Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 177 (Pt 5) : 941-947, 1994.
 
14) Niermeijer JM, et al : Prognosis of polyneuropathy due to IgM monoclonal gammopathy : a prospective cohort study. Neurology 74 : 406-412, 2010.
PubMed
15) Nobile-Orazio E, et al : Long-term prognosis of neuropathy associated with anti-MAG IgM Mproteins and its relationship to immune therapies. Brain 123 (Pt 4) : 710-717, 2000.
PubMed
16) Comi G, et al : A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249 : 1370-1377, 2002.
PubMed
17) Codron P, et al : Therapeutic plasma exchange in chronic dysimmune peripheral neuropathies : A 10-year retrospective study. J Clin Apher 32 : 413-422, 2017.
PubMed
18) Lunn MP, Nobile-Orazio E : Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 10 : CD002827, 2016.
PubMed
19) Dalakas MC : Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord 11 : 1756285617746640, 2018.
PubMed
20) Vos JM, et al : High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. J Neurol Neurosurg Psychiatry 89 : 1007-1009, 2018.
PubMed
21) Castellani F, et al : The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. Neurol Neuroimmunol Neuroinflamm 7 : e720, 2020.
PubMed
22) Aliu B, et al : Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen-specific glycopolymer. J Neurochem 154 : 486-501, 2020.
PubMed

IV 脱髄以外の中枢神経免疫疾患

P.286 掲載の参考文献
1) 飯塚高浩 : 自己免疫性脳炎およびその類縁疾患における最近の進歩. 臨床神経学 59 : 491-501, 2019.
 
2) Graus F, et al : A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15 : 391-404, 2016.
PubMed
3) Mattozzi S, et al : Hashimoto encephalopathy in the 21st century. Neurology 94 : e217-e224, 2020.
PubMed
4) Geis C, et al : Autoimmune seizures and epilepsy. J Clin Invest 129 : 926-940, 2019.
 
5) Steriade C, et al : Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy : Conceptual definitions. Epilepsia 61 : 1341-1351, 2020.
PubMed
6) Hirsch LJ, et al : Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 59 : 739-744, 2018.
PubMed
7) Iizuka T, et al : Cryptogenic NORSE : Its distinctive clinical features and response to immunotherapy. Neurol Neuroimmunol Neuroinflamm 4 : e396, 2017.
PubMed
8) Yanagida A, et al : Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus. Neurol Neuroimmunol Neuroinflamm 7 : e849, 2020.
PubMed
9) Graus F, et al : Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm 8 : e1014, 2021.
PubMed
10) Cellucci T, et al : Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm 7 : e663, 2020.
 
11) Nosadini M, et al : International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm 8 : e1052, 2021.
PubMed
12) Dubey D, et al : Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 83 : 166-177, 2018.
 
13) Martinez-Hernandez E, et al : Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology 94 : e2302-e2310, 2020.
 
14) Landa J, et al : Encephalitis with Autoantibodies against the Glutamate Kainate Receptors GluK2. Ann Neurol 90 : 101-117, 2021.
PubMed
15) Kikuchi A, et al : High prevalence of serum anti-NH2-terminal of α-enolase antibodies in patients with multiple system atrophy and corticobasal syndrome. J Neurol 268 : 4291-4295, 2021.
 
P.293 掲載の参考文献
1) Levite M : Autoimmune epilepsy. Nat Immunol 3 : 500, 2002.
PubMed
2) 田中惠子 : 免疫とてんかん症候群. Epilepsy 8 : 93-97, 2014.
Medical*Online
3) Scheffer IE, et al : ILAE classification of the epilepsies : Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58 : 512-521, 2017.
PubMed
4) 松本理器 : 自己免疫性脳炎. 別冊BIO Clinica 9 : 27-34, 2020.
 
5) 松本理器, ほか : てんかんと自己免疫. Brain and Nerve 69 : 1115-1124, 2017.
 
6) 原敦, 松本理器 : 精神科医が見逃しがちな自己免疫性脳炎・精神病について : 診断と治療update. 精神科治療学 36 : 609-614, 2021.
 
7) Jarius S, et al : MOG encephalomyelitis : international recommendations on diagnosis and antibody testing. J Neuroinflammation 15 : 134, 2018.
PubMed
8) Fang B, et al : Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy : A Novel Meningoencephalomyelitis. JAMA Neurol 73 : 1297-1307, 2016.
PubMed
9) Graus F, et al : A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15 : 391-404, 2016.
PubMed
10) Sakamoto M, et al : [Proposal of a diagnostic algorithm for autoimmune epilepsy : preliminary investigation of its utility]. Rinsho Shinkeigaku 58 : 609-616, 2018.
PubMed
11) Dubey D, et al : Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology. JAMA Neurol 74 : 397-402, 2017.
PubMed
12) Toledano M, et al : Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 82 : 1578-1586, 2014.
PubMed
13) de Bruijn MAAM, et al : Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score. Ann Neurol 89 : 698-710, 2021.
PubMed
14) Geis C, et al : Autoimmune seizures and epilepsy. J Clin Invest 129 : 926-940, 2019.
 
15) Smith KM, et al : Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis. Neurology 97 : e1141-e1149, 2021.
PubMed
16) Yeshokumar AK, et al : Seizures in autoimmune encephalitis-A systematic review and quantitative synthesis. Epilepsia 62 : 397-407, 2021.
PubMed
17) Bordonne M, et al : Brain 18F-FDG PET for the diagnosis of autoimmune encephalitis : a systematic review and a meta-analysis. Eur J Nucl Med Mol Imaging 48 : 3847-3858, 2021.
 
18) Heine J, et al : Imaging of autoimmune encephalitis--Relevance for clinical practice and hippocampal function. Neuroscience 309 : 68-83, 2015.
PubMed
19) Kanazawa K, et al : Persistent frequent subclinical seizures and memory impairment after clinical remission in smoldering limbic encephalitis. Epileptic Disord 16 : 312-317, 2014.
PubMed
20) Steriade C, et al : Subclinical temporal EEG seizure pattern in LGI1-antibody-mediated encephalitis. Epilepsia 57 : e155-160, 2016.
PubMed
21) Aurangzeb S, et al : LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures. Seizure 50 : 14-17, 2017.
PubMed
22) Steriade C, et al : Extreme delta-With or without brushes : A potential surrogate marker of disease activity in anti-NMDA-receptor encephalitis. Clin Neurophysiol 129 : 2197-2204, 2018.
PubMed
23) Baykan B, et al : Delta Brush Pattern Is Not Unique to NMDAR Encephalitis : Evaluation of Two Independent Long-Term EEG Cohorts. Clin EEG Neurosci 49 : 278-284, 2018.
PubMed
24) Thaler FS, et al : Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis : Real-world Evidence From the GENERATE Registry. Neurol Neuroimmunol Neuroinflamm 8 : e1088, 2021.
PubMed
25) Uy CE, et al : Autoimmune encephalitis : clinical spectrum and management. Pract Neurol 21 : 412-423, 2021.
PubMed
26) Dubey D, et al : Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. Ann Neurol 87 : 313-323, 2020.
PubMed
27) Feyissa AM, et al : Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm 4 : e353, 2017.
PubMed
28) de Bruijn MAAM, et al : Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 92 : e2185-e2196, 2019.
PubMed
29) Steriade C, et al : Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy : Conceptual definitions. Epilepsia 61 : 1341-1351, 2020.
PubMed
30) Hoftberger R, et al : Encephalitis and AMPA receptor antibodies : Novel findings in a case series of 22 patients. Neurology 84 : 2403-2412, 2015.
 
31) Petit-Pedrol M, et al : Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor : a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 13 : 276-286, 2014.
 
32) Budhram A, et al : Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg Psychiatry 92 : 645-654, 2021.
 
33) Dalmau J, et al : Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev 97 : 839-887, 2017.
PubMed
P.301 掲載の参考文献
1) Mckeon A, et al : Autoimmune movement disorders. Handb Clin Neurol 133 : 301-315, 2016.
PubMed
2) Damato V, et al : The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders. Mov Disord 33 : 1376-1389, 2018.
PubMed
3) Balint B, et al : Movement disorders with neuronal antibodies : syndromic approach, genetic parallels and pathophysiology. Brain 141 : 13-36, 2018.
PubMed
4) Gaig C, et al : Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology 97 : e1367-e1381, 2021.
 
5) Titulaer MJ, et al : Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis : an observational cohort study. Lancet Neurol 12 : 157-165, 2013.
PubMed
6) Dalmau J, et al : An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists : mechanisms and models. Lancet Neurol 18 : 1045-1057, 2019.
PubMed
7) Armangue T, et al : Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis : a prospective observational study and retrospective analysis. Lancet Neurol 17 : 760-772, 2018.
PubMed
8) Varley JA, et al : The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic : an expert video-rating study. J Neurol Neurosurg Psychiatry 90 : 724-726, 2019.
PubMed
9) Irani SR, et al : Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69 : 892-900, 2011.
PubMed
10) Lopez Chiriboga AS, et al : Striking basal ganglia imaging abnormalities in LGI1 ab faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm 4 : e336, 2017.
PubMed
11) Sabater L, et al : A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5 : a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13 : 575-586, 2014.
 
12) Gelpi E, et al : Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 132 : 531-543, 2016.
PubMed
13) Landa J, et al : Effects of IgLON5 Antibodies on Neuronal Cytoskeleton : A Link between Autoimmunity and Neurodegeneration. Ann Neurol 88 : 1023-1027, 2020.
PubMed
14) Fang B, et al : Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy : A Novel Meningoencephalomyelitis. JAMA Neurol 73 : 1297-1307, 2016.
PubMed
15) Flanagan EP, et al : Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy : Analysis of 102 patients. Ann Neurol 81 : 298-309, 2017.
PubMed
P.307 掲載の参考文献
1) Rasmussen T, et al : Focal seizures due to chronic localized encephalitis. Neurology 8 : 435-445, 1958.
PubMed
2) 高橋幸利, ほか : ラスムッセン脳炎の特徴と治療の実際. 新薬と臨牀 66 : 684-689, 2017.
Medical*Online
3) Bien CG, et al : Pathogenesis, diagnosis and treatment of Rasmussen encephalitis : a European consensus statement. Brain 128 : 454-471, 2005.
PubMed
4) Bien CG, et al : Diagnosis and staging of Rasmussen's encephalitis by serial MRI and histopathology. Neurology 58 : 250-257, 2002.
 
5) Takahashi Y, et al : A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFα, and Granzyme B in CSF. Epilepsia 50 : 1419-1431, 2009.
 
6) Fukuyama T, et al : Semi-quantitative analyses of antibodies to N-methyl-d-aspartate type glutamate receptor subunits (GluN2B & GluN1) in the clinical course of Rasmussen syndrome. Epilepsy Res 113 : 34-43, 2015.
 
7) Granata T, et al : Rasmussen encephalitis. In : Epileptic Syndromes in Infancy, Childhood and Adolescence, 6th edition, with Video supplements (ed by Bureau M, et al), p357-377, John Libbey Eurotext, 2019.
 
8) Dupont S, et al : Late-onset Rasmussen Encephalitis : A literature appraisal. Autoimmun Rev 16 : 803-810, 2017.
PubMed
9) 宮城哲哉, ほか : 失語発作を主症状とする成人型ラスムッセン症候群の一例. てんかん研究 32 : 556-563, 2015.
 
10) 小松原孝夫, ほか : てんかん発作が先行せずに発症したRasmussen脳炎の女児例. 脳と発達 51 : 254-259, 2019.
Medical*Online
11) Takahashi Y, et al : Epilepsia partialis continua of childhood involving bilateral brain hemispheres. Acta Neurol Scand 96 : 345-352, 1997.
PubMed
12) Takei H, et al : Dual pathology in Rasmussen's encephalitis : a study of seven cases and review of the literature. Neuropathology 30 : 381-391, 2010.
 
13) Takahashi Y, et al : Immunomodulatory therapy versus surgery for Rasmussen syndrome in early childhood. Brain Dev 35 : 778-785, 2013.
PubMed
14) Takahashi Y, et al : Genetic variations of immunoregulatory genes associated with Rasmussen syndrome. Epilepsy Res 107 : 238-243, 2013.
PubMed
P.313 掲載の参考文献
1) Mizuguchi M, et al : Guidelines for the diagnosis and treatment of acute encephalopathy in childhood. Brain Dev 43 : 2-31, 2021.
PubMed
2) Mizuguchi M, et al : Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand Suppl 186 : 45-56, 2007.
PubMed
3) Hoshino A, et al : Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev 34 : 337-343, 2012.
PubMed
4) Kasai M, et al : Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 42 : 508-514, 2020.
PubMed
5) 小児急性脳症診療ガイドライン 2016 (日本小児神経学会監, 小児急性脳症診療ガイドライン策定委員会編), 診断と治療社, 2016.
 
6) Mizuguchi M, et al : Acute necrotising encephalopathy of childhood : a new syndrome presenting with multifocal, symmetric brain lesions. J Neurol Neurosurg Psychiatry 58 : 555-561, 1995.
PubMed
7) Neilson DE, et al : Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet 84 : 44-51, 2009.
 
8) Takanashi J, et al : Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology 66 : 1304-1309 ; discussion 1291, 2006.
 
9) Takanashi J, et al : Excitotoxicity in acute encephalopathy with biphasic seizures and late reduced diffusion. AJNR Am J Neuroradiol 30 : 132-135, 2009.
PubMed
10) Nishiyama M, et al : Targeted temperature management of acute encephalopathy without AST elevation. Brain Dev 37 : 328-333, 2015.
PubMed
11) Hirsch LJ, et al : Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 59 : 739-744, 2018.
PubMed
12) Sakuma H, et al : Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus. J Neurol Neurosurg Psychiatry 86 : 820-822, 2015.
PubMed
13) Tada H, et al : Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology 63 : 1854-1858, 2004.
PubMed
14) Kurahashi H, et al : MYRF is associated with encephalopathy with reversible myelin vacuolization. Ann Neurol 83 : 98-106, 2018.
PubMed
15) Takanashi J, et al : Clinical and radiological features of rotavirus cerebellitis. AJNR Am J Neuroradiol 31 : 1591-1595, 2010.
PubMed
16) Takanashi J, et al : Clinical and radiologic features of encephalopathy during 2011 E coli O111 outbreak in Japan. Neurology 82 : 564-572, 2014.
PubMed
P.317 掲載の参考文献
1) Brain L, et al : Hashimoto's disease and encephalopathy. Lancet 2 : 512-514, 1966.
PubMed
2) Shaw PJ, et al : Hashimoto's encephalopathy : a steroid-responsive disorder associated with high antithyroid antibody titers--report of 5 cases. Neurology 41 : 228-233, 1991.
 
3) 森昌朋 : 甲状腺疾患の診断と治療-現状と展望-. 日本内科学会雑誌 99 : 683-685, 2010.
 
4) Yoneda M, et al : Hashimoto's encephalopathy. In : Neuroimmunological Diseases (ed by Kusunoki S), p235-244, Springer Japan, Tokyo, 2016.
 
5) Kishitani T, et al : Limbic encephalitis associated with anti-NH2-terminal of α-enolase antibodies : A clinical subtype of Hashimoto encephalopathy. Medicine (Baltimore) 96 : e6181, 2017.
 
6) Matsunaga A, et al : Hashimoto's encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. Eur Neurol 69 : 14-20, 2013.
PubMed
7) Cossu G, et al : Creutzfeldt-Jakob disease associated with high titer of antithyroid autoantibodies : case report and literature review. Neurol Sci 24 : 138-140, 2003.
PubMed
8) Fujii A, et al : Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto's encephalopathy. J Neuroimmunol 162 : 130-136, 2005.
 
9) Yoneda M, et al : High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto's encephalopathy. J Neuroimmunol 185 : 195-200, 2007.
PubMed
10) Montagna G, et al : Hashimoto's encephalopathy : A rare proteiform disorder. Autoimmun Rev 15 : 466-476, 2016.
 
11) Nolte KW, et al : Hashimoto encephalopathy : a brainstem vasculitis? Neurology 54 : 769-770, 2000.
PubMed
12) Doherty CP, et al : Hashimoto's encephalopathy mimicking Creutzfeldt-Jakob disease : brain biopsy findings. J Neurol Neurosurg Psychiatry 73 : 601-602, 2002.
 
13) Matsunaga A, et al : Serial brain MRI changes related to autoimmune pathophysiology in Hashimoto encephalopathy with anti-NAE antibodies : A case-series study. J Neurol Sci 406 : 116453, 2019.
 
14) 米田誠, ほか : Wes(TM) を用いた自動ウエスタンブロットによる橋本脳症の診断バイオマーカー (抗NAE抗体) の測定系開発. 医学と薬学 78 : 969-976, 2021.
Medical*Online
15) Drulovic J, et al : Hashimoto's encephalopathy : a long-lasting remission induced by intravenous immunoglobulins. Vojnosanit Pregl 68 : 452-454, 2011.
PubMed
P.322 掲載の参考文献
1) Yoshida K, et al : Idiopathic cerebellar ataxia (IDCA) : Diagnostic criteria and clinical analyses of 63 Japanese patients. J Neurol Sci 384 : 30-35, 2018.
PubMed
2) Mitoma H, et al : Consensus Paper : Neuroimmune Mechanisms of Cerebellar Ataxias. Cerebellum 15 : 213-232, 2016.
PubMed
3) Hadjivassiliou M, et al : Causes of progressive cerebellar ataxia : prospective evaluation of 1500 patients. J Neurol Neurosurg Psychiatry 88 : 301-309, 2017.
PubMed
4) 吉倉延亮, ほか : 自己免疫性小脳性運動失調症からのアプローチ. BRAIN and NERVE 72 : 961-967, 2020.
 
5) Mitoma H, et al : Immune-Mediated Cerebellar Ataxias : Clinical Diagnosis and Treatment Based on Immunological and Physiological Mechanisms. J Mov Disord 14 : 10-28, 2021.
PubMed
6) 三苫博 : 自己免疫性小脳性運動失調症. BRAIN and NERVE 73 : 611-619, 2021.
 
7) Mitoma H, et al : Consensus Paper. Cerebellar Reserve : From Cerebellar Physiology to Cerebellar Disorders. Cerebellum 19 : 131-153, 2020.
 
8) Zaborowski MP, Michalak S : Cell-mediated immune responses in paraneoplastic neurological syndromes. Clin Dev Immunol 2013 : 630602, 2013.
PubMed
9) Mitoma H, et al : Pathogenic Roles of Glutamic Acid Decarboxylase 65 Autoantibodies in Cerebellar Ataxias. J Immunol Res 2017 : 2913297, 2017.
PubMed
10) Sillevis Smitt P, et al : Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342 : 21-27, 2000.
PubMed
11) 南里和紀, ほか : 脊髄小脳変性症と自己抗体. BRAIN and NERVE 70 : 371-382, 2018.
 
12) Hadjivassiliou M, et al : Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet 352 : 1582-1585, 1998.
PubMed
13) Hadjivassiliou M, et al : Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 74 : 1221-1224, 2003.
PubMed
14) Arino H, et al : Cerebellar ataxia and glutamic acid decarboxylase antibodies : immunologic profile and long-term effect of immunotherapy. JAMA Neurol 71 : 1009-1016, 2014.
PubMed
15) Fukuda T, et al : Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 53 : 21-28, 2003.
PubMed
16) Shimizu F, et al : GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain 142 : 2253-2264, 2019.
PubMed
17) Hadjivassiliou M, et al : Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord 23 : 1370-1377, 2008.
PubMed
P.327 掲載の参考文献
1) Bickerstaff ER, Cloake PC : Mesencephalitis and rhombencephalitis. Br Med J 2 : 77-81, 1951.
PubMed
2) Bickerstaff ER : Brain-stem encephalitis ; further observations on a grave syndrome with benign prognosis. Br Med J 1 : 1384-1387, 1957.
 
3) Fisher M : An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 255 : 57-65, 1956.
PubMed
4) Yuki N, et al : An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 118 : 83-87, 1993.
 
5) Yuki N : Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmunol 215 : 1-9, 2009.
PubMed
6) Koga M, et al : Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis : epidemiological and clinical characteristics. J Neurol Neurosurg Psychiatry 83 : 1210-1215, 2012.
PubMed
7) Yoshikawa K, et al : Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody. Neurol Neuroimmunol Neuroinflamm 7 : 2020.
 
8) 古賀道明 : ビッカースタッフ型脳幹脳炎の疫学と診断・治療. 日本臨牀 71 : 898-903, 2013.
Medical*Online
9) Koga M : Experimental approach in a research of Guillain-Barre syndrome : a range of pathogeneses mediated by molecular mimicry. Clin Exp Neuroimmunol 9 : 93-100, 2018.
 
10) Ito M, et al : Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum : clinical analysis of 581 cases. J Neurol 255 : 674-682, 2008.
 
11) Kimoto K, et al : Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 67 : 1837-1843, 2006.
PubMed
12) Chiba A : Miller Fisher Syndrome. In : GBS100 : Celebrating a Century of Progress in Guillain-Barre Syndrome, 1916-2016 (ed by Willison HJ, Goodfellow JA), p109-119, Peripheral Nerve Society, La Jolla, 2016.
 
13) Saito K, et al : Blood-brain barrier destruction determines Fisher/Bickerstaff clinical phenotypes : an in vitro study. J Neurol Neurosurg Psychiatry 84 : 756-765, 2013.
 
14) Odaka M, et al : Bickerstaff's brainstem encephalitis : clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 126 : 2279-2290, 2003.
 
15) Overell JR, et al : Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007 (1) : CD004761, 2007.
 
P.333 掲載の参考文献
1) Cravioto H, Feigin I : Noninfectious granulomatous angiitis with a predilection for the nervous system. Neurology 9 : 599-609, 1959.
PubMed
2) Calabrese LH, Mallek JA : Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore) 67 : 20-39, 1988.
PubMed
3) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
4) Salvarani C, et al : An Update of the Mayo Clinic cohort of patients with adult primary central nervous system vasculitis : description of 163 patients. Medicine (Baltimore) 94 : e738, 2015.
 
5) Beuker C, et al : Primary Angiitis of the CNS : A Systematic Review and Meta-analysis. Neurol Neuroimmunol Neuroinflamm 8 : e1093, 2021.
PubMed
6) Krawczyk M, et al : Primary CNS vasculitis : A systematic review on clinical characteristics associated with abnormal biopsy and angiography. Autoimmun Rev 20 : 102714, 2021.
PubMed
7) 日下博 : 内科医のための脳疾患講座脳の血管炎Primary angiitis of the central nervous system (PACNS). Brain Medical 10 : 213-215, 1998.
 
8) Birnbaum J, Hellmann DB : Primary angiitis of the central nervous system. Arch Neurol 66 : 704-709, 2009.
PubMed
9) Calabrese LH, et al : Narrative review : reversible cerebral vasoconstriction syndromes. Ann Intern Med 146 : 34-44, 2007.
PubMed
10) Kraayvanger L, et al : Cerebrospinal fluid findings in reversible cerebral vasoconstriction syndrome : a way to differentiate from cerebral vasculitis? Clin Exp Immunol 193 : 341-345, 2018.
PubMed
11) Salvarani C, et al : Adult primary central nervous system vasculitis. Lancet 380 : 767-777, 2012.
PubMed
12) Shimoda M, et al : Centripetal Propagation of Vasoconstriction at the Time of Headache Resolution in Patients with Reversible Cerebral Vasoconstriction Syndrome. AJNR Am J Neuroradiol 37 : 1594-1598, 2016.
PubMed
13) Miller DV, et al : Biopsy findings in primary angiitis of the central nervous system. Am J Surg Pathol 33 : 35-43, 2009.
PubMed
14) 越智一秀 : 単一臓器血管炎 原発性中枢神経系血管炎. 日本臨牀 76 (増刊号 6) : 430-435, 2018.
 
15) Salvarani C, et al : Management of primary and secondary central nervous system vasculitis. Curr Opin Rheumatol 28 : 21-28, 2016.
PubMed
16) Salvarani C, et al : Mycophenolate mofetil in primary central nervous system vasculitis. Semin Arthritis Rheum 45 : 55-59, 2015.
PubMed
17) Ohtomo R, et al : Successful treatment of recurrent primary CNS vasculitis with etanercept. J Neurol Sci 381 : 200-202, 2017.
PubMed
18) Hajj-Ali RA, et al : Long-term outcomes of patients with primary angiitis of the central nervous system. Clin Exp Rheumatol 37 (Suppl 117) : 45-51, 2019.
 
P.338 掲載の参考文献
1) Kupersmith MJ, et al : Idiopathic hypertrophic pachymeningitis. Neurology 62 : 686-694, 2004.
PubMed
2) 勇亜衣子, 河内泉 : 肥厚性硬膜炎-最近の話題-肥厚性硬膜炎の歴史と概念 新たな診断基準. 脳神経内科 91 : 340-351, 2019.
 
3) Naffziger HC, Stern WE : Chronic pachymeningitis ; report of a case and review of the literature. Arch Neurol Psychiatry 62 : 383-411, 1949.
PubMed
4) Yokoseki A, et al : Hypertrophic pachymeningitis : significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain 137 : 520-536, 2014.
PubMed
5) Yonekawa T, et al : A nationwide survey of hypertrophic pachymeningitis in Japan. J Neurol Neurosurg Psychiatry 85 : 732-739, 2014.
PubMed
6) Umehara H, et al : The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31 : 529-533, 2021.
PubMed
7) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
PubMed
8) Smirniotopoulos JG, et al : Patterns of contrast enhancement in the brain and meninges. Radiographics 27 : 525-551, 2007.
PubMed
9) Friedman DP, Flanders AE : Enhanced MR imaging of hypertrophic pachymeningitis. AJR Am J Roentgenol 169 : 1425-1428, 1997.
PubMed
10) 中島章博, 河内泉 : 肥厚性硬膜炎の診断と治療. 脊髄外科 34 : 25-31, 2020.
 
11) Thurtell MJ, et al : Tuberculous cranial pachymeningitis. Neurology 68 : 298-300, 2007.
PubMed
12) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
13) Lionaki S, et al : Classification of antineutrophil cytoplasmic autoantibody vasculitides : the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64 : 3452-3462, 2012.
PubMed
14) Harabuchi Y, et al : Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (OMAAV) proposed by Japan Otological Society. Auris Nasus Larynx 48 : 2-14, 2021.
PubMed
15) Stone JH, et al : IgG4-related disease. N Engl J Med 366 : 539-551, 2012.
PubMed
16) Lu LX, et al : IgG4-related hypertrophic pachymeningitis : clinical features, diagnostic criteria, and treatment. JAMA Neurol 71 : 785-793, 2014.
PubMed
17) Wallace ZS, et al : The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 79 : 77-87, 2020.
PubMed
18) Deshpande V, et al : Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25 : 1181-1192, 2012.
PubMed
19) Lindstrom KM, et al : IgG4-related meningeal disease : clinico-pathological features and proposal for diagnostic criteria. Acta Neuropathol 120 : 765-776, 2010.
PubMed
20) Levraut M, et al : Immunoglobulin G4-related hypertrophic pachymeningitis : A case-oriented review. Neurol Neuroimmunol Neuroinflamm 6 : e568, 2019.
PubMed
P.345 掲載の参考文献
1) Satake M, et al : Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan : a nationwide retrospective cohort analysis. Lancet Infect Dis 16 : 1246-1254, 2016.
PubMed
2) HTLV-1関連脊髄症 (HAM) 診療ガイドライン 2019 (「HTLV-1関連脊髄症 (HAM) 診療ガイドライン 2019」作成委員会編), 南江堂, 2019.
 
3) Kamoi K, et al : Horizontal transmission of HTLV-1 causing uveitis. Lancet Infect Dis 21 : 578, 2021.
PubMed
4) Kamoi K, et al : HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision. Lancet 399 : 60, 2022.
PubMed
5) Nagasaka M, et al : Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis. Proc Natl Acad Sci U S A 117 : 11685-11691, 2020.
PubMed
6) Bangham CR, et al : HTLV-1-associated myelopathy/tropical spastic paraparesis. Nat Rev Dis Primers 1 : 15012, 2015.
 
7) Saito M : Association Between HTLV-1 Genotypes and Risk of HAM/TSP. Front Microbiol 10 : 1101, 2019.
PubMed
8) Penova M, et al : Genome wide association study of HTLV-1-associated myelopathy/tropical spastic paraparesis in the Japanese population. Proc Natl Acad Sci U S A 118 : 2021.
PubMed
9) Yamauchi J, et al : Risk of Human T-Cell Leukemia Virus Type 1 Infection in Kidney Transplantation. N Engl J Med 380 : 296-298, 2019.
PubMed
10) Sato T, et al : Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy. N Engl J Med 378 : 529-538, 2018.
PubMed
11) Araya N, et al : HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. J Clin Invest 124 : 3431-3442, 2014.
 
12) Ando H, et al : Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain 136 : 2876-2887, 2013.
PubMed
13) Coler-Reilly ALG, et al : Effectiveness of Daily Prednisolone to Slow Progression of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis : A Multicenter Retrospective Cohort Study. Neurotherapeutics 14 : 1084-1094, 2017.
PubMed
14) Yamauchi J, et al : Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy : A Randomized Controlled Trial (HAMLET-P). Viruses 14 : 136, 2022.
 
15) Yamauchi J, et al : An update on human T-cell leukemia virus type I (HTLV-1) -associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. Pharmacol Ther 218 : 107669, 2021.
 
P.353 掲載の参考文献
1) Kira J, et al : Acute myelitis associated with hyperIgEemia and atopic dermatitis. J Neurol Sci 148 : 199-203, 1997.
PubMed
2) Kira J, et al : Acute myelitis with hyperIgEaemia and mite antigen specific IgE : atopic myelitis. J Neurol Neurosurg Psychiatry 64 : 676-679, 1998.
PubMed
3) Hopkins IJ : A new syndrome : poliomyelitis-like illness associated with acute asthma in childhood. Aust Paediatr J 10 : 273-276, 1974.
PubMed
4) Kira J, et al : Clinical, immunological and MRI features of myelitis with atopic dermatitis (atopic myelitis). J Neurol Sci 162 : 56-61, 1999.
PubMed
5) Kira J, et al : History of allergic disorders in common neurologic diseases in Japanese patients. Acta Neurol Scand 105 : 215-220, 2002.
PubMed
6) Osoegawa M, et al : Myelitis with atopic diathesis : a nationwide survey of 79 cases in Japan. J Neurol Sci 209 : 5-11, 2003.
PubMed
7) Isobe N, et al : Neural damage associated with atopic diathesis : a nationwide survey in Japan. Neurology 73 : 790-797, 2009.
PubMed
8) Ainiding G, et al : Clinical disability progression and platelet GP IIb/IIIa values in patients with atopic myelitis. J Neuroimmunol 246 : 108-112, 2012.
PubMed
9) Osoegawa M, et al : High incidence of subclinical peripheral neuropathy in myelitis with hyperIgEaemia and mite antigen-specific IgE (atopic myelitis) : an electrophysiological study. Intern Med 41 : 684-691, 2002.
PubMed
10) Kira J, et al : Atopic myelitis with focal amyotrophy : a possible link to Hopkins syndrome. J Neurol Sci 269 : 143-151, 2008.
PubMed
11) Osoegawa M, et al : Eosinophilic myelitis associated with atopic diathesis : a combined neuroimaging and histopathological study. Acta Neuropathol 105 : 289-295, 2003.
PubMed
12) Yamasaki R, et al : Allergic Inflammation Leads to Neuropathic Pain via Glial Cell Activation. J Neurosci 36 : 11929-11945, 2016.
PubMed
13) Tanaka M, et al : Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 71 : 974-981, 2008.
PubMed
14) Wu XM, et al : Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. J Neurol Sci 177 : 24-31, 2000.
PubMed
15) Sato S, et al : HLA-DPB1*0201 is associated with susceptibility to atopic myelitis in Japanese. J Neuroimmunol 251 : 110-113, 2012.
PubMed
16) Fujii T, et al : A Novel Autoantibody against Plexin D1 in Patients with Neuropathic Pain. Ann Neurol 84 : 208-224, 2018.
 
17) Fujii T, et al : Painful trigeminal neuropathy associated with anti-Plexin D1 antibody. Neurol Neuroimmunol Neuroinflamm 7 : e819, 2020.
PubMed
18) Murai H, et al : Effect of immunotherapy in myelitis with atopic diathesis. J Neurol Sci 227 : 39-47, 2004.
PubMed
19) Kanamori Y, et al : Multimodality evoked potentials for discrimination of atopic myelitis and multiple sclerosis. Clin Exp Neuroimmunol 4 : 29-35, 2013.
 
20) Isobe N, et al : First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis. J Neurol Sci 316 : 30-35, 2012.
PubMed
21) 吉良潤一 : Hopkins症候群の疾患分類学的位置とその今日的意義. 神経内科 56 : 32-40, 2002.
 
22) Horiuchi I, et al : Acute myelitis after asthma attacks with onset after puberty. J Neurol Neurosurg Psychiatry 68 : 665-668, 2000.
PubMed
23) Hayashi F, et al : Hopkins syndrome following the first episode of bronchial asthma associated with enterovirus D68 : a case report. BMC Neurol 18 : 71, 2018.
PubMed
24) Saitoh BY, et al : Early postnatal allergic airway inflammation induces dystrophic microglia leading to excitatory postsynaptic surplus and autism-like behavior. Brain Behav Immun 95 : 362-380, 2021.
PubMed
P.360 掲載の参考文献
1) Moersch FP, et al : Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome) ; report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin 31 : 421-427, 1956.
PubMed
2) Gordon EE, et al : A critical survey of stiff-man syndrome. Am J Med 42 : 582-599, 1967.
PubMed
3) Solimena M, et al : Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322 : 1555-1560, 1990.
PubMed
4) Hutchinson M, et al : Progressive encephalomyelitis, rigidity, and myoclonus : a novel glycine receptor antibody. Neurology 71 : 1291-1292, 2008.
PubMed
5) Dalakas MC : Stiff person syndrome : advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 11 : 102-110, 2009.
PubMed
6) Dalakas MC, et al : The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 55 : 1531-1535, 2000.
PubMed
7) Graus F, et al : GAD antibodies in neurological disorders-insights and challenges. Nat Rev Neurol 16 : 353-365, 2020.
PubMed
8) Rakocevic G, Floeter MK : Autoimmune stiff person syndrome and related myelopathies : understanding of electrophysiological and immunological processes. Muscle Nerve 45 : 623-634, 2012.
PubMed
9) 松井尚子, ほか : スティッフパーソン症候群. Brain Nerve 73 : 640-646, 2021.
 
10) De Camilli P, et al : The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 178 : 2219-2223, 1993.
PubMed
11) Butler MH, et al : Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 26 : 307-312, 2000.
PubMed
12) El-Abassi R, et al : SPS : Understanding the complexity. J Neurol Sci 404 : 137-149, 2019.
PubMed
13) Dalmau J, Graus F : Antibody-Mediated Encephalitis. N Engl J Med 378 : 840-851, 2018.
PubMed
14) Petit-Pedrol M, et al : Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor : a case series, characterization of the antigen, and analysis of the effects of antibodies. Lancet Neurol 13 : 276-286, 2014.
 
15) Balint B, et al : Progressive encephalomyelitis with rigidity and myoclonus : a new variant with DPPX antibodies. Neurology 82 : 1521-1528, 2014.
PubMed
16) Dalakas MC, et al : A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol 82 : 271-277, 2017.
PubMed
17) McKeon A, et al : Stiff-man syndrome and variants : clinical course, treatments, and outcomes. Arch Neurol 69 : 230-238, 2012.
PubMed
18) Martinez-Hernandez E, et al : Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. JAMA Neurol 73 : 714-720, 2016.
PubMed
P.365 掲載の参考文献
1) Blennow G, et al : Encephalo-myelo-radiculo-neuropathy. Dev Med Child Neurol 10 : 485-490, 1968.
PubMed
2) 糸数直哉, ほか : 多発性脳神経麻痺と大脳病変を伴った急性多発根神経炎の1例. 脳と発達 30 : 423-429, 1998.
Medical*Online
3) Kinoshita A, et al : Inflammatory demyelinating polyradiculitis in a patient with acute disseminated encephalomyelitis (ADEM). J Neurol Neurosurg Psychiatry 60 : 87-90, 1996.
 
4) Shima S, et al : Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy. Neurology 82 : 114-118, 2014.
PubMed
5) Takeuchi Y, et al : A Case of Limbic Encephalitis with Anti-Neutral Glycosphingolipid Antibodies. Neurol Clin Neurosci 4 : 70-72, 2016.
 
6) Nanaura H, et al : A Patient With Encephalomyeloradiculoneuropathy Exhibiting a Relapsing-Remitting Clinical Course : Correlation of Serum and Cerebrospinal Fluid Anti-Neutral Glycosphingolipids Antibodies With Clinical Relapse. Front Neurol 9 : 206, 2018.
PubMed
7) 林智弘, ほか : 急性散在性脊髄炎と多発神経炎を併発した抗ラクトシルセラミド (LacCer) 抗体陽性の1例. 臨床神経学 58 : 297-301, 2018.
 
8) Saito K, et al : Anti-neutral glycolipids antibody-positive combined central and peripheral demyelination mimicking encephalomyeloradiculoneuropathy phenotype. Clin Neurol Neurosurg 172 : 90-92, 2018.
PubMed
9) Harada M, et al : Reversible Conduction Failure in Anti-lactosylceramide-antibody-positive Combined Central and Peripheral Demyelination. Front Neurol, 10 : 600, 2019. (DOI : 10.3389/fneur.2019.00600)
 
10) Ogata H, et al : A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry 87 : 29-36, 2016.
PubMed
11) Cortese A, et al : Neurofascin-155 as a putative antigen in combined central and peripheral demyelination. Neurol Neuroimmunol Neuroinflamm 3 : e238, 2016.
PubMed
12) Mutoh T, et al : Species-specific accumulation of ceramides in cerebrospinal fluid from encephalomyeloradiculoneurpathy patients associated with peripheral complement activation : A pilot study. Biochim Biophys Acta Mol Cell Biol Lipids 1867 : 159092, 2022.
 
13) Nakayama H, et al : Lyn-coupled LacCer-enriched lipid rafts are required for CD11b/CD18-mediated neutrophil phagocytosis of nonopsonized microorganisms. J Leukoc Biol 83 : 728-741, 2008.
PubMed
14) Mayo L, et al : Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med 20 : 1147-1156, 2014.
PubMed
15) Pandey MK, et al : Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature 543 : 108-112, 2017.
PubMed
P.374 掲載の参考文献
1) Pittock SJ, et al : Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 133 : 2626-2634, 2010.
PubMed
2) Taieb G, et al : A central nervous system B-cell lymphoma arising two years after initial diagnosis of CLIPPERS. J Neurol Sci 344 : 224-226, 2014.
PubMed
3) Limousin N, et al : Brain biopsy is required in steroid-resistant patients with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). J Neurooncol 107 : 223-224, 2012.
PubMed
4) Jones JL, et al : 'Radiologically compatible CLIPPERS' may conceal a number of pathologies. Brain 134 : e187, 2011.
PubMed
5) Tobin WO, et al : Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 140 : 2415-2425, 2017.
PubMed
6) Taieb G, et al : Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome. Neurol Neuroimmunol Neuroinflamm 8 : e970, 2021.
PubMed
7) Debinski C, et al : Exploring the Intersection of Isolated-CNS Hemophagocytic Lymphohistiocytosis and Pediatric Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids. J Child Neurol 36 : 935-942, 2021.
PubMed
8) Obeidat AZ, et al : "Peppering the Pons" : CLIPPERS or Myelin Oligodendrocyte Glycoprotein Associated Disease? Mult Scler Relat Disord 51 : 102874, 2021.
PubMed
9) Yin HX, et al : A Case Report of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Diagnosed After Long Term Diagnosis of Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids. Front Neurol 11 : 598650, 2020.
PubMed
10) Symmonds M, et al : Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS. Neurology 84 : 1177-1179, 2015.
PubMed
11) Ferreira RM, et al : CLIPPERS-like MRI findings in a patient with multiple sclerosis. J Neurol Sci 327 : 61-62, 2013.
 
12) Sonoda K, et al : Case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids showing features common to multiple sclerosis. Clin Exp Neuroimmunol 4 : 104-106, 2013.
 
13) Nagano, et al : Recurrent Epstein-Barr Virus-positive (EBV+) Primary Central Nervous System Lymphoma (PCNSL) in a Patient with Clinical Features of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). Intern Med 58 : 849-854, 2019.
 
14) Mele N, et al : Effective antituberculous therapy in a patient with CLIPPERS : New insights into CLIPPERS pathogenesis. Neurol Neuroimmunol Neuroinflamm 1 : e6, 2014.
 
15) Tan BL, et al : CLIPPERS : Induction and maintenance of remission using hydroxychloroquine. Neurol Neuroimmunol Neuroinflamm 2 : e56, 2015.
PubMed
16) Taieb G, et al : Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. Arch Neurol 69 : 847-855, 2012.
 
17) Jarius S, et al : Clinical, paraclinical and serological findings in Susac syndrome : an international multicenter study. J Neuroinflammation 11 : 46, 2014.
PubMed
18) Gross CC, et al : CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuroinflammation in Susac syndrome. Nat Commun 10 : 5779, 2019.
PubMed
19) Dorr J, et al : Characteristics of Susac syndrome : a review of all reported cases. Nat Rev Neurol 9 : 307-316, 2013.
PubMed
20) Egan RA, et al : Gass plaques and fluorescein leakage in Susac Syndrome. J Neurol Sci 299 : 97-100, 2010.
PubMed
21) Bernard JT, et al : Optical coherence tomography in Susac's syndrome. Mult Scler Relat Disord 3 : 110-116, 2014.
PubMed
22) Ringelstein M, et al : Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology 85 : 610-618, 2015.
PubMed
23) Rennebohm RM, et al : Guidelines for treatment of Susac syndrome-An update. Int J Stroke 15 : 484-494, 2020.
PubMed
24) Marrodan M, et al : Susac syndrome : Challenges in the diagnosis and treatment. Brain, 2021. (DOI : 10.1093/brain/awab476)
 
25) Buelens T, et al : EVALUATION OF TUMOR NECROSIS FACTOR INHIBITOR THERAPY IN SUSAC SYNDROME. Retina 40 : 581-590, 2020.
PubMed
26) Ryerson LZ, et al : Incomplete Susac syndrome exacerbated after natalizumab. Neurol Neuroimmunol Neuroinflamm 2 : e151, 2015.
 

V 脱髄以外の末梢神経免疫疾患

P.383 掲載の参考文献
1) Crow RS : Peripheral neuritis in myelomatosis. Br Med J 2 : 802-804, 1956.
PubMed
2) 深瀬政市, ほか : 多発性神経炎および内分泌異常を惹起した孤立性骨髄腫. 日本臨牀 26 : 2440-2456, 1968.
 
3) Bardwick PA, et al : Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes : the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) 59 : 311-322, 1980.
 
4) Nakanishi T, et al : The Crow-Fukase syndrome : a study of 102 cases in Japan. Neurology 34 : 712-720, 1984.
PubMed
5) Suichi T, Misawa S : Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome : Diagnosis, treatment and the current status in Japan. Clin Exp Neuroimmunol 11 : 101-108, 2020.
 
6) Abe D, et al : Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome. Blood 112 : 836-839, 2008.
PubMed
7) Nagao Y, et al : Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia 33 : 1723-1735, 2019.
PubMed
8) Watanabe O, et al : Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347 : 702, 1996.
PubMed
9) Kanai K, et al : Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome. Neurology 79 : 575-582, 2012.
PubMed
10) Suichi T, et al : Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology 93 : e975-e983, 2019.
PubMed
11) Dispenzieri A : POEMS Syndrome : 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol 94 : 812-827, 2019.
PubMed
12) Suichi T, et al : Proposal of new clinical diagnostic criteria for POEMS syndrome. J Neurol Neurosurg Psychiatry 90 : 133-137, 2019.
PubMed
13) He T, et al : Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy. Ann Hematol 98 : 735-743, 2019.
 
14) Morizane R, et al : A case of atypical POEMS syndrome without polyneuropathy. Eur J Haematol 80 : 452-455, 2008.
PubMed
15) Misawa S, et al : Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response : retrospective cohort study. BMJ Open 5 : e009157, 2015.
PubMed
16) Van den Bergh PYK, et al : European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint Task Force-Second revision. Eur J Neurol 28 : 3556-3583, 2021.
PubMed
17) Nasu S, et al : Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 83 : 476-479, 2012.
PubMed
18) Kourelis TV, et al : Long-term outcome of patients with POEMS syndrome : An update of the Mayo Clinic experience. Am J Hematol 91 : 585-589, 2016.
 
19) D'Souza A, et al : Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma) : a single-center experience. Blood 120 : 56-62, 2012.
PubMed
20) Li J, et al : Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome. Leukemia 31 : 1375-1381, 2017.
PubMed
21) Ohwada C, et al : Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood 131 : 2173-2176, 2018.
PubMed
22) Misawa S, et al : Safety and efficacy of thalidomide in patients with POEMS syndrome : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15 : 1129-1137, 2016.
PubMed
23) Li J, et al : A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol 93 : 803-809, 2018.
 
24) Nozza A, et al : Lenalidomide and dexamethasone in patients with POEMS syndrome : results of a prospective, open-label trial. Br J Haematol 179 : 748-755, 2017.
PubMed
25) Suichi T, et al : Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome : A Prospective Single-arm Clinical Trial. Intern Med 59 : 1149-1153, 2020.
PubMed
26) He H, et al : Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Br J Haematol 181 : 126-128, 2018.
PubMed
27) Gao XM, et al : Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome. Ann Hematol 100 : 2755-2761, 2021.
PubMed
28) Humeniuk MS, et al : Outcomes of patients with POEMS syndrome treated initially with radiation. Blood 122 : 68-73, 2013.
PubMed
P.389 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Nakazawa D, et al : Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 15 : 91-101, 2019.
PubMed
3) 松本美富士, ほか : 日本における難治性血管炎の全国疫学調査. 厚生省特定疾患に関する疫学調査研究班, 1998年度研究報告書. p15-23, 1998.
 
4) Guillevin L, et al : Microscopic polyangiitis : clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42 : 421-430, 1999.
PubMed
5) Sada KE, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 : R101, 2014.
 
6) Nishino H, et al : Neurological involvement in Wegener's granulomatosis : an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 33 : 4-9, 1993.
 
7) Mizisin AP, Weerasuriya A : Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult. Acta Neuropathol 121 : 291-312, 2011.
PubMed
8) Nishi R, et al : Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology 94 : e1726-e1737, 2020.
PubMed
9) Oka N, et al : Two subtypes of Churg-Strauss syndrome with neuropathy : the roles of eosinophils and ANCA. Mod Rheumatol 21 : 290-295, 2011.
PubMed
10) Ueki S, et al : Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood 121 : 2074-2083, 2013.
PubMed
11) 石黒直子 : 血管炎における皮膚病変. Brain and Nerve 71 : 339-344, 2019.
 
12) Guillevin L, et al : The Five-Factor Score revisited : assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90 : 19-27, 2011.
 
13) Said G, Lacroix C : Primary and secondary vasculitic neuropathy. J Neurol 252 : 633-641, 2005.
PubMed
14) 古賀道明 : 血管炎性末梢神経障害のevidenced-based treatment. Brain and Nerve 68 : 243-251, 2016.
 
15) 神田隆 : 血管炎に伴うニューロパチー. 日本内科学会雑誌 108 : 1517-1523, 2019.
 
16) 竹下幸男 : 好酸球性多発血管炎性肉芽腫症 脳神経内科医から呼吸器内科医へ. 呼吸器内科 40 : 295-300, 2021.
 
P.394 掲載の参考文献
1) Isaacs H : A SYNDROME OF CONTINUOUS MUSCLE-FIBRE ACTIVITY. J Neurol Neurosurg Psychiatry 24 : 319-325, 1961.
 
2) Mertens HG, Zschocke S : [Neuromyotonia]. Klin Wochenschr 43 : 917-925, 1965.
PubMed
3) Vincent A, et al : Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia. JAMA Neurol 75 : 1519-1527, 2018.
PubMed
4) Irani SR, et al : Morvan syndrome : clinical and serological observations in 29 cases. Ann Neurol 72 : 241-255, 2012.
PubMed
5) Watanabe O : [Isaacs's syndrome and associated diseases]. Rinsho Shinkeigaku 53 : 1067-1070, 2013.
 
6) Arimura K, et al : Antibodies to potassium channels of PC12 in serum of Isaacs' syndrome : Western blot and immunohistochemical studies. Muscle Nerve 20 : 299-305, 1997.
PubMed
7) Sinha S, et al : Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 338 : 75-77, 1991.
PubMed
8) Shillito P, et al : Acquired neuromyotonia : evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 38 : 714-722, 1995.
PubMed
9) Shimatani Y, et al : Abnormal gating of axonal slow potassium current in cramp-fasciculation syndrome. Clin Neurophysiol 126 : 1246-1254, 2015.
PubMed
10) Barber PA, et al : Morvan's syndrome associated with voltage-gated K+ channel antibodies. Neurology 54 : 771-772, 2000.
 
11) Buckley C, et al : Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50 : 73-78, 2001.
PubMed
12) Irani SR, et al : Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010.
 
13) Ahmed A, Simmons Z : Isaacs syndrome : A review. Muscle Nerve 52 : 5-12, 2015.
PubMed
14) Van Engelen BG, et al : Are muscle cramps in Isaacs' syndrome triggered by human immunoglobulin? J Neurol Neurosurg Psychiatry 58 : 393, 1995.
PubMed
P.401 掲載の参考文献
1) Young RR, et al : Pure pan-dysautonomia with recovery. Trans Am Neurol Assoc 94 : 355-357, 1969.
PubMed
2) Low PA, et al : Acute panautonomic neuropathy. Ann Neurol 13 : 412-417, 1983.
PubMed
3) Okada F, et al : Two cases of acute pandysautonomia. Arch Neurol 32 : 146-151, 1975.
PubMed
4) Hayashi M, Ishii Y : A Japanese case of autoimmune autonomic ganglionopathy (AAG) and a review of AAG cases in Japan. Auton Neurosci 146 : 26-28, 2009.
 
5) Klein CM, et al : The spectrum of autoimmune autonomic neuropathies. Ann Neurol 53 : 752-758, 2003.
PubMed
6) Nakane S, et al : Autoimmune autonomic ganglionopathy : an update on diagnosis and treatment. Expert Rev Neurother 18 : 953-965, 2018.
PubMed
7) Sterman AB, et al : The acute sensory neuronopathy syndrome : a distinct clinical entity. Ann Neurol 7 : 354-358, 1980.
PubMed
8) Colan RV, et al : Acute autonomic and sensory neuropathy. Ann Neurol 8 : 441-444, 1980.
PubMed
9) Vernino S, et al : Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci 146 : 3-7, 2009.
 
10) Nakane S, et al : A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy. J Autoimmun 108 : 102403, 2020.
PubMed
11) Dhamija R, et al : Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol 6 : 988-992, 2008.
PubMed
12) Kimpinski K, et al : Sudomotor dysfunction in autoimmune autonomic ganglionopathy. Neurology 73 : 1501-1506, 2009.
PubMed
13) Goldstein DS, et al : Clinical laboratory evaluation of autoimmune autonomic ganglionopathy : Preliminary observations. Auton Neurosci 146 : 18-21, 2009.
PubMed
14) Winston N, Vernino S : Recent advances in autoimmune autonomic ganglionopathy. Curr Opin Neurol 23 : 514-518, 2010.
PubMed
15) Bouxin M, et al : Rituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy : Case-report and literature review. J Neuroimmunol 326 : 28-32, 2019.
PubMed
16) Vernino S, et al : Invited Article : Autonomic ganglia : target and novel therapeutic tool. Neurology 70 : 1926-1932, 2008.
PubMed
17) 長谷川康博 : 急性自律性感覚性ニューロパチーの自律神経症候. 神経内科 71 : 555-560, 2009.
 
18) Koike H, et al : Clinicopathological features of acute autonomic and sensory neuropathy. Brain 133 : 2881-2896, 2010.
PubMed
19) Fagius J, et al : Acute pandysautonomia and severe sensory deficit with poor recovery. A clinical, neurophysiological and pathological case study. J Neurol Neurosurg Psychiatry 46 : 725-733, 1983.
PubMed
20) Koike H, et al : The spectrum of immune-mediated autonomic neuropathies : insights from the clinicopathological features. J Neurol Neurosurg Psychiatry 84 : 98-106, 2013.
PubMed
21) Benarroch EE : The clinical approach to autonomic failure in neurological disorders. Nat Rev Neurol 10 : 396-407, 2014.
PubMed
22) 中尾紘一, ほか : 頻回の失神が感覚障害に先行したサイトメガロウイルス感染症に伴う亜急性自律性感覚性ニューロパチーの1例. 臨床神経学 56 : 555-559, 2016.
 
23) 石倉照之, ほか : ガラクトセレブロシド・リン脂質複合体に対するIgG抗体陽性急性自律性感覚性ニューロパチーの1例. 臨床神経学 57 : 33-36, 2017.
 
24) 楠進 : Guillain-Barre症候群と自律神経障害. 自律神経 47 : 195-197, 2010.
 
25) Yokota T, et al : Dysautonomia with acute sensory motor neuropathy. A new classification of acute autonomic neuropathy. Arch Neurol 51 : 1022-1031, 1994.
PubMed
P.406 掲載の参考文献
1) Scholz J, et al : The IASP classification of chronic pain for ICD-11 : chronic neuropathic pain. Pain 160 : 53-59, 2019.
PubMed
2) Attal N, et al : The specific disease burden of neuropathic pain : results of a French nationwide survey. Pain 152 : 2836-2843, 2011.
PubMed
3) Xu M, et al : Pain and the immune system : emerging concepts of IgG-mediated autoimmune pain and immunotherapies. J Neurol Neurosurg Psychiatry 91 : 177-188, 2020.
PubMed
4) Fujii T, et al : A Novel Autoantibody against Plexin D1 in Patients with Neuropathic Pain. Ann Neurol 84 : 208-224, 2018.
 
5) Fujii T, et al : Painful trigeminal neuropathy associated with anti-Plexin D1 antibody. Neurol Neuroimmunol Neuroinflamm 7 : e819, 2020.
PubMed
6) Fujii T, et al : Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals. Neurol Neuroimmunol Neuroinflamm 8 : 2021.
PubMed
7) Saini P, et al : Clinical presentation and management in cryptogenic immune small fiber neuropathy with TS-HDS, FGFR-3, or Plexin-D1 antibodies. Neurology 96 (15 Suppl) : 1649, 2021.
 
8) Gadoth A, et al : Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol 82 : 79-92, 2017.
PubMed
9) Pestronk A, et al : Sensory neuropathy with monoclonal IgM binding to a trisulfated heparin disaccharide. Muscle Nerve 27 : 188-195, 2003.
PubMed
10) Pestronk A, et al : Clinical and laboratory features of neuropathies with serum IgM binding to TSHDS. Muscle Nerve 45 : 866-872, 2012.
PubMed
11) Antoine JC, et al : Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. J Neurol Neurosurg Psychiatry 86 : 1347-1355, 2015.
PubMed
12) Kovvuru S, et al : Clinical characteristics of fibroblast growth factor receptor 3 antibody-related polyneuropathy : a retrospective study. Eur J Neurol 27 : 1310-1318, 2020.
PubMed
13) Chan ACY, et al : Novel Autoantibodies in Idiopathic Small Fiber Neuropathy. Ann Neurol 91 : 66-77, 2022.
PubMed

VI 免疫性神経筋接合部疾患

P.416 掲載の参考文献
1) 辻畑光宏 : 神経筋接合部の微細構造. Clinical Neuroscience 26 : 959-961, 2008.
 
2) Koneczny I, Herbst R : Myasthenia Gravis : Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. Cells 8 : 671, 2019.
 
3) Fichtner ML, et al : Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Front Immunol 11 : 776, 2020.
PubMed
4) 重症筋無力症診療ガイドライン (ランバート・イートン筋無力症候群を含めて) CQ1-1 神経筋接合部の病態 CQ10-1 LEMSの病因はなにか 2021.
 
5) Rodriguez Cruz PM, et al : Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. JAMA Neurol 72 : 642-649, 2015.
 
6) Higuchi O, et al : Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69 : 418-422, 2011.
PubMed
7) Shiraishi H, et al : Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57 : 289-293, 2005.
PubMed
8) Masuda T, et al : Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry 83 : 935-940, 2012.
PubMed
9) Cao M, et al : Myasthenia Gravis With Antibodies Against Muscle Specific Kinase : An Update on Clinical Features, Pathophysiology and Treatment. Front Mol Neurosci 13 : 159, 2020.
PubMed
10) Takata K, et al : Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight 4 : e127167, 2019.
PubMed
11) Tzartos JS, et al : LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol 1 : 80-87, 2014.
 
12) Fukuda T, et al : Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 53 : 21-28, 2003.
PubMed
13) Shimizu F, et al : GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain 142 : 2253-2264, 2019.
PubMed
14) Nakao YK, et al : Seronegative Lambert-Eaton myasthenic syndrome : study of 110 Japanese patients. Neurology 59 : 1773-1775, 2002.
PubMed
15) Tsujihata M, et al : Ultrastructural study of the motor end-plate in botulism and Lambert-Eaton myasthenic syndrome. J Neurol Sci 81 : 197-213, 1987.
PubMed
P.419 掲載の参考文献
1) Grob D, et al : Lifetime course of myasthenia gravis. Muscle Nerve 37 : 141-149, 2008.
PubMed
2) 重症筋無力症診療ガイドライン 2014 (日本神経学会監, 「重症筋無力症診療ガイドライン」作成委員会編), 南江堂, 2014.
 
3) 平山宗広, ほか : 重症筋無力症の疫学的研究. 昭和48年度厚生省特定疾患重症筋無力症調査研究班報告書, p50-66, 1974.
 
4) 高守正治, 井形昭弘 : 重症筋無力症疫学調査報告. 厚生省特定疾患免疫性神経疾患調査研究班昭和62年度研究報告書, p227-245, 1988.
 
5) Murai H, et al : Characteristics of myasthenia gravis according to onset-age : Japanese nationwide survey. J Neurol Sci 305 : 97-102, 2011.
PubMed
6) 吉川弘明, ほか : 重症筋無力症の全国疫学調査-二次調査による臨床像解析-. 神経免疫疾患のエビデンスによる診断基準・重症度分類・ガイドラインの妥当性と患者QOLの検証に関する研究 総括研究報告書, p22-25, 2019.
 
7) Somnier FE : Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 65 : 928-930, 2005.
PubMed
8) Zhong H, et al : HLA in myasthenia gravis : From superficial correlation to underlying mechanism. Autoimmun Rev 18 : 102349, 2019.
PubMed
9) Santos E, et al : HLA and age of onset in myasthenia gravis. Neuromuscul Disord 27 : 650-654, 2017.
PubMed
10) Spagni G, et al : Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis. Ann Clin Transl Neurol 8 : 656-665, 2021.
PubMed
11) Suzuki S, et al : Heterogeneous immunogenetic background in Japanese adults with myasthenia gravis. J Neurol Sci 189 : 59-64, 2001.
PubMed
12) Suzuki S, et al : Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 230 : 148-152, 2011.
PubMed
13) Shinomiya N, et al : A variant of childhood-onset myasthenia gravis : HLA typing and clinical characteristics in Japan. Clin Immunol 110 : 154-158, 2004.
PubMed
14) Kanai T, et al : HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients. J Neurol Sci 363 : 116-118, 2016.
PubMed
15) Gregersen PK, et al : Risk for myasthenia gravis maps to a 151Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol 72 : 927-935, 2012.
 
16) Seldin MF, et al : Genome-Wide Association Study of Late-Onset Myasthenia Gravis : Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations. Mol Med 21 : 769-781, 2016.
PubMed
17) Renton AE, et al : A genome-wide association study of myasthenia gravis. JAMA Neurol 72 : 396-404, 2015.
PubMed
18) Topaloudi A, et al : Myasthenia gravis genome-wide association study implicates AGRN as a risk locus. J Med Genet, 2021. (DOI : 10.1136/jmedgenet-2021-107953)
 
19) Handunnetthi L, et al : Genomic Insights into Myasthenia Gravis Identify Distinct Immunological Mechanisms in Early and Late Onset Disease. Ann Neurol 90 : 455-463, 2021.
PubMed
20) Cavalcante P, et al : Etiology of myasthenia gravis : innate immunity signature in pathological thymus. Autoimmun Rev 12 : 863-874, 2013.
PubMed
21) Berrih-Aknin S, et al : Myasthenia gravis : a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 52 : 90-100, 2014.
PubMed
22) Westerberg E, et al : Lifestyle factors and disease-specific differences in subgroups of Swedish Myasthenia Gravis. Acta Neurol Scand 138 : 557-565, 2018.
PubMed
P.426 掲載の参考文献
1) 村井弘之 : 重症筋無力症・炎症性筋疾患 日本内科学会雑誌 110 : 1575-1581, 2021.
 
2) Gilhus NE, Verschuuren JJ : Myasthenia gravis : subgroup classification and therapeutic strategies. Lancet Neurol 14 : 1023-1036, 2015.
PubMed
3) Bou Ali H, et al : New strategy for improving the diagnostic sensitivity of repetitive nerve stimulation in myasthenia gravis. Muscle Nerve 55 : 532-538, 2017.
PubMed
4) Abraham A, et al : Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. Muscle Nerve 55 : 166-170, 2017.
 
5) Padua L, et al : Reliability of SFEMG in diagnosing myasthenia gravis : sensitivity and specificity calculated on 100 prospective cases. Clin Neurophysiol 125 : 1270-1273, 2014.
PubMed
6) Handunnetthi L, et al : Genomic Insights into Myasthenia Gravis Identify Distinct Immunological Mechanisms in Early and Late Onset Disease. Ann Neurol 90 : 455-463, 2021.
PubMed
7) Suzuki S, et al : Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 230 : 148-152, 2011.
PubMed
8) Meager A, et al : Hypothetical review : thymic aberrations and type-I interferons ; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. Clin Exp Immunol 154 : 141-151, 2008.
PubMed
9) Jaretzki A, et al : Myasthenia gravis : recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 : 16-23, 2000.
PubMed
10) Muppidi S : The myasthenia gravis-specific activities of daily living profile. Ann N Y Acad Sci 1274 : 114-119, 2012.
PubMed
11) Burns TM, et al : Construction of an efficient evaluative instrument for myasthenia gravis : the MG composite. Muscle Nerve 38 : 1553-1562, 2008.
PubMed
12) Burns TM, et al : International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve 54 : 1015-1022, 2016.
PubMed
13) Drachman DB : Myasthenia gravis. N Engl J Med 330 : 1797-1810, 1994.
PubMed
14) Nakata R, et al : Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis. Eur J Neurol 20 : 1272-1276, 2013.
PubMed
15) Suzuki S, et al : Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66 : 1334-1338, 2009.
PubMed
P.433 掲載の参考文献
1) Masuda M, et al : The MG-QOL15 Japanese version : validation and associations with clinical factors. Muscle Nerve 46 : 166-173, 2012.
PubMed
2) Utsugisawa K, et al : Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle Nerve 50 : 493-500, 2014.
PubMed
3) Suzuki S, et al : Quality of life in purely ocular myasthenia in Japan. BMC Neurol 14 : 142, 2014.
PubMed
4) Nagane Y, et al : Social disadvantages associated with myasthenia gravis and its treatment : a multicentre cross-sectional study. BMJ Open 7 : e013278, 2017.
PubMed
5) Clinical Question 4-1 治療の基本的な考え方は. 重症筋無力症診療ガイドライン 2014 (重症筋無力症診療ガイドライン作成委員会編, 日本神経学会監), p26-29, 南江堂, 2014.
 
6) Utsugisawa K, et al : Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve 55 : 794-801, 2017.
PubMed
7) Nagane Y, et al : Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 65 : 16-22, 2011.
PubMed
8) Clinical Question 5-1-1 治療の基本的考え方は. 重症筋無力症診療ガイドライン 2022 (ランバート・イートン筋無力症候群を含めて) (重症筋無力症/ランバート・イートン筋無力症候群診療ガイドライン作成委員会編, 日本神経学会監), p50-53, 南江堂, 2022.
 
9) Clinical Question 5-1-2 早期速効性治療戦略とは何か. 重症筋無力症診療ガイドライン 2022 (ランバート・イートン筋無力症候群を含めて) (重症筋無力症/ランバート・イートン筋無力症候群診療ガイドライン作成委員会編, 日本神経学会監), p54-56, 南江堂, 2022.
 
10) Utsugisawa K, et al : Health-related quality of life and treatment strategies in myasthenia gravis. Clin Exp Neuroimmunol 11 : 209-217, 2020.
 
11) Grob D, et al : Lifetime course of myasthenia gravis. Muscle Nerve 37 : 141-149, 2008.
PubMed
12) Jaretzki A, et al : Myasthenia gravis : recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 : 16-23, 2000.
PubMed
13) Imai T, et al : Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle Nerve 51 : 692-696, 2015.
PubMed
14) Imai T, et al : Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis : a multicentre cross-sectional study in Japan. J Neurol Neurosurg Psychiatry 89 : 513-517, 2018.
PubMed
15) Sharshar T, et al : Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis : A Randomized Clinical Trial. JAMA Neurol 78 : 426-433, 2021.
PubMed
16) Clinical Question 6-2 メチルプレドニゾロン静脈内大量投与 (ステロイドパルス療法) をどのように行うか. 重症筋無力症診療ガイドライン 2014 (重症筋無力症診療ガイドライン作成委員会編, 日本神経学会監), p62-63, 南江堂, 2014.
 
P.438 掲載の参考文献
1) Meriggioli MN, Sanders DB : Autoimmune myasthenia gravis : emerging clinical and biological heterogeneity. Lancet Neurol 8 : 475-490, 2009.
PubMed
2) Conti-Fine BM, et al : Myasthenia gravis : past, present, and future. J Clin Invest 116 : 2843-2854, 2006.
PubMed
3) Utsugisawa K, et al : Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve 55 : 794-801, 2017.
PubMed
4) Howard JF, et al : Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN) : a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16 : 976-986, 2017.
PubMed
5) Walport MJ : Complement. First of two parts. N Engl J Med 344 : 1058-1066, 2001.
PubMed
6) Rother RP, et al : Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25 : 1256-1264, 2007.
PubMed
7) Engel AG, Arahata K : The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 505 : 326-332, 1987.
PubMed
8) Engel AG, et al : Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis : ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 52 : 267-280, 1977.
PubMed
9) Sahashi K, et al : Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 39 : 160-172, 1980.
PubMed
10) Zhou Y, et al : Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 179 : 8562-8567, 2007.
PubMed
11) Ozawa Y, et al : Long-term outcomes and prognostic factors in generalized myasthenia gravis. J Neurol 268 : 3781-3788, 2021.
PubMed
12) Barohn RJ, Brey RL : Soluble terminal complement components in human myasthenia gravis. Clin Neurol Neurosurg 95 : 285-290, 1993.
PubMed
13) Romi F, et al : The role of complement in myasthenia gravis : serological evidence of complement consumption in vivo. J Neuroimmunol 158 : 191-194, 2005.
PubMed
14) Liu A, et al : Correlation of C3 level with severity of generalized myasthenia gravis. Muscle Nerve 40 : 801-808, 2009.
PubMed
15) Howard JF, et al : Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis : Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol 77 : 582-592, 2020.
PubMed
P.445 掲載の参考文献
1) Eaton LM, Lambert EH : Electromyography and electric stimulation of nerves in diseases of motor unit ; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc 163 : 1117-1124, 1957.
PubMed
2) Lang B, et al : Antibodies to motor nerve terminals : an electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol 344 : 335-345, 1983.
PubMed
3) Wirtz PW, et al : The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology 63 : 397-398, 2004.
PubMed
4) Lefter S, et al : A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology 88 : 304-313, 2017.
PubMed
5) Abenroth DC, et al : Lambert-Eaton myasthenic syndrome : Epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve 56 : 421-426, 2017.
PubMed
6) Titulaer MJ, et al : Screening for small-cell lung cancer : a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 26 : 4276-4281, 2008.
PubMed
7) Anwar A, et al : Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome. Cureus 11 : e5450, 2019.
PubMed
8) Titulaer MJ, et al : The Lambert-Eaton myasthenic syndrome 1988-2008 : a clinical picture in 97 patients. J Neuroimmunol 201-202 : 153-158, 2008.
 
9) Cho JJ, et al : Paraneoplastic Lambert-Eaton Myasthenic Syndrome With Limbic Encephalitis : Clinical Correlation With the Coexistence of Anti-VGCC and Anti-GABAB Receptor Antibodies. J Clin Neuromuscul Dis 19 : 84-88, 2017.
 
10) Motomura M, et al : Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 147 : 35-42, 1997.
 
11) Lennon VA, et al : Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332 : 1467-1474, 1995.
PubMed
12) Tim RW, et al : Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Ann N Y Acad Sci 841 : 823-826, 1998.
PubMed
13) Oh SJ, et al : Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 32 : 515-520, 2005.
PubMed
14) Wirtz PW, et al : P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 164 : 161-165, 2005.
PubMed
15) Maddison P, et al : Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353 : 117-118, 1999.
PubMed
16) Wirtz PW, et al : Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol 251 : 1255-1259, 2004.
PubMed
17) McEvoy KM, et al : 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 321 : 1567-1571, 1989.
PubMed

VII 免疫性筋疾患

P.456 掲載の参考文献
1) Lundberg IE, et al : Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7 : 86, 2021.
PubMed
2) Hodgkinson LM, et al : Dermatomyositis autoantibodies : how can we maximize utility? Ann Transl Med 9 : 433, 2021.
PubMed
3) Barsotti S, Lundberg IE : Myositis an evolving spectrum of disease. Immunol Med 41 : 46-54, 2018.
PubMed
4) Rietveld A, et al : Autoantibody testing in idiopathic inflammatory myopathies. Pract Neurol 19 : 284-294, 2019.
 
5) Mammen AL, et al : 239th ENMC International Workshop : Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscul Disord 30 : 70-92, 2020.
PubMed
6) McHugh NJ, Tansley SL : Autoantibodies in myositis. Nat Rev Rheumatol 14 : 290-302, 2018.
PubMed
7) Maeda MH, et al : Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain 135 : 1767-1777, 2012.
PubMed
8) Hoogendijk JE, et al : 119th ENMC international workshop : trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14 : 337-345, 2004.
PubMed
9) Uruha A, et al : Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1. Brain 139 : e50, 2016.
PubMed
10) Hida A, et al : Anti-TIF1-γ antibody and cancer-associated myositis : A clinicohistopathologic study. Neurology 87 : 299-308, 2016.
 
11) Greenberg SA, et al : Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57 : 664-678, 2005.
PubMed
12) Mozaffar T, Pestronk A : Myopathy with anti-Jo-1 antibodies : pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 68 : 472-478, 2000.
PubMed
13) Aouizerate J, et al : Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol Commun 2 : 154, 2014.
PubMed
14) Mescam-Mancini L, et al : Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 138 : 2485-2492, 2015.
PubMed
15) Arouche-Delaperche L, et al : Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies : Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol 81 : 538-548, 2017.
PubMed
P.462 掲載の参考文献
1) Lundberg IE, et al : Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7 : 86, 2021.
PubMed
2) Bohan A, Peter JB : Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 : 403-407, 1975.
PubMed
3) van der Meulen MF, et al : Polymyositis : an overdiagnosed entity. Neurology 61 : 316-321, 2003.
PubMed
4) Hoogendijk JE, et al : 119th ENMC international workshop : trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14 : 337-345, 2004.
PubMed
5) Allenbach Y, et al : 224th ENMC International Workshop : Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 28 : 87-99, 2018.
PubMed
6) Benveniste O, et al : Biomarkers in Inflammatory Myopathies-An Expanded Definition. Front Neurol 10 : 554, 2019.
PubMed
7) Troyanov Y, et al : Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies : analysis of 100 French Canadian patients. Medicine (Baltimore) 84 : 231-249, 2005.
PubMed
8) Siegert E, et al : Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathol 141 : 917-927, 2021.
PubMed
9) Lundberg IE, et al : 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76 : 1955-1964, 2017.
PubMed
10) Loarce-Martos J, et al : Polymyositis : is there anything left? A retrospective diagnostic review from a tertiary myositis centre. Rheumatology (Oxford) 60 : 3398-3403, 2021.
PubMed
11) Mammen AL, et al : 239th ENMC International Workshop : Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscul Disord 30 : 70-92, 2020.
PubMed
12) Tsuji H, et al : Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol 72 : 488-498, 2020.
PubMed
13) Sontheimer RD : Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46 : 626-636, 2002.
PubMed
14) Concha JSS, et al : The diagnosis and classification of amyopathic dermatomyositis : a historical review and assessment of existing criteria. Br J Dermatol 180 : 1001-1008, 2019.
PubMed
15) 多発性筋炎・皮膚筋炎治療ガイドライン (厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究班 多発筋炎・皮膚筋炎分科会編), 診断と治療社, 2015.
 
P.470 掲載の参考文献
1) Suzuki N, et al : Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol 259 : 554-556, 2012.
PubMed
2) Greenberg SA, et al : Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain 139 : 1348-1360, 2016.
 
3) Greenberg SA : Inclusion body myositis : clinical features and pathogenesis. Nat Rev Rheumatol 15 : 257-272, 2019.
PubMed
4) Benveniste O, Allenbach Y : Inclusion body myositis : accumulation of evidence for its autoimmune origin. Brain 142 : 2549-2551, 2019.
PubMed
5) Oyama M, et al : HLA-DRB1 allele and autoantibody profiles in Japanese patients with inclusion body myositis. PLoS One 15 : e0237890, 2020.
PubMed
6) Amlani A, et al : Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis. Front Immunol 10 : 745, 2019.
PubMed
7) Tawara N, et al : Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. Ann Neurol 81 : 512-525, 2017.
PubMed
8) Nakano S, et al : The role of p62/SQSTM1 in sporadic inclusion body myositis. Neuromuscul Disord 27 : 363-369, 2017.
PubMed
9) Kitajima Y, et al : Proteasome dysfunction induces muscle growth defects and protein aggregation. J Cell Sci 127 : 5204-5217, 2014.
PubMed
10) Suzuki N, et al : Multicenter questionnaire survey for sporadic inclusion body myositis in Japan. Orphanet J Rare Dis 11 : 146, 2016.
PubMed
11) Cox FM, et al : Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 50 : 1153-1161, 2011.
PubMed
12) Guimaraes JB, et al : Musculoskeletal Ultrasound in Inclusion Body Myositis : A Comparative Study with Magnetic Resonance Imaging. Ultrasound Med Biol 47 : 2186-2192, 2021.
PubMed
13) Langdon PC, et al : Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature. Dysphagia 27 : 408-417, 2012.
PubMed
14) Rose MR, et al ; ENMC IBM Working Group : 188th ENMC International Workshop : Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 23 : 1044-1055, 2013.
 
15) Hanna MG, et al : Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT) : a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol 18 : 834-844, 2019.
PubMed
P.478 掲載の参考文献
1) Bohan A, Peter JB : Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292 : 344-347, 1975.
PubMed
2) Griggs RC, et al : Inclusion body myositis and myopathies. Ann Neurol 38 : 705-713, 1995.
PubMed
3) Reeves WH, et al : Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A 83 : 9507-9511, 1986.
PubMed
4) Hoogendijk JE, et al : 119th ENMC international workshop : trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14 : 337-345, 2004.
PubMed
5) Miller T, et al : Myopathy with antibodies to the signal recognition particle : clinical and pathological features. J Neurol Neurosurg Psychiatry 73 : 420-428, 2002.
 
6) Mammen AL, et al : Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63 : 713-721, 2011.
PubMed
7) Allenbach Y, Benveniste O : Acquired necrotizing myopathies. Curr Opin Neurol 26 : 554-560, 2013.
PubMed
8) Watanabe Y, et al : Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 87 : 1038-1044, 2016.
PubMed
9) 漆葉章典, 西野一三 : 炎症性筋疾患の筋病理からの診断. 日本医事新報 (4908) : 35-42, 2018.
Medical*Online
10) Liang WC, et al : Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology (Oxford) 56 : 287-293, 2017.
PubMed
11) 斎藤良彦, 西野一三 : 免疫介在性壊死性ミオパチーの臨床と筋病理. 日本臨牀 78 : 1798-1803, 2020.
Medical*Online
12) Walter P, Blobel G : Purification of a membrane-associated protein complex required for protein translocation across the endoplasmic reticulum. Proc Natl Acad Sci U S A 77 : 7112-7116, 1980.
PubMed
13) Walter P, Blobel G : Signal recognition particle contains a 7S RNA essential for protein translocation across the endoplasmic reticulum. Nature 299 : 691-698, 1982.
PubMed
14) Romisch K, et al : Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther 8 : R39, 2006.
PubMed
15) Benveniste O, et al : Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 63 : 1961-1971, 2011.
PubMed
16) Suzuki S, et al : Inflammatory myopathy with anti-signal recognition particle antibodies : case series of 100 patients. Orphanet J Rare Dis 10 : 61, 2015.
PubMed
17) Kishi T, et al : Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07 : 01 and Severe Myositis in Juvenile Myositis Patients. Arthritis Care Res (Hoboken) 69 : 1088-1094, 2017.
PubMed
18) Ueki M, et al : Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. Mod Rheumatol 29 : 351-356, 2019.
PubMed
19) Hengstman GJ, et al : Anti-signal recognition particle autoantibodies : marker of a necrotising myopathy. Ann Rheum Dis 65 : 1635-1638, 2006.
PubMed
20) Kao AH, et al : Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 50 : 209-215, 2004.
PubMed
21) Goldstein JL, Brown MS : Regulation of the mevalonate pathway. Nature 343 : 425-430, 1990.
PubMed
22) 鈴木重明 : 壊死性筋症 ; 免疫性神経疾患. 多発筋炎・皮膚筋炎・封入体筋炎・壊死性筋症. 日本臨牀 (増刊号 7) 73 : 587-591, 2015.
 
23) Christopher-Stine L, et al : A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62 : 2757-2766, 2010.
PubMed
24) Allenbach Y, et al : Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies : inconstant exposure to statin. Medicine (Baltimore) 93 : 150-157, 2014.
PubMed
25) Drouot L et al : Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther 16 : R39, 2014.
PubMed
26) Allenbach Y, et al : High risk of cancer in autoimmune necrotizing myopathies : usefulness of myositis specific antibody. Brain 139 : 2131-2135, 2016.
PubMed
27) Meyer A, et al : Incidence and prevalence of inflammatory myopathies : a systematic review. Rheumatology (Oxford) 54 : 50-63, 2015.
PubMed
28) Ronnelid J, et al : Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 9 : 58-61, 2009.
PubMed
29) Mammen AL : Statin-Associated Autoimmune Myopathy. N Engl J Med 374 : 664-669, 2016.
PubMed
30) Pinal-Fernandez I, et al : Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Arthritis Care Res (Hoboken) 69 : 263-270, 2017.
 
31) Rothwell S, et al : Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis 78 : 996-1002, 2019.
PubMed
32) Kang EH, et al : Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients. Semin Arthritis Rheum 49 : 283-287, 2019.
PubMed
33) Ohnuki Y, et al : HLA-DRB1 alleles in immune-mediated necrotizing myopathy. Neurology 87 : 1954-1955, 2016.
PubMed
34) Ge Y, et al : Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies. PLoS One 10 : e0141616, 2015.
PubMed
35) Limaye V, et al : Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerv 52 : 196-203, 2015.
 
36) Mammen AL, et al : Increased frequency of DRB1*11 : 01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 64 : 1233-1237, 2012.
PubMed
37) Arouche-Delaperche L, et al : Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies : Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol 81 : 538-548, 2017.
PubMed
38) Pinal-Fernandez I, et al : Myositis Autoantigen Expression Correlates With Muscle Regeneration but Not Autoantibody Specificity. Arthritis Rheumatol 71 : 1371-1376, 2019.
 
39) Horsley V, et al : IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 113 : 483-494, 2003.
PubMed
40) Jacquemin V, et al : IL-13 mediates the recruitment of reserve cells for fusion during IGF-1-induced hypertrophy of human myotubes. J Cell Sci 120 : 670-681, 2007.
PubMed
41) Allenbach Y, et al : 224th ENMC International Workshop : Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 28 : 87-99, 2018.
PubMed
42) Lim J, et al : Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol Neuroimmunol Neuroinflamm 6 : e513, 2019.
 
43) Meyer A, et al : Statin-induced anti-HMGCR myopathy : successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther 22 : 5, 2020.
PubMed
44) Ramanathan S, et al : Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm 2 : e96, 2015.
PubMed
45) Binns EL, et al : Effective induction therapy for anti-SRP associated myositis in childhood : a small case series and review of the literature. Pediatr Rheumatol Online J 15 : 77, 2017.
PubMed
46) Kusumoto T, et al : Development of Necrotizing Myopathy Following Interstitial Lung Disease with Anti-signal Recognition Particle Antibody. Intern Med 57 : 2045-2049, 2018.
PubMed
47) Giudizi MG, et al : Anti-HMGCR antibody-associated necrotizing myopathy : diagnosis and treatment illustrated using a case report. Scand J Rheumatol 45 : 427-429, 2016.
PubMed
48) Mammen AL, Tiniakou E : Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. N Engl J Med 373 : 1680-1682, 2015.
PubMed
49) US National Library of Medicine. ClinicalTrials.gov [https://clinicaltrials.gov/ct2/show/NCT04025632] Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy.
 
50) Kadoya M, et al : Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm 3 : e290, 2016.
PubMed
51) Tiniakou E, et al : More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford) 56 : 787-794, 2017.
PubMed
52) Allenbach Y, et al : Immune-mediated necrotizing myopathy : clinical features and pathogenesis. Nat Rev Rheumatol 16 : 689-701, 2020.
PubMed
53) 大貫優子, ほか : 免疫介在性壊死性ミオパチー (IMNM) とHLA多型. 日本組織適合性学会誌 24 : 46-53, 2017.
Medical*Online
P.485 掲載の参考文献
1) Shulman LE : Diffuse fasciitis with eosinophilia : a new syndrome? Trans Assoc Am Physicians 88 : 70-86, 1975.
PubMed
2) Florell SR, et al : Eosinophilic fasciitis occurring four weeks after the onset of dialysis in a renal failure patient. J Cutan Med Surg 5 : 33-36, 2001.
 
3) Bachmeyer C, et al : Eosinophilic fasciitis following idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Hashimoto's disease. Dermatology 199 : 282, 1999.
 
4) Lakhanpal S, et al : Eosinophilic fasciitis : clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17 : 221-231, 1988.
PubMed
5) Nassonova VA, et al : Eosinophilic fasciitis. Review and report of six cases. Scand J Rheumatol 8 : 225-233, 1979.
PubMed
6) Pinal-Fernandez I, et al : Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 13 : 379-382, 2014.
PubMed
7) 神人正寿, ほか : 好酸球性筋膜炎 診断基準・重症度分類・診療ガイドライン. 日本皮膚化学会雑誌 126 : 2241-2250, 2016.
 
8) Lebeaux D, et al : Eosinophilic fasciitis (Shulman disease) : new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford) 51 : 557-561, 2012.
PubMed
9) Salvarani C, et al : Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 38 : 369-373, 1995.
PubMed
10) Crowson CS, et al : The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 63 : 633-639, 2011.
PubMed
11) Salvarani C, et al : Polymyalgia rheumatica and giant-cell arteritis. Lancet 372 : 234-245, 2008.
PubMed
12) 山下裕之 : 核医学検査. 日本医師会雑誌 149 (特別号 2) : 118-121, 2020.
 
13) Dasgupta B, et al : 2012 provisional classification criteria for polymyalgia rheumatica : a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71 : 484-492, 2012.
PubMed
14) Dejaco C, et al : 2015 Recommendations for the management of polymyalgia rheumatica : a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74 : 1799-1807, 2015.
PubMed
15) Hernandez-Rodriguez J, et al : Treatment of polymyalgia rheumatica : a systematic review. Arch Intern Med 169 : 1839-1850, 2009.
PubMed

VIII 内科疾患や腫瘍に伴う神経免疫疾患

P.493 掲載の参考文献
1) Hanly JG : Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 10 : 338-347, 2014.
PubMed
2) Muscal E, Brey RL : Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 28 : 61-73, 2010.
PubMed
3) Tanaka Y : [Neuropsychiatric Systemic Lupus Erythematosus]. Brain Nerve 71 : 445-458, 2019.
PubMed
4) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42 : 599-608, 1999.
PubMed
5) Ainiala H, et al : The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57 : 496-500, 2001.
PubMed
6) Unterman A, et al : Neuropsychiatric syndromes in systemic lupus erythematosus : a meta-analysis. Semin Arthritis Rheum 41 : 1-11, 2011.
PubMed
7) Schwartz N, et al : Neuropsychiatric lupus : new mechanistic insights and future treatment directions. Nat Rev Rheumatol 15 : 137-152, 2019.
PubMed
8) Hanly JG, et al : Review : Nervous System Disease in Systemic Lupus Erythematosus : Current Status and Future Directions. Arthritis Rheumatol 71 : 33-42, 2019.
PubMed
9) Moore E, et al : Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. Curr Opin Rheumatol 32 : 152-158, 2020.
PubMed
10) Florica B, et al : Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum 41 : 203-211, 2011.
PubMed
11) 柳下章 : 全身性エリテマトーデス (systemic lupus erythematosus : SLE). 神経内科疾患の画像診断 (柳下章編), p382-385, 秀潤社, 2011.
 
12) Xiong W, Lahita RG : Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 10 : 97-107, 2014.
PubMed
13) Bombardier C, et al : Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35 : 630-640, 1992.
 
14) Plus M, et al : Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus. Front Med (Lausanne) 7 : 222, 2020.
 
15) Tokunaga M, et al : Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66 : 470-475, 2007.
PubMed
P.498 掲載の参考文献
1) Akman-Demir G, et al : Clinical patterns of neurological involvement in Behcet's disease : evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 122 (Pt 11) : 2171-2182, 1999.
 
2) 廣畑俊成 : 神経病変CQ. ベーチェット病診療ガイドライン 2020 (日本ベーチェット病学会監), p212-215, 診断と治療社, 2020.
 
3) Sweet RD : An acute febrile neutrophilic dermatosis. Br J Dermatol 76 : 349-356, 1964.
PubMed
4) Hisanaga K, et al : Neuro-Sweet disease : clinical manifestations and criteria for diagnosis. Neurology 64 : 1756-1761, 2005.
PubMed
5) Hirohata S, et al : Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 22 : 405-413, 2012.
PubMed
6) Hirohata S, et al : Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 24 : 961-965, 2014.
PubMed
7) Kikuchi H, et al : Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Behcet's disease. J Neurol Sci 337 : 80-85, 2014.
PubMed
8) Matsui T, et al : An attack of acute neuro-Behcet's disease during the course of chronic progressive neuro-Behcet's disease : report of two cases. Mod Rheumatol 20 : 621-626, 2010.
 
9) Hirohata S : Histopathology of central nervous system lesions in Behcet's disease. J Neurol Sci 267 : 41-47, 2008.
PubMed
10) Kokubo Y, et al : Neuro-Sweet disease : report of the first autopsy case. J Neurol Neurosurg Psychiatry 78 : 997-1000, 2007.
 
11) 廣畑俊成, ほか : 神経ベーチェット病の診療のガイドライン. 厚生労働科学研究補助金 難治性疾患克服研究事業 ベーチェット病に関する調査研究事業 平成23-25年度総括・分担研究報告書, p247-252, 2014.
 
12) Hibi T, et al : Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease : Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95 : e3863, 2016.
 
13) Hirohata S, et al : Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. J Neurol Sci 349 : 143-148, 2015.
 
14) Kikuchi H, et al : Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 272 : 99-105, 2008.
PubMed
P.506 掲載の参考文献
1) Chai J, et al : Neurological manifestations of primary Sjogren's syndrome. Curr Opin Neurol 23 : 509-513, 2010.
 
2) Tobon GJ, et al : Neurological Disorders in Primary Sjogren's Syndrome. Autoimmune Dis 2012 : 645967, 2012.
 
3) Gono T, et al : Clinical manifestations of neurological involvement in primary Sjogren's syndrome. Clin Rheumatol 30 : 485-490, 2011.
 
4) Mori K, et al : The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain 128 : 2518-2534, 2005.
PubMed
5) Delalande S, et al : Neurologic manifestations in primary Sjogren syndrome : a study of 82 patients. Medicine (Baltimore) 83 : 280-291, 2004.
PubMed
6) Tsuboi H, et al : Primary and secondary surveys on epidemiology of Sjogren's syndrome in Japan. Mod Rheumatol 24 : 464-470, 2014.
PubMed
7) Fasano S, et al : Pathogenesis of primary Sjogren's syndrome beyond B lymphocytes. Clin Exp Rheumatol 38 (Suppl 126) : 315-323, 2020.
 
8) 奥野龍禎, 村田尚 : シェーグレン症候群. BRAIN and NERVE 73 : 552-559, 2021.
 
9) 難病情報センター : シェーグレン症候群 (指定難病53). [https://www.nanbyou.or.jp/entry/267]
 
10) Karakus S, et al : Clinical Correlations of Novel Autoantibodies in Patients with Dry Eye. J Immunol Res 2019 : 7935451, 2019.
PubMed
11) Margaretten M : Neurologic Manifestations of Primary Sjogren Syndrome. Rheum Dis Clin North Am 43 : 519-529, 2017.
PubMed
12) Mochizuki H, et al : Motor dominant neuropathy in Sjogren's syndrome : report of two cases. Intern Med 41 : 142-146, 2002.
 
13) Birnbaum J, et al : Biopsy-proven small-fiber neuropathy in primary Sjogren's syndrome : neuropathic pain characteristics, autoantibody findings, and histopathological features. Arthritis Care Res (Hoboken) 71 : 936-948, 2019.
 
14) 齋藤万有, ほか : 多発性単神経炎を呈し緩徐進行性の運動障害を主徴とした原発性シェーグレン症候群の1例. 臨床神経 55 : 753-758, 2015.
 
15) Gross M : Chronic relapsing inflammatory polyneuropathy complicating sicca syndrome. J Neurol Neurosurg Psychiatry 50 : 939-940, 1987.
PubMed
16) van Doorn PA, et al : HLA antigens in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 32 : 133-139, 1991.
PubMed
17) Park Y, et al : Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjogren's syndrome : data from a nationwide cohort for Sjogren's syndrome in Korea. Clin Exp Rheumatol 37 (Suppl 118) : 107-113, 2019.
 
18) Massara A, et al : Central nervous system involvement in Sjogren's syndrome : unusual, but not unremarkable--clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford) 49 : 1540-1549, 2010.
 
19) Vrethem M, et al : Immunoglobulins within the central nervous system in primary Sjogren's syndrome. J Neurol Sci 100 : 186-192, 1990.
 
20) Sumida T, et al : The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjogren's syndrome : a critical review. J Autoimmun 51 : 44-50, 2014.
PubMed
21) 吉村賢二, ほか : 抗N-methyl D-aspartate (NMDA) 受容体脳炎と類似した臨床像を呈したシェーグレン症候群関連辺縁系脳炎の1例. 臨床神経学 58 : 229-234, 2018.
 
22) Nagaishi A, et al : Clinical features of neuromyelitis optica in a large Japanese cohort : comparison between phenotypes. J Neurol Neurosurg Psychiatry 82 : 1360-1364, 2011.
 
23) Matsuzaki T, et al : Aquaporins : a water channel family. Anat Sci Int 77 : 85-93, 2002.
PubMed
24) Yoshimura S, et al : Abnormal distribution of AQP5 in labial salivary glands is associated with poor saliva secretion in patients with Sjogren's syndrome including neuromyelitis optica complicated patients. Mod Rheumatol 26 : 384-390, 2016.
 
25) Lisi S, et al : Pro-inflammatory role of Anti-Ro/SSA autoantibodies through the activation of Furin-TACE-amphiregulin axis. J Autoimmun 35 : 160-170, 2010.
 
26) Chihara N, et al : Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108 : 3701-3706, 2011.
PubMed
27) Javed A, et al : Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler 14 : 809-814, 2008.
 
28) Mori M, et al : Detection of mumps virus RNA in cerebrospinal fluid of patients with neuromyelitis optica. Neurol Sci 32 : 795-799, 2011.
PubMed
29) Maeshima S, et al : Clinicopathological features of sarcoidosis manifesting as generalized chronic myopathy. J Neurol 262 : 1035-1045, 2015.
PubMed
30) 抗SS-A抗体陽性女性の妊娠に関する診療の手引き (厚生労働科学研究費補助金成育疾患克服等次世代育成基盤研究事業「自己抗体陽性女性の妊娠管理指針の作成及び新生児ループスの発症リスクの軽減に関する研究」研究班編), 2013年3月. [https://www.ncchd.go.jp/hospital/about/section/perinatal/bosei/699ba3ce063e73aa36e1461f8196a7bada02fca6.pdf]
 
31) 日本リウマチ学会 : 新型コロナウイルス (COVID-19) と新型コロナワクチンについて (患者様向け情報). [https://www.ryumachi-jp.com/information/medical/covid-19_2/]
 
32) Sene D, et al : Peripheral neuropathies associated with primary Sjogren syndrome : immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine (Baltimore) 90 : 133-138, 2011.
PubMed
P.512 掲載の参考文献
1) Seve P, et al : Sarcoidosis : A Clinical Overview from Symptoms to Diagnosis. Cells 10 : 766, 2021.
PubMed
2) 日本サルコイドーシス/肉芽腫性疾患学会 : サルコイドーシス診療の手引き 2020, 2021. [https://www.jssog.com/journal#journal-guide]
 
3) Morimoto T, et al : Epidemiology of sarcoidosis in Japan. Eur Respir J 31 : 372-379, 2008.
PubMed
4) Pirau L, Lui F : Neurosarcoidosis. StatPearls Publishing, Treasure Island (FL), 2021.
 
5) Fritz D, et al : Clinical features, treatment and outcome in neurosarcoidosis : systematic review and meta-analysis. BMC Neurol 16 : 220, 2016.
PubMed
6) Bridel C, et al : Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol 285 : 1-3, 2015.
PubMed
7) Kidd DP : Neurosarcoidosis : clinical manifestations, investigation and treatment. Pract Neurol 20 : 199-212, 2020.
PubMed
8) Chazal T, et al : The cerebrospinal fluid CD4/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis : a multicenter, pragmatic, comparative study. Eur J Neurol 26 : 1274-1280, 2019.
PubMed
9) Arun T, et al : Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis : A retrospective study. Neurology 94 : e2545-e2554, 2020.
PubMed
10) Stern BJ, et al : Neurologic presentations of sarcoidosis. Neurol Clin 28 : 185-198, 2010.
PubMed
11) Joubert B, et al : Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis. JAMA Neurol 74 : 1336-1344, 2017.
PubMed
12) Kidd DP : Sarcoidosis of the central nervous system : Safety and efficacy of treatment, and experience of biological therapies. Clin Neurol Neurosurg 194 : 105811, 2020.
PubMed
P.518 掲載の参考文献
1) Dalmau J, et al : Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev 97 : 839-887, 2017.
PubMed
2) Vogrig A, et al : Epidemiology of paraneoplastic neurological syndromes : a population-based study. J Neurol 267 : 26-35, 2020.
PubMed
3) Tanaka K, et al : Antibodies to brain proteins in paraneoplastic cerebellar degeneration. Neurology 36 : 1169-1172, 1986.
PubMed
4) Graus F, et al : Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm 8 : e1014, 2021.
PubMed
5) Albert ML, et al : Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 47 : 9-17, 2000.
PubMed
6) Tanaka M, et al : Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 161 : 88-90, 1998.
PubMed
7) Graus F, et al : Anti-Hu-associated paraneoplastic encephalomyelitis : analysis of 200 patients. Brain 124 : 1138-1148, 2001.
PubMed
8) Dubey D, et al : Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology 90 : e103-e110, 2018.
PubMed
9) Dalmau J, et al : Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 (Pt 8) : 1831-1844, 2004.
 
10) Dubey D, et al : Amphiphysin-IgG autoimmune neuropathy : A recognizable clinicopathologic syndrome. Neurology 93 : e1873-e1880, 2019.
PubMed
11) Peterson K, et al : Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42 : 1931-1937, 1992.
 
12) Graus F, Dalmau J : Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16 : 535-548, 2019.
PubMed
P.523 掲載の参考文献
1) 国立がん研究センターがん情報サービス「がん統計」 (全国がん登録). [https://ganjoho.jp/reg_stat/index.html]
 
2) Hughes RA, et al : Effects of lymphoma on the peripheral nervous system. J R Soc Med 87 : 526-530, 1994.
PubMed
3) Walsh JC : Neuropathy associated with lymphoma. J Neurol Neurosurg Psychiatry 34 : 42-50, 1971.
PubMed
4) Grisariu S, et al : Neurolymphomatosis : an International Primary CNS Lymphoma Collaborative Group report. Blood 115 : 5005-5011, 2010.
 
5) Tomita M, et al : Clinicopathological features of neuropathy associated with lymphoma. Brain 136 (Pt 8) : 2563-2578, 2013.
 
6) Keddie S, et al : Peripheral nerve neurolymphomatosis : Clinical features, treatment, and outcomes. Muscle Nerve 62 : 617-625, 2020.
PubMed
7) Baehring JM, Batchelor TT : Diagnosis and management of neurolymphomatosis. Cancer J 18 : 463-468, 2012.
PubMed
8) Chhabra A, et al : High-resolution 3T MR neurography of the brachial plexus and its branches, with emphasis on 3D imaging. AJNR Am J Neuroradiol 34 : 486-497, 2013.
PubMed
9) 末吉健志 : MR neurographyの臨床応用でわかったこと. 脊椎脊髄ジャーナル 29 : 853-859, 2016.
 
10) Jaeckle KA : Neurological manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol 24 : 385-393, 2004.
PubMed
11) Cheson BD : Role of functional imaging in the management of lymphoma. J Clin Oncol 29 : 1844-1854, 2011.
PubMed
12) Weiler-Sagie M, et al : 18F-FDG avidity in lymphoma readdressed : a study of 766 patients. J Nucl Med 51 : 25-30, 2010.
PubMed
13) Wu LM, et al : The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma : A meta-analysis. Eur J Radiol 81 : 1798-1805, 2012.
PubMed
14) Lagarde S, et al : Primary neurolymphomatosis diagnosis and treatment : a retrospective study. J Neurol Sci 342 : 178-181, 2014.
PubMed
15) Wright GW, et al : A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37 : 551-568.e14, 2020.
 
P.528 掲載の参考文献
1) Hamano H, et al : High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344 : 732-738, 2001.
PubMed
2) Stone JH, et al : IgG4-related disease. N Engl J Med 366 : 539-551, 2012.
PubMed
3) Kamisawa T, et al : IgG4-related disease. Lancet 385 : 1460-1471, 2015.
PubMed
4) Umehara H, et al : Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22 : 21-30, 2012.
PubMed
5) Umehara H, et al : The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31 : 529-533, 2021.
PubMed
6) 梅原久範, ほか : 2020年改訂IgG4関連疾患包括診断基準. 日本内科学会雑誌 110 : 962-969, 2021.
 
7) AbdelRazek MA, et al : IgG4-related disease of the central and peripheral nervous systems. Lancet Neurol 17 : 183-192, 2018.
PubMed
8) Saitakis G, Chwalisz BK : The neurology of IGG4-related disease. J Neurol Sci 424 : 117420, 2021.
 
9) Yonekawa T, et al : A nationwide survey of hypertrophic pachymeningitis in Japan. J Neurol Neurosurg Psychiatry 85 : 732-739, 2014.
PubMed
10) Lu LX, et al : IgG4-related hypertrophic pachymeningitis : clinical features, diagnostic criteria, and treatment. JAMA Neurol 71 : 785-793, 2014.
PubMed
11) Bando H, et al : The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature. Eur J Endocrinol 170 : 161-172, 2014.
PubMed
12) Shikuma J, et al : Critical review of IgG4-related hypophysitis. Pituitary 20 : 282-291, 2017.
PubMed
13) Goto H, et al : Diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Ophthalmol 59 : 1-7, 2015.
 
14) Goto H, et al : Clinical features and symptoms of IgG4-related ophthalmic disease : a multicenter study. Jpn J Ophthalmol 65 : 651-656, 2021.
PubMed
15) Japanese study group of IgG4-related ophthalmic disease : A prevalence study of IgG4-related ophthalmic disease in Japan. Jpn J Ophthalmol 57 : 573-579, 2013.
 
16) Ohyama K, et al : IgG4-related neuropathy : a case report. JAMA Neurol 70 : 502-505, 2013.
PubMed
17) 鈴木祐, ほか : 著明な軸索障害を認め治療に抵抗性であったIgG4関連末梢神経障害の1例. 臨床神経学 56 : 323-327, 2016.
 
18) Zhan L, et al : Combination of autoimmune pancreatitis and peripheral neuropathy on an IgG4-related disease patient with 4 years following-up. J Neuroimmunol 348 : 577378, 2020.
 
19) Kawazoe T, et al : Immunoglobulin G4-related Disease Accompanied by Peripheral Neuropathy : A Report of Two Cases. Intern Med 60 : 1941-1947, 2021.
PubMed
20) Ohyama K, et al : Immunoglobulin G4-related pathologic features in inflammatory neuropathies. Neurology 85 : 1400-1407, 2015.
PubMed
21) Inoue D, et al : IgG4-Related Perineural Disease. Int J Rheumatol 2012 : 401890, 2012.
PubMed
22) Kim EH, et al : Immunoglobulin G4-related hypertrophic pachymeningitis involving cerebral parenchyma. J Neurosurg 115 : 1242-1247, 2011.
PubMed
23) Regev K, et al : Central nervous system manifestation of IgG4-related disease. JAMA Neurol 71 : 767-770, 2014.
PubMed
24) Lui PC, et al : Inflammatory pseudotumors of the central nervous system. Hum Pathol 40 : 1611-1617, 2009.
PubMed
25) Moss HE, et al : IgG4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil. J Neurol Sci 318 (1-2) : 31-35, 2012.
 

IX トピックス・今知りたいこと

P.536 掲載の参考文献
1) Marsh EB, et al : COVID-19 and vaccination in the setting of neurologic disease : An emerging issue in neurology. Neurology 97 : 720-728, 2021.
 
2) Moriguchi T, et al : A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 94 : 55-58, 2020.
PubMed
3) 下畑享良 : 【脳神経内科におけるCOVID-19】COVID-19と脳炎・脳症. 脳神経内科 95 : 306-311, 2021.
 
4) Palaiodimou L, et al : Prevalence, clinical characteristics and outcomes of Guillain-Barre syndrome spectrum associated with COVID-19 : A systematic review and meta-analysis. Eur J Neurol 28 : 3517-3529, 2021.
PubMed
5) Keddie S, et al : Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome. Brain 144 : 682-693, 2021.
PubMed
6) 杉江和馬 : 【脳神経内科におけるCOVID-19】COVID-19と筋障害. 脳神経内科 95 : 342-350, 2021.
 
7) Restivo DA, et al : Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med 173 : 1027-1028, 2020.
PubMed
8) Ghosh R, et al : A case of area postrema variant of neuromyelitis optica spectrum disorder following SARS-CoV-2 infection. J Neuroimmunol 350 : 577439, 2020.
 
9) 令和元年度厚生労働行政推進調査事業費補助金 新興・再興感染症及び予防接種政策推進研究事業 : 新型コロナウイルス感染症 (COVID-19) 診療の手引き別冊罹患後症状のマネジメント (暫定版), 2021. [https://www.mhlw.go.jp/content/000860932.pdf]
 
10) 蕨陽子 : 【COVID-19と神経治療学】COVID-19と神経免疫疾患診療. 神経治療学 38 : 14-19, 2021.
 
11) Neumann B, et al : Myasthenic crisis demanding mechanical ventilation : A multicenter analysis of 250 cases. Neurology 94 : e299-e313, 2020.
PubMed
12) Gupta L, et al : COVID-19 and myositis-unique challenges for patients. Rheumatology (Oxford) 60 : 907-910, 2021.
PubMed
13) Simpson-Yap S, et al : Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology 97 : e1870-e1885, 2021.
PubMed
14) Yin H, et al : The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder beyond infection risk. Front Neurol 12 : 657037, 2021.
PubMed
15) Achiron A, et al : COVID-19 vaccination in patients with multiple sclerosis : What we have learnt by February 2021. Mult Scler 27 : 864-870, 2021.
PubMed
16) Kitazawa Y, et al : Elderly-onset neuromyelitis optica which developed after the diagnosis of prostate adenocarcinoma and relapsed after a 23-valent pneumococcal polysaccharide vaccination. Intern Med 51 : 103-107, 2012.
 
17) Ismail II, Salama S : A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol 362 : 577765, 2022.
 
18) Achiron A, et al : Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination : Up to 6 months cross-sectional study. J Neuroimmunol 361 : 577746, 2021.
PubMed
19) Warabi Y, et al : Effects of oral care on prolonged viral shedding in coronavirus disease 2019 (COVID-19). Spec Care Dentist 40 : 470-474, 2020.
PubMed
P.542 掲載の参考文献
1) Abbas AK, et al : Cellular and Molecular Immunology, 8th edition, Elsevier Saunders, Philadelphia, 2014.
 
2) Postow MA, et al : Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 378 : 158-168, 2018.
PubMed
3) Cuzzubbo S, et al : Neurological adverse events associated with immune checkpoint inhibitors : Review of the literature. Eur J Cancer 73 : 1-8, 2017.
PubMed
4) Spain L, et al : Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma : a single centre experience and review of the literature. Ann Oncol 28 : 377-385, 2017.
PubMed
5) Kao JC, et al : Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies. JAMA Neurol 74 : 1216-1222, 2017.
PubMed
6) Wang DY, et al : Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors : A Systematic Review and Meta-analysis. JAMA Oncol 4 : 1721-1728, 2018.
PubMed
7) Dubey D, et al : Severe Neurological Toxicity of Immune Checkpoint Inhibitors : Growing Spectrum. Ann Neurol 87 : 659-669, 2020.
PubMed
8) Guidon AC, et al : Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9 : e002890, 2021.
PubMed
9) がん免疫療法ガイドライン 第2版 (日本臨床腫瘍学会編), 金原出版, 2019.
 
10) Schneider BJ, et al : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : ASCO Guideline Update. J Clin Oncol 39 : 4073-4126, 2021.
PubMed
P.548 掲載の参考文献
1) Matricardi S, et al : Understanding Childhood Neuroimmune Diseases of the Central Nervous System. Front Pediatr 7 : 511, 2019.
PubMed
2) McMillan HJ, et al : Autoimmune neuromuscular disorders in childhood. Curr Treat Options Neurol 13 : 590-607, 2011.
PubMed
3) Golumbek P : Pharmacologic agents for pediatric neuroimmune disorders. Semin Pediatr Neurol 17 : 245-253, 2010.
PubMed
4) Torisu H, et al : Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 32 : 454-462, 2010.
PubMed
5) Kochhar PK, et al : Transient neonatal myasthenia gravis : refining risk estimate for infants born to women with myasthenia gravis. J Perinatol 41 : 2279-2283, 2021.
PubMed
6) Zuppa AA, et al : Neonatal lupus : Follow-up in infants with anti-SSA/Ro antibodies and review of the literature. Autoimmun Rev 16 : 427-432, 2017.
PubMed
7) Armangue T, et al : Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies : a multicentre observational study. Lancet Neurol 19 : 234-246, 2020.
 
8) Wilbur C, et al : PANDAS/PANS in childhood : Controversies and evidence. Paediatr Child Health 24 : 85-91, 2019.
PubMed
9) Nosadini M, et al : Herpes simplex virus-induced anti-N-methyl-d-aspartate receptor encephalitis : a systematic literature review with analysis of 43 cases. Dev Med Child Neurol 59 : 796-805, 2017.
PubMed
10) Graus F, et al : A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15 : 391-404, 2016.
PubMed
11) Pranzatelli MR, et al : Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome : A Cross-sectional Study. Front Neurol 8 : 468, 2017.
PubMed
12) Reddick WE, et al : Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol 26 : 1263-1269, 2005.
PubMed
13) Yang SK, et al : A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 46 : 1017-1020, 2014.
PubMed
P.557 掲載の参考文献
1) 持田智 : 免疫再構築症候群とは免疫抑制療法中のB型肝炎ウイルス再活性化と劇症化. 分子リウマチ治療 11 : 61-65, 2018.
 
2) B型肝炎治療ガイドライン (第3.4版) (日本肝臓学会肝炎診療ガイドライン作成委員会編), 2021.
 
3) Smith TE, Kister I : Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. Curr Neurol Neurosci Rep 21 : 36, 2021.
PubMed
4) Biolato M, et al : The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury : A Narrative Review. CNS Drugs 35 : 861-880, 2021.
PubMed
5) Dizdar O, et al : Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. Eur J Haematol 80 : 381-385, 2008.
PubMed
6) Klotz L, et al : Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 12 : 1756286419836571, 2019.
PubMed
7) Kucharzik T, et al : ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 15 : 879-913, 2021.
PubMed
8) Banko A, et al : New Evidence of Significant Association between EBV Presence and Lymphoproliferative Disorders Susceptibility in Patients with Rheumatoid Arthritis : A Systematic Review with Meta-Analysis. Viruses 14 : 115, 2022.
PubMed
9) Iwanaga M : Epidemiology of HTLV-1 Infection and ATL in Japan : An Update. Front Microbiol 11 : 1124, 2020.
PubMed
10) Umekita K, Okayama A : HTLV-1 Infection and Rheumatic Diseases. Front Microbiol 11 : 152, 2020.
PubMed
11) Bloomgren G, et al : Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366 : 1870-1880, 2012.
PubMed
12) Schwab N, et al : Natalizumab-associated PML : Challenges with incidence, resulting risk, and risk stratification. Neurology 88 : 1197-1205, 2017.
PubMed
13) Campagnolo D, et al : Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016 : outcomes after introduction of the Stratify JCV DxSelect(TM) antibody assay. J Neurovirol 22 : 880-881, 2016.
 
14) McGuigan C, et al : Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk : recommendations from an expert group. J Neurol Neurosurg Psychiatry 87 : 117-125, 2016.
 
15) Ryerson LZ, et al : Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93 : e1452-e1462, 2019.
PubMed
P.562 掲載の参考文献
1) 今日の治療薬 2022 : 解説と便覧, 巻末付録 4 ; 妊婦授乳婦へ投与する際の注意点. (島田和幸, ほか編), 南江堂, 2022.
 
2) 産婦人科診療ガイドライン-産科編 2020 (日本産科婦人科学会, 日本産婦人科医会編), 日本産科婦人科学会, 2020.
 
3) 国立成育医療研究センター : 妊娠と薬情報センター. [https://www.ncchd.go.jp/kusuri/about.html]
 
4) Tisovic T, Amezcua L : Women's Health : Contemporary Management of MS in Pregnancy and Post-Partum. Biomedicines 7 : 32, 2019.
 
5) Dobson R, et al : UK consensus on pregnancy in multiple sclerosis : ‘Association of British Neurologists' guidelines. Pract Neurol 19 : 106-114, 2019.
 
6) Liguori NF, et al : Consensus recommendations for family planning and pregnancy in multiple sclerosis in argentina. Mult Scler Relat Disord 43 : 102147, 2020.
PubMed
7) Hellwig K, et al : Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry. Neurol Neuroimmunol Neuroinflamm 9 : 2022.
 
8) 深澤俊行, ほか : フマル酸ジメチル (テクフィデラ) の多発性硬化症患者に対する安全性と有効性 : 国内使用成績調査中間報告. 診療と新薬 58 : 298-316, 2021.
 
9) Bianco A, et al : Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients. Neurotherapeutics 18 : 2598-2607, 2021.
PubMed
10) Krysko KM, et al : Association Between Breastfeeding and Postpartum Multiple Sclerosis Relapses : A Systematic Review and Meta-analysis. JAMA Neurol 77 : 327-338, 2020.
PubMed
11) Mao-Draayer Y, et al : Neuromyelitis optica spectrum disorders and pregnancy : therapeutic considerations. Nat Rev Neurol 16 : 154-170, 2020.
PubMed
12) Kim W, et al : Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 78 : 1264-1267, 2012.
PubMed
13) Bourre B, et al : Neuromyelitis optica and pregnancy. Neurology 78 : 875-879, 2012.
PubMed
14) Shimizu Y, et al : Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler 22 : 1413-1420, 2016.
PubMed
15) Klawiter EC, et al : High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology 89 : 2238-2244, 2017.
PubMed
16) Nour MM, et al : Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology 86 : 79-87, 2016.
PubMed
17) Collongues N, et al : Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder. Neurology 96 : e2006-e2015, 2021.
PubMed
18) Borisow N, et al : Neuromyelitis optica spectrum disorders and pregnancy : relapse-preventive measures and presonalized treatment strategies. EPMA J 9 : 249-256, 2018.
PubMed
19) Tugizova M, et al : New Therapeutic Landscape in Neuromyelitis Optica. Curr Treat Options Neurol 23 : 13, 2021.
PubMed
20) 臼杵憲祐 : 発作性夜間ヘモグロビン尿症の妊娠・分娩管理. 臨床血液 56 : 785-794, 2015.
 
21) Vu T, et al : Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis : A Case Report. Case Rep Neurol 13 : 65-72, 2021.
 
22) 中外製薬 (株) : エンスプリング(R) 皮下注120 mg シリンジ 2020年9月改訂 (第3 版).
 
23) 田辺三菱製薬 (株) : 抗CD19モノクローナル抗体製剤 ユプリズナ(R) 点滴静注100 mg. 2021年3月作成 (第1版).
 
24) 中外製薬 (株) : 抗CD20モノクロ-ナル抗体製剤 リツキサン(R) 点滴静注100 mg. 2021年12月改訂 (第6版).
 
25) Drugs and Lactation Database (LactMed). [https://www.toxnet.nlm.nih.gov/newtoxnet/lactmed.htm]
 
26) Jarius S, et al : MOG-IgG in NMO and related disorders : a multicenter study of 50 patients. Part 2 : Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13 : 280, 2016.
PubMed
27) Shimizu Y, Kitagawa K : Management of myasthenia gravis in pregnancy. Clin Exp Neuroimmunol 7 : 199-204, 2016.
 
28) Hamel J, et al : An Update : Myasthenia Gravis and Pregnancy. Neurol Clin 36 : 355-365, 2018.
PubMed
29) Waters J : Management of Myasthenia Gravis in Pregnancy. Neurol Clin 37 : 113-120, 2019.
PubMed
30) Tsurane K, et al : Management of labor and delivery in myasthenia gravis : A new protocol. Obstet Gynaecol Res 45 : 974-980, 2019.
PubMed
31) Kalidindi M, et al : Myasthenia gravis and pregnancy. J Obstet Gynecol 27 : 30-32, 2007.
 
32) 神崎昭浩, 本村政勝 : 抗MuSK抗体陽性の重症筋無力症の妊婦例と新生児一過性重症筋無力症児例. 臨床神経学 51 : 188-191, 2011.
 
33) Santos E, et al : MuSK myasthenia gravis and pregnancy. Neuromuscul Disord 28 : 150-153, 2018.
PubMed
P.568 掲載の参考文献
1) Moriyama T, et al : NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 48 : 367-373, 2016.
PubMed
2) Lucchinetti CF, et al : Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365 : 2188-2197, 2011.
PubMed
3) Giovannoni G, et al : Brain health : time matters in multiple sclerosis. Mult Scler Relat Disord 9 (Suppl 1) : S5-S48, 2016.
 
4) Akatani R, et al : Validation of the Guy's Neurological Disability Scale as a screening tool for cognitive impairment in multiple sclerosis. Mult Scler Relat Disord 35 : 272-275, 2019.
 
5) Yamamoto T, et al : [Validation of the Japanese-translated version Multiple Sclerosis Quality of Life-54 instrument]. Rinsho Shinkeigaku 44 : 417-421, 2004.
PubMed
6) Kikuchi H, et al : Impact and characteristics of quality of life in Japanese patients with multiple sclerosis. Qual Life Res 20 : 119-131, 2011.
PubMed
7) Paling J : Strategies to help patients understand risks. BMJ 327 : 745-748, 2003.
PubMed
P.573 掲載の参考文献
1) 難病情報センター ; Japan Intractable Diseases Information Center. [https://www.nanbyou.or.jp/]
 
2) 厚生労働省 : 障害者総合支援法の対象疾病 (難病等). [https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hukushi_kaigo/shougaishahukushi/hani/index.html]
 
3) 厚生労働省・都道府県労働局・ハローワーク : 難病の方の就労を支援しています. [https://www.mhlw.go.jp/content/000761866.pdf]
 

書評

最近チェックした商品履歴

Loading...